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Abstract 
Polycystic ovarian syndrome (PCOS) is one of the most common endocrine 
disorders, affecting 5 % to 10 % of women of reproductive age.  The Syndrome is 
associated with Type II diabetes and endometrial carcinoma but an association 
with epithelial ovarian cancer has also been suggested. The studies described in 
this thesis were designed to investigate this association at population, cellular and 
molecular levels. 
In the first study, a cross sectional questionnaire survey was conducted of 121 
women aged between the ages of 20 and 40, with or without PCOS. Analysis of 
the replies from 52 women with PCOS and 82 controls, showed that women with 
PCOS were significantly more likely to give a positive family history of breast 
cancer and myocardial infarction (20% vs 5%, p<0.05 and 35% vs 15%, p, 0.05, 
respectively). 
The second study was performed on 102 formalin fixed, paraffin embedded 
ovarian biopsies. In this study the surface epithelium of PCOS ovaries was 
compared with controls. The results showed significant epithelial changes in the 
PCOS group, with a higher prevalence of Psammoma bodies and mitoses (p< 0.01 
and p < 0.02, respectively). Expression of cell cycle and apoptotic (p53, Cyclin D, 
Ki67 and bcl2) proteins in the ovarian surface epithelium was assessed using 
immunohistochemistry in 15 PCOS subjects and 15 controls. P53 expression was 
significantly (p= 0.003) increased in the PCOS women compared with controls.  
The third project was performed to identify gene expression in ovaries from 
women with PCOS, ovarian cancer and healthy controls (three ovaries from each 
group were utilized). 34(2%) genes consistently varied in abundance between 
normal and PCOS samples, 12 genes were over expressed in PCOS and 22 under 
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expressed. One of the over expressed genes identified is human alpha 2 smooth 
muscle actin. It was 15 fold higher in PCOS ovary, than in normal ovary p< 0.001. 
Conclusions: the results of these studies do not provide convincing evidence of a 
correlation between PCOS and ovarian cancer 
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Chapter One 
 
Introduction 
 
Polycystic ovary syndrome (PCOS) is a complex multisystem disorder 
characterised by infrequent ovulation and androgen excess. These features together 
with morphological changes highlight the central role of the ovary in this 
Syndrome but more than 75 years after it was first described, the mechanism 
underlying the functional abnormalities in the ovary are still unknown.  In this 
thesis, I will describe a series of studies which were designed to explore one aspect 
of this condition which has received less scientific attention; the possible 
association between PCOS and epithelial ovarian cancer.  Firstly, I will describe 
the anatomy of the normal ovary followed be an overview of the diagnosis and 
management of PCOS. The different types of ovarian cancer will later be 
described including the pathogenesis and the staging of the disease and its 
progression. Emphasis will be placed on epithelial ovarian cancer. This will be 
followed by a description of the cell cycle and putative genetic factors which 
might contribute to PCOS and ovarian cancer. 
 
1.1 Hypothesis 
Women with PCOS are not at increased risk of developing epithelial ovarian 
cancer compared to controls that do not have PCOS. 
 
1.2Aim 
To establish whether or not there is an association between PCOS and ovarian 
cancer. 
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1.3 Objectives 
1. Establish the history of ovarian cancer in first degree relatives of women with 
PCOS. 
2. Assess the degree of morphological abnormalities in the ovarian epithelium of 
women with PCOS 
3. Assess cell cycle and apoptotic protein expression in the ovarian surface 
epithelium of women with PCOS and healthy controls. 
4. Assess gene expression in the ovaries of women with PCOS, healthy controls 
and women diagnosed with serous epithelial ovarian cancer 
 
1.4 Background  
PCOS affects 5–10% of women worldwide (Knochenhauer et al, 1998 Diamanti-
Kandarakis et al, 1999, Asunción et al, 2000,
 
Aziz et al, 2004&
 
Broekmans et al, 
2006). In view of this, PCOS is one of the most common human disorders and the 
single most common endocrinopathy in women of reproductive age. Although 
hetrogeneous in presentation the syndrome is characterised by signs of 
hyperandrogenism (hirsutism, acne or alopecia) and oligo ovulation (menstrual 
dysfunction or anovulatory infertility).   
 
Additionally, ovarian cancer is the second most common gynaecological cancer in 
UK. In 2008, 6,537cases of ovarian cancer were diagnosed in the UK (Table1). 
The incidence of ovarian cancer in British women has increased over the last 30 
years from around 15 per 100,000 women in 1975 to around 17 per 100,000 
women in 2005; an increase of 15-17%. Surface epithelial tumours account for 
approximately 80% of ovarian cancers and occur predominantly in the older 
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reproductive and postmenopausal age groups (Capo-chichi et al, 2002, Yang et al, 
2002 and Sheng et al, 2000). The main reason for the high mortality rate in women 
with ovarian cancer is that it usually remains clinically silent until it has 
metastasized (stage III or IV). There is therefore an urgent need for a non invasive 
screening test for early detection of ovarian cancer. In 2008, there were around 
4,400 deaths from ovarian cancer in the UK, accounting for 6% of all female 
deaths from cancer (Office for National Statistics). 
 
 Cases AS rate 
Cervix 2,938 8.7 
Ovary 6,537 16.2 
Uterus 7,703 19.4 
Vagina 258 0.6 
Vulva 1,157 2.5 
 
 
Table1: Gynaecological Cancers in the UK 2008. Numbers of New Cases and 
Age-Standardised Incidence (AS) Rates per 100,000 
Office for National Statistics. Cancer Statistics. http://www.statistics.gov.uk 
 
1.4.1 Justification 
There is some evidence to suggest a possible link between PCOS and ovarian 
cancer.  This study was designed to explore whether there is any correlation 
between both conditions.  Based on the high prevalence of PCOS, even a weak 
association with ovarian cancer could have an important effect on mortality. 
1.4. 2 Ethical Considerations 
Ethical approval was obtained from the Research Ethics Committee of Enfield and 
Haringey Health Authority.  
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1.5 Anatomy of the Ovary 
The ovary is an important organ in the female reproductive system responsible for 
ovulation and production of steroid hormones. 
 
1.5.1 Gross anatomy (Figure 1) 
Outside the peritoneum, forming the floor of the ovarian fossa, are the obturator 
nerve and vessels. The tubal extremity of the ovary lies marginally below the level 
of the external iliac vessels, while the uterine extremity is immediately above the 
peritoneum of the pelvic floor. 
 
The medial surface of each ovary is largely covered by the adjacent fallopian tube 
which, passing upwards near the mesovarian border, arches over the tubal 
extremity and then turns downwards in relation to the free border and posterior 
part of the medial surface before joining the uterus. The position of the ovaries is 
considerably more variable in women who have had children, because they are 
displaced during the first pregnancy and normally fail to return to their location 
within the ovarian fossae. 
Anteriorly, the ovary is connected to the broad ligament by the mesovarium along 
the length of its mesovarian border.  
 
A small peritoneal fold - the suspensory ligament - also passes upwards from the 
tubal end of the ovary to the peritoneum over the external iliac vessels and the 
psoas major muscles. This ligament is continuous below the ovary with the 
mesovarium and in front with the broad ligament. Between its two layers it 
contains the ovarian vessels and nerves as they pass down into the lesser pelvis to 
reach the hilum of the ovary via the mesovarium. 
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Figure 1: Gross anatomy of the Ovary: A. Female pelvic viscera B. Blood supply 
and venous drainage of ovaries, uterus and vagina 
Anatomytopics.worldpress.com. All right preserved. 
 
The uterine extremity is also connected with the uterus by the proper ligament of 
the ovary, which lies in the free border of the medial part of the mesovarium and is 
attached to the lateral angle of the uterus posterosuperior to the point of entrance 
of the fallopian tube. The tubal end of the ovary is directly connected with the 
ovarian fimbria, one of the largest of the fimbriae of the fallopian tube. 
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The ovarian arteries arise from the front of the aorta below the origin of the renal 
vessels. Each artery descends to the suspensory ligament and runs through it to 
enter the ovary at its mesovarian border. Close to the ovary the ovarian artery 
anastomoses with branches of the uterine artery. The smaller arteries within the 
adult ovary are spiral. Blood exits the ovary via a series of communicating veins, 
which eventually form one vein draining into the inferior vena cava on the right 
side and the renal vein on the left. The lymph vessels of the ovary follow the blood 
vessels and run with those from the fallopian tube and upper part of the uterus to 
end in the lymph nodes beside the aorta and inferior vena cava.  
 
1.5. 2 Micro anatomy (Figure 2) 
The ovary consists of three parts, the cortex which is the outermost layer, the 
central medulla and the hilum. The hilum is the point of attachment of the ovary to 
the mesovarium. It contains nerves, blood vessels, and hilus cells which have the 
potential to produce steroid hormones or to form tumours, these cells are very 
similar to the testosterone – producing Leydig cells of the testes. The outermost 
portion of the cortex is called the tunica albuginea; its surface is covered by a 
single layer of cuboidal epithelium, referred to as the ovarian surface epithelium or 
the ovarian methothelium. The oocytes, enclosed in complexes called follicles, are 
in the inner part of the cortex embedded in stromal tissue. The stromal tissue is 
composed of connective tissue and interstitial cells which are derived from 
mesenchymal cells, and have the ability to respond to LH or GnRH with androgen 
production. The central medullary area of the ovary is derived largely from 
mesonephric cells (Kumar et al, 2008).  
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Ovarian surface epithelium cells (OSE) are more complicated and physiologically 
adaptable than would be predicted from their ordinary appearance. The OSE has 
the capacity to modify the ovarian cortex through synthetic and physical functions 
which may influence ovulation and repair of ovulatory defects, as well as the 
ovarian shrinkage and cyst formation which occur with age (Kruk et al, (1994). 
OSE cells secrete biologically active cytokines and growth factors, and that they 
have oestrogen receptors suggest that they play an integral part in the network of 
hormones and paracrine acting factors which regulate normal ovarian physiology.  
 
Surface epithelial inclusion cysts are usually multiple, scattered singly or in small 
clusters throughout the superficial cortex. They are formed when the cortical 
invaginations of the ovarian surface epithelium lose their connection with the 
surface (Figure 2). There is an increased frequency of inclusion cysts (Figure 3) in 
apparently normal ovaries contralateral to ovarian cancer compared to ovaries 
from age matched women without ovarian cancer (Mittal et al, (1993). The surface 
epithelium of ovaries adjacent to epithelial ovarian cancer has a higher incidence 
of metaplastic and hyperplasic change than ovaries from healthy women (Resta et 
al, (1993).  
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 Figure 2:  Ovary micro anatomy: 1 cortex, 2 medulla, 3 area where primordial 
follicles are located, 4 primordial follicles, 5 secondary follicles, 6 tertiary 
follicles, 7 mature follicles, 8 atretic follicles. http://www.histol.chuvashia.com. all right preserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Inclusion Cyst (H&E stained): 1-4 show the invagination of the surface 
epithelium to form the inclusion cyst 
Downloaded from endo.endojournals.org at Northwestern Univ Sci-Engineering Library on August 1, 2007 
 
29 
 
1.6 Overview of Polycystic Ovary Syndrome 
 
Polycystic Ovary Syndrome (PCOS) is one of the most common hormonal 
disorders affects approximately 5 - 10 % of women in reproductive age (Aziz et al, 
2004).  
 
1.6.1 Clinical presentation 
The characteristic features are menstrual changes and androgen excess (hirsutism 
and acne). It is a heterogeneous condition in which symptoms vary from woman to 
woman. 
1.6.2 Historical aspects and diagnosis 
The association of oligo/amenorrhoea, obesity, hirsutism with enlarged ovaries 
with multiple cysts and thickened tunica was first described in 1935 by Stein and 
Leventhal (Stein et al, (1935). In 1990, a consensus workshop sponsored by NIH 
suggested the following criteria:  
 Menstrual irregularity due to oligo- or anovulation.  
 Hyperandrogenism, whether clinical (hirsutism, acne, or male 
pattern balding) or biochemical (high serum androgen 
concentrations). 
 Exclusion of other causes of hyperandrogenism and menstrual 
irregularity, such as congenital adrenal hyperplasia, androgen-
secreting tumours, and hyperprolactinemia. 
Notably, this NIH definition of PCOS did not include any criteria related to 
morphology of the ovary. However, in 2003, following a meeting of members of 
the European society of Human Reproduction and Embryology and the American 
Society of Reproductive Medicine (ESHRE /ASRM) new criteria were developed 
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to diagnose PCOS.  According to this consensus definition the Syndrome could be 
diagnosed when two or three of the following criteria were met:  
1. Oligo or anovulation. 
      2. Clinical and or biochemical signs of hyperandrogenism. 
      3. Polycystic ovaries as evidenced on ultrasound (Figure 4). 
1.6.3 Ultrasound appearance of the ovaries 
The criteria for the diagnosis of polycystic ovary morphology, using ultrasound 
were also agreed (Balen et al, 2003): 
1. The PCO should have at least one of the following: either 12 or more follicles 
measuring 2-9 mm in diameter or increased ovarian volume (>10 cm
3
). If there is 
evidence of a dominant follicle (>10 mm) or a corpus luteum (Figure 4), the scan 
should be repeated during the next cycle. 
2. The subjective appearance of PCOS should not be substituted for this definition. 
The follicle distribution should be omitted as well as the increase in stromal 
echogenicity and/or volume. Although the latter is specific to polycystic ovary, it 
has been shown that measurement of the ovarian volume is a good surrogate for 
the quantification of the stroma in clinical practice. 
3. Only one ovary fitting this definition or a single occurrence of one of the above 
criteria is sufficient to define the PCO. If there is evidence of a dominant follicle 
(>10 mm) or corpus luteum, the scan should be repeated next cycle. The presence 
of an abnormal cyst or ovarian asymmetry, which may suggest a homogeneous 
cyst, necessitates further investigation. 
4. This definition does not apply to women taking the oral contraceptive pill, as 
ovarian size is reduced, even though the `polycystic' appearance may persist. 
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5. A woman having PCO in the absence of an ovulation disorder or 
hyperandrogenism (`asymptomatic PCO) should not be considered as having 
PCOS, until more is known about the situation. 
6. In addition to its role in the definition of PCO, ultrasound is helpful to predict 
fertility outcome in patients with PCOS (response to clomiphene citrate, risk for 
ovarian hyperstimulation syndrome (OHSS), decision for in-vitro maturation of 
oocytes). It is recognized that the appearance of PCOs may be seen in women 
undergoing ovarian stimulation for IVF in the absence of overt signs of PCOS. 
Ultrasound also provides the opportunity to screen for endometrial hyperplasia. 
7. The following technical recommendations are specified: 
a) State-of-the-art equipment is required and should be operated by appropriately 
trained personnel. 
b) Whenever possible, the transvaginal approach should be preferred, particularly 
in obese patients. 
c) Regularly menstruating women should be scanned in the early follicular phase 
(days 3-5). Oligo-/amenorrhoeic women should be scanned either at random or 
between days 3-5 after a progestogen-induced bleed. 
d) If there is evidence of a dominant follicle (>10mm) or a corpus luteum, the scan 
should be repeated the next cycle. 
e) Follicle number should be estimated both in longitudinal, transverse and antero-
posterior cross-sections of the ovaries. Follicle size should be expressed as the 
mean of the diameters measured in the three sections. 
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Figure 4: Ultrasound characteristic features of PCOS: (1) Thickened capsule, (2) 
cysts (12 in total) and (3) Increase in stromal echogenicity 
www.gynaeonline.com/images/pcos.jpg 
 
1.6.4 Histopathology of Polycystic Ovary  
Typically the polycystic ovary is enlarged, two to five times the normal size with a 
white thickened cortex with multiple cysts that are typically less than 1 cm in 
diameter. 
Microscopically, the superficial cortex is fibrotic and hypocellular and may 
contain prominent blood vessels. In addition to smaller atretic follicles, there are 
an increased number of follicles with luteinized theca interna. The stroma may 
contain luteinized stroma cells (Clement et al, (1987). 
 
1. 6.5 Ovarian surface epithelial changes in PCOS 
A small number of studies have demonstrated a possible correlation between 
PCOS and ovarian cancer but the results are conflicting (Spritzer et al, 2005). 
Resta et al, (1989) in a quantitative study examined ovarian surface epithelium in 
50 women with PCOS having inclusion cysts and they were compared with 50 
women with endometrial carcinoma and 50 women without any hyperplastic or 
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neoplastic genital tract pathology. In 34 women (68%) surface papillomatosis, 
hyperplastic and metaplastic changes were present on the ovarian surface and/or in 
the inclusion cysts. These findings were similar to those observed in the group of 
women with endometrial adenocarcinoma, while the surface epithelium was often 
normal in the control group. Their observations are compatible with the hypothesis 
of a hormonal influence in the hyper plastic and metaplastic modifications of the 
ovarian epithelium and in the related common epithelial tumours of the ovary. 
 
In another study by the same author (Resta et al, 1993) sections of 200 specimens 
from hysterectomy and bilateral salpingo-oophorectomy were subjected to detailed 
histological examination.  The cases were divided into four groups: those without 
hyperplastic or neoplastic disease in the tube, uterus, or vagina; those with contra- 
lateral epithelial ovarian tumours; those with endometrial adenocarcinomas; and 
those with polycystic ovary disease. A high frequency of hyperplastic and 
metaplastic changes in the surface epithelium or in the inclusion cysts in ovaries 
with contralateral epithelial ovarian tumours (92%), endometrial adenocarcinomas 
(76%), and polycystic ovary disease (68%) compared to ovaries without hyper- 
plastic or neoplastic disease (22%) were observed. These changes were frequently 
associated with intracystic papillae and psammoma bodies similar to those 
observed in epithelial tumours (Psammoma bodies are microscopic, laminated, 
calcified, extracellular bodies). 
 
Resta et al, (1993) concluded that the hyperplastic and metaplastic changes of the 
surface epithelium and related inclusion cysts can be considered morphologic 
precursors of common epithelial tumours. Similar changes are found as a response 
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to a hormonal ovarian or extraovarian stimulus, which may play an important role 
in ovarian carcinogenesis. 
 
Schildkraut et al, in 1996 reported similar findings in case control studies designed 
to investigate the relationship between PCOS and ovarian cancer. 476 subjects 
with histologically confirmed epithelial ovarian cancer were identified from 8 
tumour registries of the Surveillance Epidemiology and End Results program. The 
study included 4081 controls ascertained via random-digit telephone dialling. All 
the candidates were aged 20-54 years. Seven subjects with ovarian cancer and 24 
controls reported that they had been diagnosed with PCOS. The risk of ovarian 
cancer was increased 2.5-fold (95% CI 1.1-5.9) among women with PCOS. This 
risk was higher in women who had never used oral contraceptives (odds ratio [OR] 
10.5, 95% CI 2.5-44.2) and women who were in the first quartile of body mass 
index (13.3-18.5) at age 18 (OR 15.6, 95% CI 3.4-71.0).  
 
An Australia-wide, population-based case-control study (Olsen et al, 2008) was 
conducted to test a hypothesis relating to the role of androgens in stimulating 
ovarian epithelial proliferation. In this study 1276 cases aged 18-79 years with a 
new diagnosis of invasive epithelial ovarian cancer or borderline malignant 
tumour. 315 were identified through a network of clinics and cancer registries 
throughout Australia. Controls (n=1508) were selected from the National Electoral 
Roll. Women self-reported a history of PCOS, acne, hirsutism or the androgenic 
medication Danazol. There was no evidence that a history of PCOS, acne or 
hirsutism was associated with ovarian cancer overall, or with specific subtypes, 
with the exception of serous borderline tumours that were associated with a history 
of PCOS. However, it is not statistically significant (OR 2.6; 95% CI 1.0-6.1). 
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1.6. 6 Management  
 
The effects of PCOS can be devastating for many patients who tend to suffer many 
psychological and physiological symptoms (hyperandrogenism or fertility 
problems or menstrual irregularity) as previously mentioned.  There is no cure for 
PCOS. However, treatment is given according to symptoms. 
1.6. 6. 1 Weight control  
Between 38% and 88% of women diagnosed with PCOS are overweight or obese 
(Legro et al, 2000 and Balen et al, 1995). It is known that weight gain is associated 
with increasing insulin resistance. Hyperinsulinemia have adverse effects in 
women with PCOS through its action at non ovarian sites. This includes increase 
the pituitary LH pulse frequency and suppression of sex hormone binding globulin 
thereby increasing the free androgen index.  
Weight control plays an important role in the improvement
 
of all PCOS symptoms.  
Kiddy et al, (1992) reported improved menstrual function in 9 of 11 patients 
(82%) with oligomenorrhoea who lost >5%
 
initial body weight (Range 5.9 to 22%) 
on a 1000 kcal/day, low-fat
 
diet over 6 to 7 months. Conversely, only 1 of 11 
patients (9%)
 
losing <5% body weight demonstrated such improvement. In the 
same study, about 40% of obese women with PCOS (mean
 
BMI ~34 kg/m
2
) who 
lost >5% of initial
 
body weight with caloric restriction achieved spontaneous 
pregnancy.  
Standtmauer et al, (2005) in a review of the management of PCOS, which included 
a Medline search between 1986 and 2005 and the Cochrane Database, concluded 
that weight loss, exercise and metformin will induce ovulation in many insulin-
resistant women and obese women with PCOS. 
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1.6. 6.2 Oral contraceptives 
Oral contraceptives which have been one of the mainstays of treatment for decades 
are usually effective in normalizing menstrual cycles.
 
Modern formulations are 
generally safer than those of years
 
past, although their use in PCOS is under 
greater
 
scrutiny with regards to their potentially detrimental effect on
 
insulin 
sensitivity. Dianette also has a higher risk of inducing venous thromboembolism 
than ‘third generation’ preparations (Diamanti-Kandarakis et al, 2003).   
1.6. 6.3 Infertility management
  
PCOS accounts for 75% of anovulatory infertility.  It is also postulated that obese 
PCOS women are at increased risk of miscarriage (Homburg et al, 1988). 
Therefore, weight loss should be encouraged (Balen et al, 2006). 
1.6. 6.3.1 Ovulation induction  
Ovulation induction with clomiphene citrate (CC) is the first-line treatment. CC is 
structurally similar to oestrogen. This similarity allows it to inhibit the action of 
oestrogen on the pituitary by binding to oestrogen receptors (ER). Since oestrogen 
can no longer effectively exert negative feedback on the hypothalamus, GnRH 
secretion becomes more pulsatile, which results in increased pituitary 
gonadotropin release. Increased FSH level causes growth of more ovarian follicles 
resulting in ovulation. 
Low-dose protocols of FSH are the second line of treatment,
 
effective in inducing 
monofollicular development. Laparoscopic
 
ovarian drilling can be an alternative 
but not as a first choice
 
treatment in clomiphene-resistant patients.  
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1.6. 6.3. 2 Wedge resection and laparoscopic ovarian drilling 
Surgical treatments for PCOS are aimed to reduce the androgen level and 
consequently restore the menstrual cycle. Although these procedures remove or 
destroy a portion of the ovaries, they generally do not impair a woman’s fertility. 
Ovarian wedge resection has been used for a long time but because of the 
significant risk of adhesion formation, it is not currently used. Since the 
development of minimally invasive surgical techniques, laparoscopic ovarian 
surgery has become feasible. The potential advantages of laparoscopic ovarian 
surgery include repeated single ovulations and less adhesion formation.  
1.6. 6.3. 3 Ultrasound-guided transvaginal ovarian interstitial laser  
Ultrasound-guided transvaginal ovarian interstitial laser treatment is considered an 
effective new method to manage ovulation in PCOS patients. It could be 
conducted as an outpatient office procedure. The ease of scheduling, reduced 
costs, and rapid recovery would suggest it as a first-line treatment for PCOS cases 
resistant to CC (Zhu et al, 2006, Badawy et al, 2009 and Zhu et al, 2009). 
 
1.7 Ovarian Cancer  
1.7.1 Clinical presentation  
Ovarian carcinoma does not cause early symptoms. As the tumour enlarges it may 
cause urinary urgency or frequency, constipation and a sense of heaviness in the 
pelvis, or dyspareunia. Malignancies of diameter >12 - 15 cm, or which initiate the 
development of ascites, cause abdominal enlargement. Other frequent symptoms 
are abdominal pain or discomfort, vaginal bleeding, bloating, dyspepsia, nausea, 
vomiting, cramps and diarrhoea. In one study (Goff et al, 2004), 22% cases were 
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referred to the surgeons because of gastrointestinal complaints. 28% of patients 
were referred with a diagnosis of pelvic mass and only 66% were referred to 
gynaecologists while the rest were referred to gastrointestinal specialists (9%), 
surgeons (9%) and occasionally to psychiatry. Ovarian cancer may present as an 
emergency because of torsion, rupture or intra-abdominal haemorrhage, though 
these are thought to be uncommon. Stages of ovarian cancer are illustrated in 
figure 5 and table 2. 
Figure 5:  FIGO stage classification for ovarian cancer (www.cancerhelp.org.uk) 
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Table 2:  FIGO staging of ovarian cancer. (www.targetovarian.org.uk) 
STAGE  1    
Tumour is confined to the ovary / ovaries 
1A  Only one ovary is affected by the tumour, the ovary capsule is 
intact 
 No tumour is detected on the surface of the ovary 
 Malignant cells are not detected in ascites or peritoneal 
washings 
1B  Both ovaries are affected by the tumour, the ovary capsule is 
intact 
 No tumour is detected on the surface of the ovaries Malignant 
cells are not detected in ascites or peritoneal washings 
1C The tumour is limited to one or both ovaries, with any of the 
following: 
 The ovary capsule is ruptured. 
 The tumour is detected on the ovary surface. 
 Positive malignant cells are detected in the ascites or 
peritoneal washings. 
STAGE 2  
Tumour involves one or both ovaries and has extended into the pelvis 
2A  The tumour has extended and/or implanted into the uterus 
and/or the fallopian tubes. 
 Malignant cells are not detected in ascites or peritoneal 
washings 
2B  The tumour has extended to another organ in the pelvis 
 Malignant cells are not detected in ascites or peritoneal 
washings 
2C  Tumours are as defined in 2A/B, and malignant cells are 
detected in the ascites or peritoneal washings  
 
STAGE 3  
The tumour involves one or both ovaries with microscopically confirmed 
peritoneal metastasis outside the pelvis and/or regional lymph node metastasis 
includes liver capsule metastasis. 
3A Microscopic peritoneal metastasis beyond the pelvis 
3B Microscopic peritoneal metastasis beyond the pelvis 2 cm or less in 
greatest dimension 
3C Microscopic peritoneal metastasis beyond the pelvis more than 2 cm 
in greatest dimension and/or regional lymph nodes metastasis 
STAGE: 4  
Distant metastasis beyond the peritoneal cavity. And, liver parenchyma 
metastasis. 
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Physical examination shows that 40 - 75% of cases have a palpable mass and 20 - 
30% detectable ascites. Only 1 - 2% will have a negative examination. The 
bimanual rectovaginal palpation of the pelvic organs is essential since it provides 
the most accurate assessment of the posterior uterine surface, the pouch of Douglas 
and the parametria. The character of the adnexal or pelvic mass is an important 
indicator of its nature. Benign ovarian tumours tend to be mobile, smooth, cystic, 
small (<10cm) and unilateral. Solid, fixed, irregular, nodular, bilateral and large 
tumours are more likely to be malignant. Paradoxically, the extremely large 
ovarian tumours are usually benign mucinous cyst adenomas. Firm diagnosis 
ultimately depends upon operative intervention. Preoperative evaluation is directed 
towards excluding other causes of a pelvic mass.  
 
1.7.2 Ovarian Cancer Screening  
Numerous studies have demonstrated the importance of preoperative serum 
CA125 measurements in identifying patients with ovarian malignancy. Falsely 
elevated CA125 levels can be associated with pregnancy, endometriosis, 
adenomyosis, benign ovarian tumours and inflammatory conditions (Roett et al, 
2009). Currently, the U.K Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) is monitoring 200,000 women between the ages of 50 and 74 based 
on two detection methods, serum CA125 and ultrasound scanning: 
 Control group ~100,000 women - no screening 
 Ultrasound scan group  ~ 50,000 women to have annual transvaginal 
scanning 
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 Multimodal group ~ 50,000 women, where annual screening using serum 
CA125 as a primary test then serum CA125 and ultrasound scanning as the 
secondary test. 
Preliminary results demonstrate the basic outcomes: 42 ovarian and tubal cancers 
were detected in the multimodal group; eight of which were borderline. 45 ovarian 
and tubal cancers were detected in the ultrasound scan group; 20 of which were 
borderline. Whether the detection of these tumours will have an effect on mortality 
rates will not be known until 2014, when the final results will be published 
(Menon et al, 2009).  
 
1.7.3 Classification of Ovarian Tumours  
The ovary is composed of a number of different cell types (surface epithelial, sex-
cord, stromal, and germ cells), and ovarian tumours are classified on the basis of 
their origin from one of these cell types as shown in the following classification 
(Table 3) (Young et al, 2005 , Ulbright  et al, 2005).  
 
1.7.4 Classification of Surface Epithelial tumours  
These tumours arise from the surface epithelium covering the ovary, which 
although not of Mullerian origin, has the potential to differentiate into a variety of 
Mullerian cell types, i.e. fallopian-tube-like epithelium (serous tumours), 
endocervical-like epithelium (mucinous tumours), endometrial-like epithelium 
(endometrioid tumours), in addition to tumours composed of clear cells (clear cell 
tumours) and transitional-type cells (most of which are Brenner tumours). In some 
tumours, the epithelial component is so poorly differentiated that it cannot be 
placed in any of the other categories and is simply diagnosed as an undifferentiated 
carcinoma. Surface epithelial tumours are further classified by the degree of 
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malignancy of the epithelial element, which is based on the degree of epithelial 
atypicality (cellular stratification, nuclear atypicality, mitotic activity) and the 
presence or absence of invasion of the fibrous stromal component by the epithelial 
component. These tumours are thus divided into benign tumours (absence of 
epithelial atypicality and invasion), tumours of low malignant potential or 
borderline malignancy (epithelial atypicality but no invasion), and carcinomas 
(epithelial atypicality and invasion) (Table 3). 
 
1.7.5 Gross Pathology of Surface Epithelial tumours  
Surface epithelial tumours are usually unilocular or multilocular cystic tumours, 
hence the diagnostic terms cystadenomas or cystadenocarcinomas. Papillary 
projections into the cystic spaces are most common in the serous tumours. The 
serous and undifferentiated carcinomas are frequently bilateral (1/3 to 1/2 of 
cases). Some of the tumours, especially the benign and borderline mucinous 
tumours, may reach enormous sizes, filling the entire pelvis or abdomen. The 
frankly carcinomatous tumours are usually focally solid, necrotic, and 
haemorrhagic. Brenner tumours differ in their gross appearance in that they are 
typically solid, tan, fibrous tumours.  
 
1.7.5.1 Serous tumours 
Serous tumours (Figure 6&7) are the most commonly found histological type, 
comprising 40 - 50% of all primary ovarian cancers (Silverberg et al, 2000). They 
tend to be large tumours and the majority exhibit mixed papillary and cystic 
characteristics, with multiple friable papillary masses and solid nodules. The fluid 
within the cyst tends to be watery, thin and straw-coloured; however in up to 28%  
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Cancer type 
Percentage 
of all 
ovarian 
cancers Characteristics 
Epithelial cell 85 to 95 Most common in patients older than 50 years; 
15 percent of epithelial cell ovarian cancers are 
borderline or have low malignant potential, with 
a 10-year survival rate up to 99 percent for 
stage I 
Serous 40 percent of all ovarian cancers; most common 
ovarian cancer 
Endometrioid 20 percent of all ovarian cancers; 15 percent of 
endometrioid carcinomas coexist with 
endometriosis; 40 percent bilateral 
Mucinous 25 percent of all ovarian cancers; origin 
unclear; may occur in association with 
endometriosis; associated with pseudomyxoma 
peritonei  
Stromal cell 5 to 8 Derived from the sex cord of embryonic gonads 
Granulosa-theca Wide age range; may produce precocious sexual 
development in prepubertal girls; may be 
associated with endometrial hyperplasia, cystic 
disease of the breast, and endometrial 
carcinoma in adults; ascites in 40 percent of 
fibroma and thecoma tumours; may be 
associated with ascites and hydrothorax (Meigs 
syndrome) 
Sertoli-Leydig 
(androblastomas) 
Common in adolescence; may be masculinising; 
may block normal female sexual development 
Germ cell 3 to 5 Found mostly in children and young adults 20 to 
30 years of age; highly malignant; usually 
unilateral 
Endodermal 
sinus tumour 
Most common germ cell ovarian cancer in 
children; usually larger than 15 cm; median age 
of patients is 18 years, one third of patients are 
premenarchal 
Embryonal 
(multipotential) 
Extra embryonic: yolk sac carcinoma 
  embryonal carcinoma (highly malignant), 
precocious puberty 
  Somatic: immature teratoma 
  Trophoblast: choriocarcinomas 
  Undifferentiated: dysgerminomas (most 
common malignant germ cell ovarian cancer), 
10 to 20 percent bilateral, radiosensitive 
Mature Mostly benign, dermoid cysts 
Metastasis to 
ovaries 
(Krukenberg 
tumour) 
5 percent Typically from breast or gastrointestinal  
Table 3: Classification of Ovarian Tumours (Roett et al, 2009) 
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of cases it is viscous and mucoid. About 8% of serous tumours are solid 
adenocarcinomas (Malpica et al, 2004). 
 
 
Figure 6: Ovarian serous papillary tumour 
Ovarian serous tumours are bilateral in 35-50% of cases and are associated with 
rapid spread, leading to widespread tumour metastases within the peritoneal 
cavity, and marked ascites formation.  Consequently, they normally have a poor 
prognosis (Silverberg et al, 2000). 
 
Serous tumours are composed of cells resembling the surface epithelium of the 
ovary or fallopian tubal mucosa. Nuclei are large, vesicular and have prominent 
nucleoli. Size and number of nucleoli increases with histological grade. Rounded 
hyaline globules similar to those seen in endodermal sinus tumours are often 
present. Small, laminated psammoma bodies are frequently found in papillary 
serous tumours.  
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Figure 7: Ovarian papillary serous cystadenocarcinoma (high magnification); the 
ovary is lined by tall columnar, ciliated epithelial cells and are filled with clear 
serous fluid. http://en.wikipedia.org/wiki/File:Ovarian_serous_adenocarcinoma_(3).jpg 
  
1.7.5.2 Mucinous tumours 
Mucinous carcinomas account for 15% of primary ovarian   malignancies and are 
bilateral in only 10% of cases; Mucinous tumours (Figures 8 & 9) histologically 
resemble endocervical epithelium.
 
They tend to be the largest epithelial ovarian 
neoplasm, with
 
a median diameter of 18 to 20 cm, but tend to remain confined
 
to 
the ovaries. Pseudomyxoma peritonei, a clinical syndrome
 
characterized by 
accumulation of a gelatinous ascites, may be
 
present. Furthermore, primary 
ovarian mucinous tumours can be
 
difficult to distinguish from metastatic mucinous 
tumours from
 
the appendix, colon/rectum, cervix, or pancreas. Primary tumours
 
tend to be large and unilateral (Danijela et al, 2011 and Khunamornpong et al, 
2006).  
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Figure 8: Ovarian  mucinous cystoadeno carcinoma (Macroscopic view)  
 
 
 
Figure 9: Ovarian  mucinous cystoadeno carcinoma (Microscopic view) 
http://www.webpathology.com/image.asp?n=14&Case=526 
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1.7.5.3 Endometrioid tumours 
Endometrioid ovarian tumours (Figures 10 & 11) have features of one or more of 
the typical forms of endometrial neoplasia. Histogenesis is possibly from the 
epithelium of antecedent endometriosis or from the surface epithelium of the 
ovary. They account for 16-30% of all ovarian malignancies and vary in size from 
2 to 35 cm. Endometrioid tumours tend to be less cystic than serous or mucinous 
tumours, but they often exhibit solid nodular areas of yellowish to dark red tissue 
alternating with cysts. Intracystic papillary projections are infrequent but, when 
present, papillae are blunt and broad rather than finely branched as in serous 
tumours.  
 
Dark haemorrhagic fluid may indicate its origin from an endometriotic cyst. While 
psammoma bodies are rare, squamous metaplasia is characteristic of endometrioid 
tumours. Ovarian endometrioid carcinoma has ultra structural features similar to 
those of well-differentiated adenocarcinoma of the endometrium. Indeed, ovarian 
endometrioid carcinoma is commonly associated with carcinoma or hyperplasia of 
the endometrium; up to 20% of women with endometrioid ovarian tumours also 
have a uterine endometrial malignancy. Up to 33% of endometrioid ovarian 
malignancies are bilateral and 5-year survival for patients with tumours is around 
50%. Ovarian endometriosis is present in up to 17% of cases while pelvic 
endometriosis has been reported in up 28% of patients (Storey et al, 2008). 
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Figure 10: Ovarian endometrioid tumour (Macroscopic view)   
 
Figure 11:   Ovarian endometrioid tumour (Microscopic view) 
http://www.webpathology.com/image.asp?case=527&n=13 
 
1.7.5. 4 Clear cell tumours 
These account for 5 - 10% of all epithelial ovarian malignancies. The histogenesis 
is generally accepted as Müllerian in nature, derived from remnants of the 
embryological paramesonephric duct system. Histologically identical clear cell 
tumours arise in the cervix, vagina and endometrium. These tumours normally 
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exceed 15cm in size and consist of a mixture of cystic and solid areas. Bilaterality 
is rare. Ovarian or pelvic endometriosis has been demonstrated in up to 25% of 
patients with clear cell ovarian tumours. 
 
Figure 12: Ovarian clear cell carcinoma (Microscopic view)   
 
Microscopically (Figure 12), clear cell carcinoma exhibits abundant clear or 
vacuolated cell cytoplasm containing glycogen. Clear cells are usually mixed with 
other cell types. They have abundant hyaline material in papillary areas. These 
cells have marked nuclear pleomorphism and scattered large hyperchromatic, 
bizarre cells. They also have a marked infiltrate of inflammatory lymphoid cells. 
Clear cell carcinomas tend to have
 
a higher percentage of stage I disease than 
advanced stage disease.
 
This suggests that clear cell carcinomas may have more 
symptoms
 
when confined to the ovary and are therefore more easily diagnosed
 
at 
an early stage, or that they have a lower propensity for
 
spread. In support of the 
former theory, clear cell carcinomas
 
may be associated with a large pelvic mass. 
Recurrences
 
are more frequent than with other histologies (Danijela et al, 2011, 
Pectasides et al, 2006, Behbakht et al, 1989). 
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1.7.6 Epidemiology of Surface Epithelial tumours 
1.7.6.1 Nulliparity 
Nulliparity appears to be associated with an increased risk of ovarian cancer. 
McGowan reported a 2.5-fold increased risk of ovarian cancer in women without 
children (McGowan et al, 1988, McGowan et al, 1979 and Fathalla et al, 1971). 
 
Hildreth et al,(1981) in a case-control study examining reproductive factors and 
ovarian cancer, studied 62 cases of ovarian cancer and 1068 controls between the 
ages of 45 and 74 years. Women with history of previous cancer of the breast or 
female reproductive tract and controls who had had their ovaries removed were 
excluded from the study. The findings revealed that women who remained 
voluntarily nulliparous had a 1.7-fold increased risk of ovarian cancer (95% CI 0.9 
- 3.1), whilst if nulliparity was involuntary (i.e. in infertile patients) there was a 2-
fold increase in risk (95% CI 1.0 - 4.1). Furthermore, the greater the number of 
pregnancies experienced by a woman, the lower was her risk of ovarian 
malignancy.  
 
It has also been reported that late age of menopause increases the risk of ovarian 
cancer. This effect is directly related to the years of ovulation experienced; the 
odds ratio (OR) for ovarian cancer being 1 in those who ovulate for less than 25 
years versus 4.5 in those who ovulate for more than 40 years. Conversely, the risk 
of ovarian cancer is unaffected by the age of menarche (OR 0.5, 95% CI 0.2 - 1.5). 
The use of the oral contraceptive pill (OCP) is associated with a reduced risk of 
ovarian cancer (Booth et al., 1989) 
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The findings further revealed that nulliparity was associated with an 8-fold 
increased risk of ovarian cancer (95% CI, 1.5 - 73.4). The large 95% confidence 
interval reflects the small sample sets analysed in this study which, to a degree, 
reduces confidence in its risk estimates. Further limitations include its 
retrospective design and the low response rates.  Additionally, the authors 
suggested that pregnancy at an early age is protective, but this apparent effect 
could not be separated from the protective effect of increasing number of 
pregnancies, due to sample size limitations. 
 
Nevertheless, similar findings were reported in Mosgaard et al, (1997) case-
control study. That study assessed the risk of invasive ovarian cancer among 684 
infertile Danish women (below the age of 60 years) with ovarian cancer during the 
period from 1989 to 1994 and 1,721 age-matched controls. Nulliparous women 
had an increased risk of ovarian cancer compared with parous women: OR 1.5 to 
2.0. Infertile, untreated nulliparous women had an OR of 2.7 (1.3 to 5.5) compared 
with non infertile nulliparous women. The OR of ovarian cancer among treated 
nulliparous women was 0.8 (0.4 to 2.0) and among treated parous 0.6 (0.2 to 1.3), 
compared with untreated nulliparous and parous infertile women, respectively. 
 
Mosgaard et al. (1997) concluded that nulliparity confers a 1.5- to 2-fold increased 
risk of ovarian cancer. It was further stated that infertility without medical 
treatment among these women increased the risk. Among parous as well as 
nulliparous women, treatment with fertility drugs did not increase the ovarian 
cancer risk compared with untreated infertile women.  
 
 
52 
 
1.7.6.2 Ovulation Induction 
The first report of invasive ovarian epithelial cancer associated with ovulation 
induction was presented by Bamford et al, (1982). A 32 years old woman with 
primary infertility had a history of eight cycles of ovulation induction using hCG 
in one year and another three cycles using FSH and LH later on. Ovulation was 
achieved in all these attempts. During the last cycle the left ovary was found to be 
slightly enlarged. Pelvic ultrasonography demonstrated bilateral ovarian cysts. At 
the end of that cycle she suffered heavy vaginal bleeding. At that stage a palpable 
left ovarian cyst was noted and arrangement was made to review the patient after 
one month. Three weeks later, she presented with sudden onset lower abdominal 
pain and tender mass arising to the umbilicus. Emergency laparotomy was 
performed to reveal a left ovarian mass (25 cm in diameter). The right ovary was 
approximately 3 cm in size. Total hysterectomy and right salpingecto-
oophrectomy was performed one week later. The histology confirmed 
endometrioid tumour with encroachment of the capsule. The uterus showed 
endometrial hyperplasia which was adenomatous and atypical in areas in 
conjunction with a well differentiated adenocarcinoma which extended to the 
superior parts of the endocervical canal. The right tube and ovary were free of 
tumour but there was evidence of stromal hyperplasia and cystic follicle formation. 
These findings suggest neoplastic changes. Similar findings were reported in three 
other cases of ovarian carcinoma associated with fertility drugs. Two patients were 
hyperstimulated by clomiphene citrate. The third had hMG + CC. Two of these 
patients had a borderline ovarian carcinoma and the third had an invasive ovarian 
carcinoma associated with endometrial carcinoma (Abboud et al, 1997). 
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Another case was reported by Bandera et al, (1995) with similar history but with 
poorer outcome. That woman was diagnosed with stage 1C grade 1 mucinous 
epithelial ovarian cancer and died of recurrent disease shortly after receiving 
gonadotrophin therapy for ovulation induction. Over three years she underwent 
two cycles of ovulation induction with exogenous gonadotrophins five months 
after the second cycle. The patient presented with bowel obstruction and extensive 
recurrence of the disease. Two months later, she died despite extensive surgical 
debulking and chemotherapy. Hull et al, (1996) presented a 40-year-old woman 
who complained of secondary infertility. She conceived after five cycles of human 
menopausal gonadotropins with intrauterine insemination. Eight months after 
delivery, she presented with right lower quadrant pain and a right adnexal mass. At 
exploratory laparotomy, the patient was found to have a poorly differentiated 
papillary serous carcinoma of the ovary.  
 
In a retrospective cohort study by Brinton et al, (2004) to assess the risk of cancer 
among infertile patients, 12,193 women with infertility problems were recruited 
for the study during the period of 1965-1988 at five clinical sites, 45 women were 
diagnosed with ovarian cancers during follow-up appointments. Standardized 
incidence ratios (SIR) were used to report the risk of cancer among the infertile 
patients to the general population, whereas analyses within the cohort allowed the 
derivation of rate ratios for fertility drug usage compared with no usage after 
adjustment for other ovarian cancer risk factors. The infertility patients had a 
significantly elevated ovarian cancer risk compared with the general population 
(standardized incidence ratio 1.98, 95% CI 1.4, 2.6). However, the rate was not 
significantly increased after adjusting for patient demographics and known risk 
factors within the infertile women, (0.82 (95% CI 0.4, 1.5) for CC and 1.09 (95% 
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CI 0.4, 2.8) for gonadotrophins. There were higher, albeit non significant, risks 
with follow-up time, with the rate ratios after 15 or more years being 1.48 (95% CI 
0.7, 3.2) for exposure to CC (5 exposed Cancer patients) and 2.46 (95% CI 0.7, 
8.3) for gonadotrophins (3 exposed Cancer patients). Although drug effects did not 
vary by causes of infertility, there was a slightly higher risk associated with CC 
use among women who remained nulligravid, based on 6 exposed patients (rate 
ratio 1.75; 95% CI 0.5, 5.7).  
Another study was conducted with women who had undergone in-vitro-
fertilisation (IVF) to investigate the incidence of invasive cancer of the breast, 
ovary, and uterus in relation to the cause of infertility or exposure to fertility drugs 
to induce super ovulation was associated with an increased risk (Venn et al, 1999). 
The cohort consisted of 29,700 women: 20,656 were exposed to fertility drugs and 
9044 were not. 143 breast cancers, 13 ovarian cancers, and 12 cancers of the uterus 
were detected among these women. Women who had been exposed to fertility 
drugs seem to have a transient increase in the risk of having breast or uterine 
cancer diagnosed in the first year after treatment, although the incidence overall 
was not significant. Unexplained infertility was associated with an increased risk 
of ovarian or endometrial cancer.  
In another population based cohort, Jensen et al, (2009) examined the effects of 
fertility drugs and risks of ovarian cancer. 54,362 women with infertility problems, 
156 women with invasive epithelial ovarian cancer (cases) and 1241 sub cohort 
members identified in the cohort during follow-up in 2006. Analyses within cohort 
showed no overall increased risk of ovarian cancer after any use of gonadotrophins 
(rate ratio 0.83, 95% CI 0.50 to 1.37), clomifene (1.14, 0.79 to 1.64), human 
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chorionic gonadotrophin (0.89, 0.62 to 1.29), or gonadotrophin releasing hormone 
(0.80, 0.42 to 1.51).  
 
Similarly, Silva Idos et al. (2009) examined the long-term health effects of ovarian 
stimulation drugs for over 20 years in a British cohort of 7355 women with 
ovulatory disorders. 43% of were prescribed ovarian-stimulation drugs. Total of 
274 deaths and 367 incident cancers. Relative to the general population, the cohort 
experienced lower mortality from most causes, including from all neoplasms 
combined, and lower incidence of cervical cancer, but higher incidence of cancers 
of the breast (relative risk: 1.13; 95% CI 0.97, 1.30) and corpus uteri (2.02; 1.37, 
2.87). There were no significant differences in the risk of cancers of the breast, 
corpus uteri, ovary, or of any other site, between women who had been prescribed 
ovarian-stimulation drugs and those who had not. 
 
In summary, a great many studies have been performed to assess a possible 
association between fertility drugs and ovarian cancer risk (Table 4), infertility and 
ovarian cancer risk (Table 5), case–control studies exploring the association between 
infertility and ovarian cancer risk (Table 6), case–control studies investigating the 
association between fertility drugs and ovarian cancer risk (Table 7). 
 
Although the results of some of these studies are to some degree contradictory, the 
balance of evidence suggests that infertility appears to increase the risk of ovarian 
cancer but this is true only for those women who do not eventually conceive. This 
increased risk is eliminated if pregnancy is achieved irrespective of the duration of 
the preceding subfertility. Nulliparous women are at an increase risk of developing 
ovarian cancer; where this is by choice the risk is half of that compared to those 
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with infertility. The cause of infertility does not seem to have a particular effect on 
the risk of ovarian cancer.  
In summary, overall the literature suggests that fertility drugs do not increase the 
risk of ovarian malignancy. 
 
Authors Population No. of ovarian cancers Standardized incidence ratios (95% CIs) vs. 
general population 
 
Rossing et al. 
1994 
3837 11 No drug 1.4 (0.2–5.0) 
Clomiphene 3.1 (1.4–5.9) 
hMG/FSH 5.6 (0.1–31.0) 
Modan et al. 
1998 
2496 12 No drug 1.6 (0.6–3.5) 
All treatments 1.7 (0.6–3.8) 
Clomiphene 2.7 (0.9–5.8) 
Doyle et al. 2002 5556 6 No treatment 1.7 (0.2–6.0) 
Treatment 0.6 (0.2–2.2) 
Brinton et al. 
2004 
12,193 45 No clomiphene 2.1 (1.4–3.0) 
Clomiphene 1.8 (1.0–3.0) 
Klip et al. 2002 23,592 15 No IVF 1.4 (0.4–3.2) 
IVF 1.4 (0.7–2.6) 
Table 4: Selected cohort studies studying the association between fertility drugs 
and ovarian cancer risk 
 
 
 
 
Authors Population No. of 
ovarian 
cancer 
Standardized incidence ratios (95% CIs) vs. 
general population 
 
Brinton et al. 
1989 
2335 11 Evaluated for infertility 1.28 (not given) 
Modan et al. 
1998 
2496 12 Infertility patients treated 1.6 (0.8–2.9) 
Venn et al. 1999 29,700 13 IVF patients evaluated 0.99 (0.57–1.70) 
Potashnik et al. 
1999 
1197 2 Evaluated for infertility 0.91 (0.1–3.27) 
Rossing et al. 
1994 
3837 11 Evaluated for infertility 2.5 (1.3–4.5) 
Brinton et al. 
2004 
12,193 45 Evaluated for infertility 1.98 (1.4–2.6) 
Table 5: Selected cohort studies studying the association between infertility and 
ovarian cancer risk 
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Authors No. of 
cases 
No. of 
controls 
Comparison OR (95% CI) 
Whittemore 
et al. 1992 
2197 8893 12 US case–control studies 
(1956–1986) 
Nulligravid: 1.4 (0.86–0.23) 
Gravid: 0.87 (0.67–1.1) 
Ness et al. 
2002 
5207 7705 Eight case–control studies 
(1989–1999) 
Nulligravid: 1.1 (0.91–1.55) 
Gravid: 1.1 (1.02–1.31) 
Table 6: Case control studies studying the association between infertility and 
ovarian cancer risk 
Authors No. of 
cases 
No. of 
controls 
Comparison OR (95% CI) 
Shu et al. 1989 229 229 Drugs vs no drugs use 2.1 (0.2–22.7) 
Whittemore et al. 
1992 
718 1236 Fertility drugs use vs no 
infertility 
2.8 (1.3–6.1) 
Franceschi et al. 1994 195 1339 Drugs vs no drugs use 0.7 (0.2–3.3) 
Ness et al. 2002 149 911 Drugs vs no drugs use 0.93 (0.7–1.2) 
Parazzini et al. 1997 971 2758 Drugs vs no drugs use 1.1 (0.4–3.3) 
≥6 cycles 1.0 (0.2–3.8) 
Table 7: Case control studies studying the association between fertility drugs and 
ovarian cancer risk 
 
 
 
1.7.7 Ovarian cancer pathogenesis 
The cell of origin of epithelial ovarian cancer has been long debated. The 
traditional view of ovarian tumours was that it derived from the ovarian surface 
epithelium and subsequent metaplastic changes leading to the development of the 
different cell types namely the serous, endometroid, clear cell, mucinous and 
transitional cell which morphologically resemble the epithelia of the fallopian 
tube, endometrium, gastrointestinal tract or endocervix and urinary bladder. 
Fathalla et al, (1971) postulated that ovulation causes a minor trauma on the 
epithelial surface, and the recurrent surface epithelial trauma contributes to the 
pathogenesis of ovarian cancer. To explore Fathalla`s theory Kosec et al, (1999) 
studied transvaginal colour Doppler ultrasonography screening for early stage 
ovarian cancer in 110 asymptomatic women who received an ovulation induction 
therapy for infertility. Seven subjects had abnormal ovarian findings. One 
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underwent surgery for a benign cyst and one was diagnosed with early stage 
ovarian malignancy.  
However, recent morphologic, immunohistochemical, and molecular genetic 
studies have led to the development of a new theory for the pathogenesis and 
origin of epithelial ovarian cancer based on a dualistic model of carcinogenesis 
that divides epithelial ovarian cancer into two broad categories designated types I 
and II. Type I tumours comprise low-grade serous, low-grade endometrioid, clear 
cell and mucinous carcinomas, and Brenner tumours. They are generally present in 
stage I (tumour confined to the ovary), and are characterized by specific mutations, 
including KRAS, BRAF, ERBB2, CTNNB1, PTEN, PIK3CA, ARID1A, and 
PPP2R1A, which target specific cell signalling pathways. Type I tumours rarely 
harbour TP53 mutations and are relatively stable genetically. Type II tumours 
comprise high-grade serous, high-grade endometrioid, malignant mixed 
mesodermal tumours (carcinosarcomas), and undifferentiated carcinomas. They 
are aggressive, present in advanced stage, and have a very high frequency of TP53 
mutations but rarely harbour the mutations detected in type I tumours. In addition, 
type II tumours have molecular alterations that perturb expression of BRCA either 
by mutation of the gene or by promoter methylation. A hallmark of these tumours 
is that they are genetically highly unstable (Kurman et al, 2011). 
In the review by Crum et al, (2007) , they concluded that a significant percentage 
of tumours currently classified as ovarian and primary peritoneal carcinoma are 
associated with, and genetically related to, an early serous carcinoma in the 
fallopian tube.  
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In that respect, Kindelberger et al (2007) surveyed a consecutive series of pelvic 
serous carcinomas in which the entire tubal epithelium was analyzed. They found 
that after exclusion of primary fallopian tube carcinomas, approximately half of 
serous carcinomas co-existed with an intraepithelial carcinoma of the fimbria. 
They went on to demonstrate that in all cases, the early tubal cancer was 
genetically identical (based on p53 mutation status) to the ovarian or peritoneal 
tumour component – compelling evidence that the two are causally related. 
 
Seidman et al., (2010) highlighted the significance of fimbrial tubal epithelium in 
the origin of serous ovarian carcinomas. They studied 613 junctional foci in 228 
fallopian tube specimens from 182 patients who underwent surgery for a variety of 
indications, including 27 risk-reducing salpingo-oophorectomy specimens. 
Transitional metaplasia was found at the junction (Figure 13) in 20% of patients 
and mesothelial hyperplasia in 17%. Inflammation at the junction was seen 
predominantly in patients with salpingitis, torsion, or tubal pregnancy. Ovarian-
type stroma was found at the junction in 5% of patients, and was found elsewhere 
in the tubal lamina propria in an additional 27% of patients.  
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Figure 13: The Fallopian Tube-Peritoneal Junction.   
The junction is tortuous with tongues of mesothelium extending for variable distances from the 
serosa at the outer edges of the fimbriae, onto the fimbrial plicae joining the tubal epithelium at 
various points along and between fimbrial plicae and at the plical tips . 
 
A recent study by Kurman et al. (2010) strongly suggest that fallopian tube 
epithelium (benign or malignant) that implants on the ovary is the source of low-
grade and high-grade serous carcinoma rather than the ovarian surface epithelium 
as initially postulated (Figure 14).  
 
Similarly, it is widely accepted that endometriosis is the precursor of endometrioid 
and clear cell carcinomas and, as endometriosis is thought to develop from 
retrograde menstruation. These tumours can also be regarded as involving the 
ovary secondarily. The origin of mucinous and transitional cell (Brenner) tumours 
is still not well established, although a possible origin from transitional epithelial 
nests located in paraovarian locations at the tuboperitoneal junction.  
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Thus, it now appears that type I and type II ovarian tumours develop 
independently along different molecular pathways and that both types develop 
outside the ovary and involves it secondarily. If this concept is confirmed, it leads 
to the conclusion that the only true primary ovarian neoplasms are gonadal stromal 
and germ cell tumours analogous to testicular tumours. This new paradigm of 
ovarian carcinogenesis has important clinical implications. By shifting the early 
events of ovarian carcinogenesis to the fallopian tube and endometrium instead of 
the ovary, prevention approaches, for example, salpingectomy with ovarian 
conservation may play an important role in reducing the burden of ovarian cancer 
while preserving hormonal function and fertility. 
 
Piek et al. (2001) in a Dutch study investigating the occurrence of preneoplastic 
lesions in overtly normal fallopian tubes from women predisposed to developing 
ovarian carcinoma, had similar conclusions. The presences of preneoplastic lesions 
were scored in histological specimens from 12 women with a genetically 
determined predisposition for ovarian cancer, of whom seven tested positive for 
BRCA1 mutation. When compared to a control group of 13 healthy women, all the 
results were normal. Immunohistochemistry was used to determine the expression 
of p21, p27, p53, Cyclin A, Cyclin D1, bcl-2, Ki67, HER-2/neu, and the oestrogen 
and progesterone receptors. Loss of heterozygosity analysis on the BRCA1 locus 
was also assessed in dysplastic tissue by polymerase chain reaction (PCR) studies. 
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Figure 14: Transfer of normal tubal epithelium to the ovary. A. Anatomical 
relationship of fallopian tube to the ovary at the time of ovulation. The fimbria 
envelops the ovary. B. Ovulation. The ovarian surface ruptures with expulsion and 
transfer of the oocyte to the fimbria. The fimbria is in intimate contact with the 
ovary at the site of rupture. C. Tubal epithelial cells from the fimbria are dislodged 
and implant on the denuded surface of the ovary resulting in the formation of an 
inclusion cyst. 
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Of the 12 women with a predisposition for ovarian cancer, six showed dysplasia, 
including a severe case. Five harboured hyperplastic lesions and in one woman, no 
histological aberrations were found in the Fallopian tube. No hyperplastic, 
dysplastic or neoplastic lesions were detected in the Fallopian tubes of control 
subjects. In the cases studied, morphologically normal tubal epithelium contained 
a higher proportion of Ki67-expressing cells (p=0.005) and lower fractions of cells 
expressing p21 (p<0.0001) and p27 (p=0.006) than in the control group. Even 
higher fractions of proliferating cells were found in dysplastic areas (p=0.07) and 
accumulation of p53 was observed in the severely dysplastic lesion. Expression 
patterns of other proteins studied, including the hormone receptors, were similar in 
both groups. However, one subject, BRCA1 mutation carrier, showed loss of the 
wild-type BRCA1 allele in the severely dysplastic lesion.  
 
The conclusion was that the Fallopian tubes of women predisposed to developing 
ovarian cancer frequently harbour dysplastic changes, accompanied by changes in 
cell-cycle and apoptosis-related proteins, indicating an increased risk of 
developing tubal cancer.  
 
Approximately 10% of EOCs are associated with inheritance of an autosomal 
dominant genetic aberration which leads to cancer predisposition with a high 
penetrance (Boyd et al, 2003). Inheritance of a deleterious mutation in one of 
BRCA genes is associated with a 45% to 80% life time risk of breast cancer and 
27% to 44% life time risk of ovarian cancer (Jelovac et al, 2011).  
The exact cells of origin for BRCA associated ovarian cancer is yet to be identified. 
However, the most common premalignant pathologic findings in risk reducing 
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salpingo-oophorectomy specimens from BRCA mutation carriers are in the distal, 
fimbriated end of the fallopian tube (Crum et al, 2009).  
Deligdisch et al, (1999) examined slides of ovarian tissue of 54 women. All had a 
family history of ovarian carcinoma; 44 women were BRCA positive, 31 women 
underwent prophylactic oophorectomy and 23 underwent oophorectomy for 
ovarian carcinoma. Normal, dysplastic, and ovarian carcinoma epithelial cells 
were analysed morphometrically combining nuclear area measurements with 
chromatin texture assessment using a novel method based on the computation of 
autocorrelation coefficients and a derived parameter. Discriminate analysis 
between classificatory algorithms was used to obtain results. Ovarian dysplasia 
was identified in 77.6% of the prophylactic oophorectomy specimens. Another 
study by Diniz et al, (2011) where thirty-four cases of serous pelvic carcinoma 
with clinical presentations suggesting an ovarian origin was analyzed. Histological 
samples of fallopian tube tissues were analyzed. Probable primary sites, types of 
tubal involvement, tissues involved in the neoplasia and vascular involvement 
were evaluated. Fallopian tube involvement was observed in 24 (70.6%) of 34 
cases. In 4 (11.8%) of these cases, an intraepithelial neoplasia was present, and 
therefore these cases were hypothesized to be primary from fallopian tubes. For an 
additional 7 (20.6%) cases, a fallopian tube origin was considered a possible 
primary. It was concluded that fallopian tubes can be the primary site for a subset 
of pelvic high-grade serous carcinomas. 
 
Ovarian dysplasia has been established as a histological entity based on 
microscopic and morphometric criteria. These changes have been considered 
important in pathogenesis of EOC but this theory is now controversial. Chêne et 
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al, (2009) conducted a retrospective cohort study using specimens from 90 patients 
who had undergone bilateral oophorectomy or ovarian cystectomy; 28 
prophylactic oophorectomies for genetic predisposition to ovarian cancer and 62 
controls- fertile with no malignancy between 1992 and 2005 and whose ovaries 
were reported as normal. The ovaries were analysed and reviewed by four 
pathologists blinded to the clinical data. An ovarian dysplasia score based on 
eleven epithelial cytological and architectural features was devised to quantify 
extent of ovarian epithelial abnormalities. The results showed a higher mean 
dysplasia score in the prophylactic oophorectomies than in the controls (9.67 vs 
4.19, P < 0.001). There was a gradation in the severity of the dysplastic lesions 
between proven BRCA mutations and prophylactic oophorectomies without 
mutations (11.26 vs. 8.1) and according to age (10.27 > 50 years vs. 8.6 before age 
50 years, P = 0.2962). 
 
Corakci et al, (2005) evaluated the effects of ovulation induction on Ki67 
expression and dysplasia scores of female rat ovaries. Twenty female rats were 
randomized either to receive 150 iu human menopausal gonadotropin on oestrous 
day 2 and 75 iu hMG on the day of preoestrous (induction group, n= 10) or saline 
as placebo on the corresponding days (control group, n= 10). After five oestrous 
cycles bilateral oophorectomy was performed to compare the Ki67 expression and 
dysplasia score of the ovarian epithelium. The mean number Ki67 positive cells 
was 159.6 +/- 101.92 in the follicles, 283.4 +/- 42 in the corpus luteum , and 151 
+/- 75.1 in the stroma of the study group compared to 41.8 +/- 35.6 (p 0.03), 43.2 
+/- 28.3 (p 0.007), and 55.6 +/- 18.6 (p 0.01), respectively, in the control group. 
The mean number and rate of cells that stained positive for Ki67 in the epithelium 
was significantly higher in the ovulation induction group (758 +/- 71 and 63 +/- 
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1.6%, respectively) compared to the control group (386 +/- 23, p < 0.001; and 60 
+/- 1.1%, p< 0.001; respectively). The mean dysplasia score was significantly 
higher (9.6 +/- 1.3) in the study group compared to the control group (5.08 +/- 0.9, 
p< 0.001). The results showed that ovulation induction in rats results in increased 
Ki67 expression and dysplastic features in the ovarian epithelial cells. 
 
Brewer et al, (2004) investigated putatitive preneoplastic changes in the ovary. 
Ovaries were collected from 10 low-risk women, from seven high-risk women and 
from three women with ovarian cancer.  Five micron sections were cut and 
haematoxylin and eosin stained. High-resolution images were recorded from the 
epithelium lining inclusion cysts and from the underlying stroma of ovaries from 
these 20 subjects. A total of 2860 epithelial nuclei and 3610 stromal nuclei were 
recorded. Karyometric features and nuclear abnormality were computed. 
Discriminate analyses and unsupervised learning algorithms defined deviations 
from normal that were designated "above threshold" and used to compute average 
nuclear abnormality of a second nuclear phenotype. Histologically normal 
epithelium from inclusion cysts of ovaries harbouring a malignant lesion was 
shown to exhibit changes in the nuclear chromatin pattern that were statistically 
significant using quantitative image analysis procedures. Similar changes were 
seen in the inclusion cyst epithelia of high-risk ovaries. A subpopulation of cells 
representing a new phenotype was detected in the underlying stroma of women 
harbouring a malignant ovarian lesion and in women at high risk of ovarian 
cancer. Brewer et al, (2004) concluded that the karyometric changes observed in 
the epithelium lining inclusion cysts and in the underlying stroma of ovaries, either 
with ovarian cancer or at high risk of ovarian cancer, suggest the presence of 
preneoplastic changes in histologically normal tissue. 
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Okamura et al, (2001) assessed specific changes in the architecture and in the 
cytological characteristics of human ovarian epithelial cells on the surface and 
within inclusion cysts. Normal ovaries were retrieved from 215 patients 
undergoing incidental oophorectomy and 33 patients with contralateral ovarian 
tumours. In addition, 75 patients diagnosed with epithelial ovarian cancer and 26 
ovarian endometriosis patients undergoing oophorectomy were selected. The 
incidence of cortical invasion, epithelial papillomatosis and pseudo stratification 
was no different in normal ovaries of pre- and post-menopausal women, whereas 
inclusion cysts were more frequently observed in post-menopausal women 
(p<0.05). The prevalence of invagination and inclusion cysts were significantly 
higher in normal ovaries examined after incidental oophorectomy (p<0.05) and in 
those with contralateral ovarian tumours (p<0.05), respectively.  
 
Although serous metaplastic change with cilia was most common and did not 
differ before and after menopause, the frequency of mucinous, endometrioid and 
transitional cell changes were low in the two groups of pre- and post-menopausal 
women. Mucinous metaplasia was more frequently observed in patients with 
contralateral ovarian tumours than those without ovarian tumours (12.1% vs. 
1.9%; p<0.05). Four out of 75 ovarian cancer patients revealed malignant 
transformed cells from a single layer of normal epithelium covering the ovarian 
surface or inclusion cyst. Ovarian or extra ovarian endometriosis was identified in 
16 out of 75 epithelial ovarian cancer patients analyzed. In situ carcinogenesis in 
an endometriotic cyst was seen in three epithelial ovarian cancers. In seven out of 
26 ovarian endometriosis cases, epithelial cells on the ovarian surface or within the 
inclusion cyst were histologically changed to endometriotic gland cells. Careful 
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and extensive observations of surgical specimens with ovarian carcinoma and 
ovarian endometriosis showed that they originated from the ovarian epithelium 
lining the surface and cortical small cysts. 
 
Feeley et al, (2001) suggested that the exposure of the mesothelial lining of an 
inclusion cyst to the ovarian stromal microenvironment may be responsible for the 
phenotypic change to Mullerian epithelium commonly seen in these cysts. 
Mullerian metaplasia is usually serous phenotype, and it is possible that undefined 
molecular events occurring in an inclusion cyst that has undergone Mullerian 
metaplasia may initiate neoplastic change in these cysts. This may be the 
developmental pathway of most invasive serous carcinomas. Occasional rare cases 
of ovarian intraepithelial neoplasia, manifested by epithelial atypia in an inclusion 
cyst or on the surface epithelium without invasive carcinoma, are identified 
histologically.  
1.8 PCOS and ovarian Cancer  
Chittenden et al (2009) conducted a systematic review to determine whether there 
is an association between PCOS and gynaecological malignancy. Medline and 
Embase databases (1968-2008) were searched. A total of 19 studies exploring the 
association between PCOS and breast, endometrial and ovarian cancer were 
identified.  They concluded a possible link between PCOS and ovarian cancer and 
the results are conflicting but suggest that this association is unlikely.  
 
1.8.1Gene expression in PCOS ovaries  
To date, the results of genetic
 
studies have failed to identify specific gene/s with
 
clear clinical significance (Diamanti-Kandarakis
 
et al, 2005) (Table 8). The 
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comparison of gene expression profiles between PCOS and
 
normal ovaries may 
reveal novel information regarding genes
 
associated with early and later stages of 
antral follicle development,
 
ovulation, and corpus luteum formation under normal 
conditions. 
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Pathophysiological 
mechanisms 
Candidate genes Comments References 
Genes involved in 
biosynthesis and 
metabolism of 
androgens 
LH and its receptor Multicentre study, mutation of LH receptor, 
no linkage or association 
Tapanainen et al. (1999) 
 
CYP11  Randomized clinical study, partial 
association 
Gharani et al. (1996), Urbanek et al. (1999), Kahsar-Miller 
et al. (2000) 
-cytochrome P450 
side chain 
cleavage enzyme 
  CYP17-
cytochrome P450 
17 
No association or linkage Carey et al. (1994), Witchel et al. (1998), Diamanti-
Kandarakis et al. (1999b) 
  CYP21-
cytochrome P450 
21-hydroxylase 
Mutation, no association Escobar-Moreale et al. (1999), Witchel and Aston (2000) 
  Androgen receptor Family studies, no association Urbanek et al. (1999), Mifsud et al. (2000) 
  Sex hormone 
binding globulin 
(SHBG) 
Polymorphism, no association Hoogeveen et al. (2002), Xita et al. (2003) 
  Other 
steroidogenic 
genes 
Family study, no association Urbanek et al. (1999) 
Genes involved in 
the secretion and 
action of insulin 
 
Insulin gene VNTR One study showed linkage and association 
of VNTR with PCOS. Further family studies 
showed no association. 
Bennett et al. (1995), Waterworth et al. (1997), Urbanek et 
al. (1999), Calvo et al. (2002), Vankova et al. (2002) 
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  Insulin receptor 
gene 
Polymorphism in the tyrosine kinase domain 
of INSR showed association with PCOS. 
Caucausian family studies, D19S884 marker 
near insulin receptor gene, chromosome 
19p13.3 showed linkage and association 
Dunaif et al. (1995), Moran et al. (2001), Tucci et al. (2001), 
Siegel et al. (2002), Ukkola et al. (2002) 
  Insulin receptor 
substrate (IRS) 
proteins 
Polymorphisms in IRS1 and IRS2, no 
association 
Ehrmann et al. (2002a), Ibanez et al. (2002) 
  Insulin-like growth 
factors (IGF) 
Association with IGF2 and PCOS in Spain, 
no linkage 
Conover et al. (1992), Buyalos et al. (1995), Urbanek et al. 
(1999), Cataldo et al. (2003), San Millan et al. (2004) 
  Calpain-10 Contradictory data, association in Spanish 
population 
Ehrmann et al. (2002b);  
Gonzalez et al (2002, 2003), Haddad et al. (2002) 
Genes involved in 
gonadotrophin 
action and 
regulation 
Dopamine receptor 
genes 
Polymorphisms, no association Kahsar-Miller et al. (1999) 
  Follistatin gene Family studies, no clear association or 
linkage 
Urbanek et al. (1999, 2000) 
Genes involved in 
obesity and insulin 
resistance 
Peroxisome 
proliferator- 
activated receptor- 
Polymorphism, prevalence in finish 
population, no association in US and Spain 
Witchel et al. (2001), Hara et al. (2002), San Millan et al. 
(2004) 
  Human sorbin and 
SH3 domain-
containing 1 gene 
(SORBS1) 
Multicentric European study, no association Lin et al. (2001), Nieters et al. (2002), Witchel et al. (2003) 
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  Paraoxonase 
(PON1) 
Polymorphism, no association Leviev et al. (2001), San Millan et al. (2004) 
  Genes encoding 
other molecules 
related to insulin 
resistance 
No association or linkage Rajkhowa et al. (1996), Oksanen et al. (2000), Urbanek et 
al. (2003), San Millan et al. (2004) 
Genes involved in 
chronic 
inflammation 
Plasminogen 
activator inhibitor-1 
(PAI-1) 
Association of 4G5G polymorphism in Greek 
population of PCOS women 
Diamanti-Kandarakis et al. (2004b) 
  Tumour Necrosis 
Factor- 
No association Hotamisligil et al. (1996, 1999), Milner et al. (1999), 
Escobar-Morreale et al. (2001) 
  Type 2 TNF 
receptor gene 
No association Fernandez-Real et al. (1998), Peralet al. (2002) 
  Interleukin-6 gene 
(IL-6) 
No linkage, or association Villuendas et al. (2002), Escobar-Morreale et al. (2003a) 
  IL-6 signal 
transducer gp130 
(IL-6ST) 
No association Escobar-Morreale et al. (2003b) 
Table 8: Systematic review of candidate genes investigated for their possible association with PCOS
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1.9 Overview of the cell cycle 
This section will review the physiology and regulation of the cell cycle and its role 
in cancer process when it is altered. In particular, I will focus on the control of the 
cell cycle by a subfamily of Cyclin-dependent kinases, their activators (Cyclins), 
and their inhibitors (CKIs), and how deregulation of their activity in cancer cells is 
associated with tumourigenesis. 
 
To start with, the cell cycle is divided into two stages: (a) Mitosis (M) which is a 
process of nuclear division which includes prophase, metaphase, anaphase and 
telophase and (b) interphase which includes G1, S and G2 phases (Norbury et al, 
(1992). Replication of DNA occurs in S phase which is preceded by a gap called 
G1 during which the cell is preparing for DNA synthesis, followed by another gap 
called G2 during which the cell prepare for mitosis (Figure 15). 
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Interphase (G1 and G2)     Prophase 
Chromosomes are not visible    The chromosomes coil,  
because they are uncoiled    The nuclear membrane disintegrates 
                                                The spindle apparatus forms. 
 
 
                                              
Metaphase      Anaphase 
The chromosomes become aligned.   The chromatids separate 
       The number of chromosomes doubles  
 
                               
Telophase      G1 Interphase 
The nuclear membrane reappears   The chromosomes have one  
The chromosomes uncoil.     chromatid  
The spindle apparatus breaks down. 
The cell divides into two.  
           
G2 Interphase 
The chromosomes have two chromatids 
 
Figure 15:  overview of the cell cycle 
http://faculty.clintoncc.suny.edu/faculty/michael.gregory/files/bio%20101/bio%20101%20lectures/
mitosis/mitosis.htm 
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1. 9.1 Control of the cell cycle 
The regulation of the cell cycle is precise and evolutionarily highly conserved. It 
involves complex and dynamic structural interactions between proteins such as 
p21, p27, p53, the retinoblastoma gene protein product (pRb), the Cyclins, the 
Cyclin-dependent protein kinases (CDK) and proliferating cell nuclear antigen or 
Ki67, which impose logic and temporal order on the cell cycle (Clurman et al, 
(1995). 
 
1. 9.1.1 Cyclin D 
Cyclin D gene is located at chromosome 11q13 and codes for the first Cyclin 
protein acting in G1. Three forms of Cyclin D have been characterized, Cyclin D1, 
D2 and D3. They are rate limiting for cell cycle progression. Cyclin D complexes 
with Cyclin dependent kinase (CDK) CDK4 and/or CDK6 and the CDK activity 
can then be positively or negatively regulated through phosphorylation/ 
dephosphorylation by CAK and Cyclin kinase inhibitors (CKI). 
 
1. 9.1.2 Cyclin dependent kinase (CDK)  
CDK are proteins that become activated at specific points of the cell cycle 
(Morgan et al, 1995 and Pines et al, (1995). 
 
Figure 16: The activated Cyclin kinase complex 
http://faculty.clintoncc.suny.edu/faculty/michael.gregory/files/bio%20101/bio%20101%20lectures/
mitosis/mitosis.htm 
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Transition through the different phases of the cell cycle is regulated by the 
activities of Cyclins, CDK and their inhibitors (CKI). CDK activity is regulated by 
phosphorylation and dephosphorylation through Cyclin-activated kinase (CAK), 
which only activates CDKs when the specific Cyclin bound reaches a critical 
concentration (Figure 16&17). Once CDKs have carried out their role they become 
deactivated and decline in concentration. Eight CDKs have been identified (CDK1 
to CDK8) which exhibit considerable structural similarity and 75% sequence 
homology (Assoian et al, 1997). Cyclins are not all involved directly in the cell 
cycle, neither are they present all the time during the cell cycle but only at 
particular phases. Before the onset of the active cell cycle, while cells lie in G0, 
p27 (a Kip/Cip family CDK inhibitor) is present in high concentrations which 
prevent CDK4 and CDK6 from being activated by Cyclin D.  
 
Activated Cyclin D/CDK4 and Cyclin D/CDK6 complexes phosphorylate pRb 
causing release of the E2F transcription factor to which it was bound (Witzel et al, 
2010). The release of activated E2F transcription factor is required to prepare the 
nucleus for DNA replication and initiate this process. At the onset of S phase, 
Cyclin D concentrations decline while Cyclin E-CDK2 complex concentrations 
rise in late G1 and drive the cell cycle transition from G1 into S phase. Once the 
cell enters the S phase, this complex declines and the Cyclin A-CDK2 complex 
takes over as the main driver of the cell cycle through the S phase, promoting 
DNA replication for example, and on into G2. There is another restriction point in 
G2, at which the cell cycle is held to allow complete and accurate DNA replication 
before progression to the M phase.  This is stimulated by mitosis promoting factor 
(MPF), a complex of CDK1 (also known as cdc2) and Cyclin A or B. The CDK1-
Cyclin, a complex considered more important in promoting the G1-M phase 
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transition, while the CDK1-Cyclin B complex is more important during the M 
phase since it controls the onset, sequence and completion of mitosis.  
CDK inhibitors also control the transition between cell cycle phases and increases 
in their activity can block CDK activation and cell proliferation. Two types of 
CDK inhibitors exist, the Kip/Cip family (p21, p27 and p57) which inhibit CDK2, 
CDK4 and CDK6, and the INK4 family (p15, p16, p18 and p19) which also inhibit 
CDK4 and CDK6 but, in addition, they inactivate murine double minute 2 
(MDM2) protein thus increasing p53 stability. This effect of INK4 proteins further 
induces cell cycle arrest because p53 induces expression of p21, a Kip/Cip 
mediator of cell cycle arrest.  
Over expression of Cyclin D1 has been found in 28% of epithelial ovarian cancers 
(Worsley et al, 1997).  
  
Figure 17: Cell cycle control. Activation of specific CDK/cyclin complexes drives 
progression through the cell cycle (CDK1=CDC2). CKIs interact with and 
inactivate CDK/cyclin holoenzymes. (Andres 2004) 
 
77 
 
1. 9.1.3 Check point control  
The restriction point ‘R’ is a point of no return in G1, following which the cell is 
committed to enter the cell cycle. Experiments demonstrate that cells starved of 
serum before the restriction point enter a G0 like state, while cells starved after R 
are unaffected and continue through mitosis ( Pardee et al, 1974). 
At the G1/S checkpoint, cell cycle arrest induced by DNA damage is p53 
dependent. Usually, cellular p53 level is low but DNA damage can lead to rapid 
induction of p53 activity (Levine et al, 1997). 
Check point control is an essential part of the cycle progression. Cell cycle check 
points sense the flows in critical events such as DNA replication and chromosomal 
segregation (Elledge et al, 1996). These signals cause delay in cycle progression, 
until the danger of mutation has been averted.  
 
1. 9.2 Cell cycle abnormalities 
The time required to complete a cycle is called generation time (GT). Tumour cells 
usually have shorter GT than normal cells and subsequently, a smaller percentage 
of cells in the resting phase. Initially, there is an increase in the growth followed 
by a plateau phase when the cell death nearly equals to the rate of formation of 
new cells. This is due to exhaustion of the nutrients and oxygen for the rapidly 
growing tumour. Generation of cancer cells is mainly due to mutations of 
oncogenes and tumour suppressor genes. These mutations affect the function and 
the amount of protein products that regulate the cell growth, division and DNA 
repair. 
 
1. 9.2.1 Oncogenes 
Oncogenes are abnormal forms of normal genes that regulate various aspects of  
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cell growth. Theses mutations affect the intracellular signal transduction, 
transcription factors, secretion of the growth factors which control the cell growth 
and division. Tumour suppressor genes, for example p53, play a role in cell 
division and DNA repair and detecting inappropriate growth signals in the cells. If 
these genes become unable to function, genetic mutation in other genes can 
precede unchecked leading to neoplastic transformation. 
1. p53 
p53 was first discovered and identified as a tumour suppressor gene (Lane et al, 
1970). Later, it was found to participate in almost all cell activities. p53 tumour 
suppressor gene is located on the short arm of chromosome 17. It controls the 
expression of the gene encoding the p21 regulatory protein of Cyclin dependent 
kinase. During p53 mediated suppression of cell proliferation, p21 and 
proliferating cell nuclear antigen (PCNA) are involved in coordinating the repair 
of damaged DNA (Levine et al, 1991) (Figure 18).  
 
p53 plays a crucial role in the cell cycle since its activity is responsive to the 
integrity of the replicated genome. It can prevent genetically damaged cells from 
progressing through the cell cycle. This occurs because p53 inhibits 
phosphorylation of pRb, which causes the cell cycle to stall allowing time for 
DNA repair.  In some cell lines, this has been attributed to it blocking S phase 
entry while in others it functions at a second restriction point in G2.   
 
The activity of p53 within a cell is normally very low since MDM2 protein 
directly inhibits p53 transcription and also binds p53, decreasing its activity and 
labelling it for nuclear export and proteasomal degradation. Expression and 
activation of p53 is rapidly increased in the presence of hypoxia, radiation, DNA 
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damage and chemotherapeutic drugs. This is partly because p53 promotes its own 
transcription and activation by phosphorylation, but also because MDM2 activity 
is decreased under these conditions, due to increased activity of its negative 
transcriptional regulator, the INK4 protein p19. The consequent increase in p53 
activity promotes the transcription of the Kip/Cip protein p21, which inhibits CDK 
4, 6 and 2 activities, reducing pRb phosphorylation and causing cell cycle arrest in 
G1.  This gives time for the activation of DNA repair mechanisms and the cell 
cycle can resume after repair. However, if damage is too severe, the continued 
elevated p53 activity can induce programmed cell death (i.e. apoptosis) through 
the bax protein pathway.  Therefore, p53 acts as a ‘gatekeeper’ in the co-ordination 
of repairs to cellular, notably genomic, damage.  
 
2. Ki-67 
Ki-67 was identified by Gerdes et al in 1991 as a nuclear nonhistone protein. The 
Ki-67 gene is on the long arm of human chromosome 10 (10q25) (Fonatcsch et al, 
1991) (Figure 9). The expression of the human Ki-67 protein is strictly associated 
with cell proliferation. During interphase, the antigen can be exclusively detected 
within the nucleus, whereas in mitosis most of the protein is relocated to the 
surface of the chromosomes. The fact that the Ki-67 protein is present during all 
active phases of the cell cycle (G 1, S, G2, and mitosis), but is absent from resting 
cells (G0), makes it an excellent marker for determining the so-called growth 
fraction of a given cell population. Ki-67 protein expression is an absolute 
requirement for progression through the cell-division cycle (Scholzen et al, 2000).
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Figure 18: Flow diagram of the P53/apoptosis pathway. (Gillham et al. 2007)  
 
3. Bcl-2 
Bcl-2, an antiapoptotic protein located on chromosome 18 (Figure 19). It has been 
reported as being critical for development,
 
tissue homeostasis, and protection 
against pathogens. 
  
 
 
 
 
 
 
Figure 19: Chromosome 18 containing the BCL-2 
http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/B/BCL-2.html 
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Bcl-2 promotes cell survival by inhibiting adapters
 
needed for activation of the 
proteases caspases that dismantle
 
the cell
 
through mechanisms that include 
displacing the adapters from the
 
pro-survival proteins. Thus, for many but not all 
apoptotic signals,
 
the balance between these competing activities determines cell
 
fate. In a healthy cell the outer membrane displays the Bcl-2 protein on the surface 
which inhibits apoptosis. Internal cell damage protein called Bax migrate to the 
surface of the cell where it inhibits the protective effect of Bcl-2 and inserted into 
the outer membrane causing cytochrome c to leak out. The release of cytochrome c 
binds to a protein called apoptotic protease activating factor 1 (Apaf-1). By the use 
of ATP these complexes aggregate to form apoptosomes which bind to and 
activate capase 9 - a protease. Caspase 9 cleaves and in so doing, activates other 
caspases (caspase-3 and -7). This leads to digestion of structural proteins in the 
cytoplasm, degradation of chromosomal DNA, and phagocytosis of the cell 
(Figure 20). Bcl-2 family members are essential for maintenance of major
 
organ 
systems, and mutations affecting them are implicated in
 
cancer (Jerry et al, 1998). 
Bcl-2 is inversely correlated with baseline Ki-67 (Bottini et al, 2001). 
 
 
 
 
 
 
 
 
Figure 20: Apoptosis process 
http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/A/Apoptosis.html#Bcl-2 
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Chapter Two 
 
Materials and Methods 
 
In this chapter, I will discuss the materials and methodologies used for the studies 
conducted.  Four areas were explored namely: 
 Family history in patients with PCOS 
 Ovarian surface epithelial morphology 
 Cell cycle and apoptotic protein expression and  
 Gene expression. 
2.1 Family history in patients with PCOS 
2.1.1 Sampling frame 
The design of the study was a cross sectional survey targeting 211 women aged 
20-54 years and from different ethnic backgrounds, with or without PCOS, 
previously seen at the Gynaecology outpatient clinics at the North Middlesex 
Hospital, London in the period between 2001 - 2005. An additional 10 women 
were seen at The Royal Free Hospital Gynaecology outpatient clinic. The 
diagnosis of PCOS was made according to Rotterdam criteria (2003) as mentioned 
in chapter one. The clinical notes of the subjects recruited into the study were 
reviewed and relevant data extracted. 
 
2.1.2 Design of the Questionnaire  
The questionnaire was designed in simple English. All the questions were placed 
on one page with adequate spacing in between each question (Stone et al, 1993, 
Streiner et al, 1989, McDowell et al, 1987 and Bennett et al, 1975). Demographic 
data included age, race and occupation.  Clinical data which included past medical 
history of PCOS, fertility treatment, diabetes, cardiovascular disease, deep vein 
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thrombosis, ovarian, breast cancer and whether or not they had children were 
obtained.  The questions were designed in ‘Yes or No’ format and where the 
answer was ‘Yes’, the subject was asked to provide further details ( Figure 21 ). 
By so doing, it was hoped that the recruits would have openly discussed their 
experiences (Stone et al, 1993 & Streiner et al, 1989). 
 
The questionnaire was sent to the candidates’ home address with a covering letter 
(Appendix2), inviting them to participate in the study and explaining the 
importance of their contribution. It was made clear that the decision of whether or 
not to complete the questionnaire would not affect the candidates’ medical care. A 
prepaid envelope was provided for their response.  For those whose first language 
was not English, an appropriate interpreter was made available to help. 
Eighty responses were received in the first two weeks and seven letters returned as 
‘not known at this address’. A reminder was sent to the remaining patients with a 
different colour questionnaire (white changed to green) and further assistance was 
offered in completing the form (Appendix 3). One week later a further 33 
responses were received. Another reminder to the remaining patients was sent and 
the following week an additional 11 responses were received. Another 10 patients 
from the gynaecology outpatient clinic also replied. The total number of responses 
received was 134 (61%) (Table 9).   
 Patients (n=221) Response (%) 
1
st
 Request 211 38 
2
nd
 Request 131 23 
3
rd
 Request 101 11 
GOPD 10 100 
Table 9: Percentage of responses in relation to questionnaire request  
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Confidential 
Infertility and general health questionnaire 
Please write your answers on the dotted lines or circle the correct answer 
 
  
Do you have any children?         Yes / No                                                                                    
If yes how many?       .......................................................................................  
 
Have you had fertility treatment in the past?      Yes / No                                                                    
If yes what treatment? .......................................................................................  
 
Are you diabetic?         Yes / No                                                                                                                 
If yes what type of treatment              .............................................................. 
Do you have a family history of diabetes?      Yes / No                                                                          
If yes who?                 .......................................................................................  
 
Do you have a family history of breast cancer?       Yes / No                                                               
If yes who?                .......................................................................................  
Have you been diagnosed with breast cancer?      Yes / No                                                                 
If yes when?        .....................................................................................  
 
Have you ever been diagnosed with Poly Cystic Ovary Syndrome (PCOS)?                   
                            Yes / No 
If yes when?            ....................................................................................... 
Have you been on medication for PCOS?      Yes / No                                                                          
If yes what treatment? & for how long?  ................................................. 
  
Do you have a family history of cancer of the ovary?              Yes / No                                                      
If yes who                                                       .................. ............................... 
 
Have you ever been diagnosed with cancer of the ovary?                Yes / No                                            
 
Has any member of your family had a heart attack?                       Yes / No                                                        
If yes who? ................................................. 
  
Have you had a heart attack?         Yes / No 
Has any member of your family been diagnosed with blood clots in their veins?   
(DVT) deep vein thrombosis.                            Yes / No                                                                                                           
If yes who?     ................................................. 
 
Have you ever been diagnosed with having blood clots in your veins?   
                                                                                                            Yes / No                                                                                                                                                                       
 
Thank you very much for your co-operation. 
 
 
Figure 21: Infertility and general health questionnaire 
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2.2 Ovarian surface epithelial morphology 
 
This was a retrospective cohort study designed to compare the degree of dysplasia 
in the ovarian surface epithelium of women who suffered from subfertility as a 
consequence of polycystic ovary syndrome. Available ovarian sections from 128 
patients who had undergone wedge resection or ovarian biopsy at the North 
Middlesex and the Royal Free Hospitals between January 1991 and December 
1995 were examined. Wedge resection was performed as part of fertility 
management at that time. 
 
The clinical notes of the recruits were examined and the diagnosis of PCOS made 
based on the hormonal analysis, patients’ presentation, and ovarian sonography 
and also by histological features. Women who had pre-existing cancer were 
excluded from the study.  Thirty PCOS patients and 72 controls (without PCOS) 
were identified. The remaining 26 patients were excluded from the study because 
there was insufficient cortical tissue to allow adequate examination of the surface 
epithelium. Approval from the local Ethical Research Committee was obtained. 
 
2.2.1 Histological features selected for assessment 
The histological features selected for dysplasia assessment and scoring were 
selected based on Chene et al., (2011), Nieto et al, (2001) and Deligdisch 1997 
studies. They comprised tufting, papillomatosis, psammoma bodies, epithelial 
stratification, mitoses, nuclear pleomorphism, chromatin pattern irregularity and 
nuclear cytoplasmic ratio.   
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3.2.2 Tissue Preparation   
 
Haematoxylin and Eosin (H&E) staining was performed by the histopathology 
department at the Royal Free Hospital where the subjects had their operations 
performed. The H&E procedure stains tissue components on the basis of their pH. 
Haematoxylin stains acidic tissue components, such as nucleic acids, while eosin 
stains more alkaline tissue components. In general therefore, nuclei appear blue-
black, the cell cytoplasm varying shades of pink, while fibrous tissue and muscle 
fibres appear a deep pinky red. 
Gill et al’s (1974) haematoxylin protocol was used. Five µm paraffin wax 
embedded ovarian sections were dewaxed in three changes of xylene for 5 minutes 
each and rehydrated in 100% v/v ethanol for 3 x 3 min, 95 % v/v ethanol for 1 x 3 
min, 80 % v/v ethanol for 1 x 3 min then in deionised water for 1 x 5 min.  Excess 
water was blotted off and the sections were stained for 5 min in Mayer’s 
haematoxylin, prepared by mixing 1.0 g haematoxylin (Cl 75290), 50 g aluminium 
ammonium sulphate and 0.2 g sodium iodate in 1L deionized water, after which 1.0 g 
citric acid and 50 g chloral hydrate were added and the solution was boiled for 5 min, 
cooled and filter before use.  Sections were rinsed in a trough filled with running tap 
water for 20 min or until the water was clear, washed in acid-alcohol (1% v/v 
concentrated HCl in 70% v/v ethanol) for a few seconds then in deionised water for 5 
min.  After blotting excess water from the sections, they were placed in eosin (1.0 g 
Eosin Yellowish dissolved in 100 ml distilled Water) for 5 min and washed for 3 x 1 
min in deionised water.  Sections were then dehydrated sequentially in 95 % v/v 
ethanol for 2 x 1 mins, 100% v/v ethanol for 2 x 1 mins and Xylene for 2 x 5 min, 
dried and mounted in DPX under cover slips.  
 
87 
 
2.3 Cell cycle and apoptotic protein expression 
2.3.1 Principles of immunohistochemistry 
Immunohistochemistry (IHC) is a combination of anatomical, immunological and 
biochemical techniques for the detection of specific tissue components by means 
of a specific antigen/antibody reaction tagged with a visible label. IHC makes it 
possible to visualize the distribution and localization of specific cellular 
components within a cell or tissue (Ramos-Vara et al, 2011). 
 
Immunohistochemistry is the study of the expression of antigens within tissues and 
cells using antibodies to detect them. Antigens within cells or on cell surfaces are 
detected through their high affinity interaction with applied target-specific 
antibodies, with subsequent development of a visual signal at the site of antigen-
antibody interaction, using fluorophores or one of several enzymatic systems 
which generate chromogenes. Examination of the antibody-stained tissue section 
with a fluorescent microscope (for fluorophores) or standard light microscope (for 
enzymatically generated chromogens) allowed for assessment of antigen 
distribution and variability of expression within the tissue specimen. 
 
2.3.2 Tissue preparation and Antibody labelling 
Immunohistochemistry for all antigens was performed on sections cut from 
formalin fixed paraffin wax embedded ovarian biopsies, therefore antigen retrieval 
was required to increase target antigenicity.  
5µm sections were cut, placed onto coated slides and dried for at least one hour at 
60ºC. De-paraffinisation, antigen retrieval, immunostaining and counterstaining 
were carried out on a Bond maX automated immunostainer (Vision Bio Systems, 
city) at UCL Advanced Diagnostics laboratory (Figure 21&22). The protocol used 
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for the study is enclosed in Appendix 5. Antibodies used for this study, supplier, 
dilution and antigen retrieval are summarised in table 10.   
Antibody Supplier Dilution Antigen Retrieval 
p53 Novocastra NCL-p53-DO7 1/100 ER1 30’ 
MIB-1 Dako M7240 1/100 ER2 20’ 
bcl-2 Novocastra NCL-L-bcl2 1/50 ER2 30’ 
Cyclin D1 Lab Vision RM-9104-S 1/40 ER2 30’ 
 
Table 10: Antibodies, supplier, dilution and antigen retrieval.  
 
 
 
 
 
  
Figure 21: Vision Automated Immunohistochemistry Staining System  
http://www.leica-microsystems.com/products/total-histology/ihc-ish-advanced-
staining/details/product/leica-bond-max/ 
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Figure 21: Immunostaining flow diagram 
www.abcam.com/ps/CMS/Images/immuno_staining2.jpg 
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2.3.3. Ovarian Epithelial Dysplasia scoring  
Assessment of the extent and intensity of specific staining in the dysplastic areas 
of the ovarian biopsies was performed independently by Dr. Soha El Sheikh, 
Consultant Histopathologist at the Royal Free Hospital and me. Scoring was 
carried out on standard histopathology grade light microscopes, at a total 
magnification of x100 with standard light field optics, on 5 randomly selected 
fields per section.  At this magnification, visual fields contained approximately 
100 cells.  Sections were examined to check for the proportion of cells staining and 
the intensity of staining.  
 Score 0: A scoring of Zero indicated that epithelium architecture was 
normal.  This score was also given when focal nuclear stratification, the 
nuclear-to-cytoplasmic ratio was normal, and nuclear pleomorphism was 
minimal.  
 Score 1:  This score was given when there was the presence of 
cytological or architectural abnormalities in 15% of the cells. 
 Score 2: This score was given where significant dysplasia was present in 
more than 30% of the cells,   The cytological features include nuclear 
pleomorphism, hyperchromatism, increased N: C ratio, markedly enlarged 
nucleoli, cytoplasmic basophilia, excessive nuclear stratification and 
increased number of abnormal mitotic figures. The architectural features 
include irregularly shaped, crowded, papillary extensions; and a villiform 
configuration of the surface. 
Some samples were not appropriate for examination where there was not any 
epithelium to comment. Three sections were reviewed for each case. The mean 
was calculated to establish the level of significance. 
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2.3.4 Imuunohistochemistry scoring 
Imuunostained sections were examined at high power fields (× 400) under a 
standard light microscope (Zeiss Axioskop2 MAT microscope) (Figure 23). 
In some cases more than one slide were used for the same specimen. Thirty to one 
hundred and fifty (30-150) cells were examined on each slide. Three pictures were 
taken from different angles of each slide. They were examined to check for the 
proportion of cells staining and the intensity of staining. For p53 and Ki-67, a 
positive score was recorded when at least 10% of ovarian epithelial cell nuclear 
stained.  For Cyclin D1 and bcl2, nuclear and/or cytoplasmic staining of at least 
10% of cells was regarded as positive. 
 
 
 
Figure 23: Zeiss Axioskop2 MAT microscope 
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2.4. Gene expression 
2.4.1 Polymerase chain reaction  
Polymerase chain reaction (PCR) is a method developed by Kary Mullis in the 
1980s for amplifying segments of DNA, by generating multiple copies using DNA 
polymerase enzymes under controlled conditions. The process of PCR has made it 
possible to perform DNA sequencing and identify the order of nucleotides in 
individual genes. Typically, PCR consists of a series of 20-40 repeated 
temperature changes, called cycles, with each cycle commonly consisting of three 
discrete temperature steps (Figure 24): 
Denaturation: This step is the first regular cycling event and consists of heating 
the reaction to 94–98 °C for 20–30 seconds. It causes melting of the DNA 
template by disrupting the hydrogen bonds between complementary bases, 
yielding single-stranded DNA molecules.  
Annealing: The reaction temperature is lowered to 50–65 °C for 20–40 seconds 
allowing annealing of the primers to the single-stranded DNA template. Typically, 
the annealing temperature is about 3-5 degrees Celsius below the temperature of 
the primers used. Hydrogen bonds are only formed when the primer sequence very 
closely matches the template sequence eg. C to G, A to T. The polymerase binds to 
the primer-template hybrid and begins DNA synthesis.  
Extension/elongation step: The temperature at this step depends on the DNA 
polymerase used. Taq polymerase has its optimum activity temperature at 75–
80 °C, and commonly a temperature of 72 °C is used with this enzyme. At this step 
the DNA polymerase synthesizes a new DNA strand complementary to the DNA 
template strand by adding dNTPs that are complementary to the template in 5' to 3' 
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direction, condensing the 5'-phosphate group of the dNTPs with the 3'-hydroxyl 
group at the end of the nascent (extending) DNA strand. The extension time 
depends both on the DNA polymerase used and on the length of the DNA 
fragment to be amplified. Under optimum conditions at each extension step, the 
amount of DNA target is doubled, leading to geometric amplification of the 
specific DNA fragment.  
Final elongation: This single step is occasionally performed at a temperature of 
70–74 °C for 5–15 minutes after the last PCR cycle to ensure that any remaining 
single-stranded DNA is fully extended.  
Final step: This step at 4–15 °C for an indefinite time may be employed for short-
term storage of the reaction.  
 
 
Figure 24: The Polymerase Chain Reaction steps. 
https://medschool.mc.vanderbilt.edu/student/igp_material/20050919081419_298_3504.ppt 
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2.4.2 Differential Display 
One of the most effective methods to investigate differential gene expression is the 
so-called ‘differential display (DD)’ method which was originally introduced by 
Liang and Padre (1994). Different variations of the original method have been 
developed which can be basically classified as ‘arbitrarily primed’ and 
‘systematic’ differential display approaches (Liang et al, 2002, Matz & Lukyanov, 
1998 and Sturtevant et al, 2000). Microarrays are another method used in gene 
expression. 
 
2.4.3 Fundamental Differences between DD and DNA Microarrays 
Both differential display (DD) and microarrays are conceptually simple to use.  
However, the two methods have key differences. The fundamental difference is 
that differential display visualizes the mRNAs in subsets directly without any data 
normalization after their amplification and labelling by either isotopes or 
fluorescent dyes. In contrast, DNA microarrays visualize the mRNAs indirectly 
after the hybridization of the extremely complex mixture of fluorescence labelled 
cDNA species derived from an RNA sample, to a set of cDNA templates spotted 
on a glass surface. In fact, a cDNA probe mixture used for microarray can be so 
complex that it consists of as many as 10,000 different species, representing 
mRNAs present from only a few copies to thousands of copies per cell. Further 
compounding the problem in signal specificity has been the fact that eukaryotic 
genes often come in families with many conserved sequences among the family 
members. 
 
Therefore, lack of sensitivity, nonspecific- and cross-hybridization are problems 
with microarrays. Microarrays have limited detection of whatever genes that are 
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spotted on a slide, making it a "closed’ system for gene discovery. In contrast, DD 
is capable of detecting both known and novel genes with much higher gene 
coverage.  
2.4.4 The advantages of differential display method (DD) over Microarray 
analysis  
The differential display method (DD) was chosen above the microarrays analysis 
method for the reasons listed below.  Additionally, at the time of conducting this 
experiment, the DDRT-PCR protocol was the established protocol in use in the 
Department of Molecular Endocrinology UCL, Middlesex Hospital. London. The 
DD method was less expensive when compared to the microarray method and this 
was a key factor in choosing that protocol.   
1. Simplicity: Technically, DD is based on well established methodologies used in 
RT-PCR and DNA sequencing gel electrophoresis. 
2. Sensitivity: Five to ten micrograms (µg) of total RNA is enough to cover the 
majority of mRNAs. Also, DD is sequence-dependent. Therefore, if the sequences 
of the arbitrary primer match the target RNA, whether abundant or rare, it will be 
amplified and detected.  
3.  Reproducibility: Up to 99% of the bands on an mRNA display are     
reproducible.  
4.  Versatility: More than two RNA samples can be compared simultaneously 
allowing complex comparisons in the same experiment.  Also, both up- and down-
regulated genes can be detected at the same time. 
5.  Detecting Novel Genes: Unlike microarray, DD does not require prior 
knowledge of the mRNA sequence to be detected. Therefore, DD is considered an 
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"open system", as opposed to a "closed system" as exemplified by microarray 
analysis (http://www.genhunter.com/products/differential/). 
  
2.4. 5 Materials  
The ovarian samples were archived at the tissue bank at the Royal Free Hospital at 
-80ºC. I started the RNA extraction using 23 normal ovaries, 19 ovarian papillary 
serous adenocarcinomas and seven ovaries from subjects with PCOS. All subjects 
were 35-45 years at the time of biopsy. 
The normal and PCOS ovaries were obtained after total hysterectomy for 
prophylactic reasons related to a family history of breast cancer or ovarian cancer.  
The clinical notes for these patients had been reviewed and data extracted on the 
clinical history, biochemical investigations, ultrasound scan report and history 
report confirming either normal or PCOS. The notes of these patients have been 
microfilmed and I had to access these files through the medical records department 
at the Royal Free Hospital, after approval from the Local Research Ethics 
Committee was obtained. 
The cancer tissue was obtained, with informed consent, from patients who were 
diagnosed with papillary serous adenocarcinoma. 
 
Figure 22 demonstrates the schematic flowchart of the reverse transcriptase-
polymerase chain reaction differential display procedure performed for the gene 
expression.  
For clarity, the main steps (Figure 25) used in DD PCR protocol were: 
1. Collecting RNA 
2. Treating RNA with DNase 
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3. Splitting RNA into aliquots and performing reverse transcription reaction 
on each using a different oligo-dT (anchored) primer 
4. Performing PCR using cDNA subsets as template with specific anchored 
primer together with an arbitrary primer, include 33P-dATP in reaction 
5. Loading PCR reactions on sequencing gel 
6. Identifying induced or inhibited genes 
7. Repeating experiment to confirm results 
8. Excising band from gel 
9. Reamplifying  cDNA using same PCR conditions 
10. Cloning cDNA’s  
11. Screening clones to identify unique species 
12. Sequencing clone and/or using it to obtain full-length cDNA. 
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Figure 25: Schematic flowchart of the reverse transcriptase-polymerase chain 
reaction differential display procedure performed  
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2.4. 6 Isolation of total RNA 
Total RNA was isolated using the acid guanidinium thiocyanate-phenol-
chloroform method (Chomzynski et al, 2006). Ovarian tissue was homogenised in 
9 vol. denaturing solution (solution D, 4M guanidinium thiocyanate, 0.5 %( w/v), 
sarcosyl, 0.1 M 2-mercaptoethanol in 25 mM sodium citrate: pH 7.0). 
Homogenates were mixed with 0.1 vol. 2M sodium acetate (pH 4.0), 1 vol. 0.1 M 
citrate buffer- saturated phenol pH 4.5 (ICN Biomedical, Inc) and 0.2 vol. 
chloroform: isoamyl alcohol (49:1 mixture). The tubes were mixed vigorously for 
60 seconds then placed on ice for 15 min, before being centrifuged (10.000 x g, 20 
min at 4ºC). The upper aqueous phase was collected into fresh tubes taking care to 
avoid contamination with DNA interface layer, and an equal volume of 
isopropanol was added.  The tubes were then mixed and incubated ≥ 1 hour or 
overnight at -20ºC to allow RNA precipitation. 
 
Tubes were recentrifuged (10.000 x g, 20 min at 4ºC), then the RNA pellet was 
resuspended in 0.5 ml solution D, transferred into a fresh tube containing an equal 
volume of isopropanol, re-precipitated for   ≥ 1 hour at -20ºC, and re-centrifuged at 
10.000x g, 10 min at 4ºC. Pellets were then washed twice with 75% ethanol (v/v), 
air dried, dissolved in nuclease free water (0.25 μl/mg wet weight tissues) at 65ºC, 
and stored at - 20ºC. 
 
2.4. 7 Spectrophotometeric determination of RNA concentration  
Samples were diluted with nuclease free water and the absorbance read in a 
Hitachi Spectrophotometer (Figure 26) at 230, 260 and 280 nm against a blank 
consisting of nuclease free water. RNA concentration was estimated based on the 
assumption that a solution of 40 μg/ml RNA has an absorbance of 1 at 260 nm 
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(Figure 27). An A260 /A 280 ratio of 1.6-2.0 indicated reasonably pure RNA, 
relatively free of protein contamination.  
 
 
Figure 26: Spectrophotometer (model U-1500; HITACHI. WOKINGHAM, UK). 
 
2.4. 8 Analysis of RNA integrity by agarose gel electrophoresis 
2 μg RNA in 4 μl nuclease free water was mixed with 16 μl RNA sample buffer, 
heated at 55ºC for 15 min and chilled on ice. Samples were mixed with 2.0 μl 
RNA loading buffer, before loading onto gels (1% (w/v) agarose (Sigma), 18% 
(v/v) formaldehyde in 1X MAE). Gels were run at 100-120 V for 0.5-1 hour. 
Bands were visualised by UV Transillumination and photographed using a digital 
camera and shroud. A 28/18S ribosomal RNA intensity ratio of approximately 2:1 
is indicative of reasonably intact RNA (Figure 27). 
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Figure 27: Total isolated RNA from normal, PCOS and cancerous ovaries  
  
2.4.9 DNase treatment of RNA samples 
Samples were treated with RNase free DNase (Invitogen) in order to remove any 
traces of contaminating genomic DNA. Reactions consisted of 2.5 μg RNA, 20 U 
RNasin, 1X DNase buffer and 0.5 U DNase I in a final vol. of 25 μl. 
Samples were incubated for 15 min at room temperature. Reactions were 
terminated by addition of 2.5 μl 25 mM EDTA, heated for 10 min at 70ºC then 
chilled on ice. 25μl water was added just before reverse transcription (total volume 
52.5 μl). 
 
2.4.10 Reverse transcription 
A. for general PCR 
Reverse transcription (RT) of RNA samples was carried out using random 
hexamer primers (1.15 μg/ μl.)  Added in 1 μl to 10 μl DNase digested RNA, 
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produced using method 2.4.7 Each sample was then reverse transcribed in a 
reaction volume of 20 μl containing 11 μl RNA/primer mix,  1X first strand buffer, 
0.01 M dithiothreitol (DTT), 2 nM deoxynucleotide triphosphates (dNTP) and 200 
U Superscript II reverse transcriptase (RT+  reactions). Duplicate reactions 
containing no enzyme were set up for each sample as a negative control (RT 
-
 
reactions). The reactions were incubated at 25ºC for 10 min, then at 42ºC for 60 
min to allow elongation. The enzyme was then deactivated by incubation at 70ºC 
for 15 min and samples were stored at - 20ºC. 
 
B.  For Differential display 
RT of RNA samples was carried out in three reactions using one of the three 
ET12X downstream primers (where E is XhoI restriction enzyme site and X is A, 
C, or G) in each reaction. Thus RNA was reverse transcribed into 3 cDNA 
populations, differing at the last nucleotide before the poly (A) tail.  To each of 
three aliquots of DNase digested RNA was added ET12A, ET12C or ET12G primer 
(4.76 μΜ) to a final vol. of 10.5 μl. Samples were mixed, denatured at 80ºC for 5 
min, and then annealed at 4ºC for 2 min.  The reaction temperature was raised to 
42ºC for 2 min before addition of reagents to: 1X first strand buffer, 10 mM DTT,  
20 μM dNTP, 10U RNasin and 200 U Superscript II  in a final vol. of 20 μl. 
Reverse transcription was allowed to proceed at 42ºC for 70 min, before enzyme 
denaturation at 80ºC for 10 min. 
 
2.4.11 PCR amplification with arbitrary primers   
To display the cDNAs present in the 3 populations, PCR was performed using the 
relevant ET12X downstream primer and one of 7 different EAP arbitrary upstream 
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primers (EAP1-7) in the presence of [α-33P] dATP. EAP primers consisted of an 
EcoRI site (E), and an arbitrary primer (AP) consisting of 10 bases of 3` random 
sequence with 50% GC content. 
 
The PCR reaction (10 μl total volume) contained 1 μl reverse transcription reaction 
containing cDNA , 0.75 U Taq DNA polymerase, 1X PCR buffer, 3 mM MgCl2 , 
20 μM  dNTP , 15 nM [α-33P] dATP , 1 μM relevant ET12X primer and 1 μM EAP 
primer. The thermal profile used for amplification of cDNA consisted of 94ºC for 
2 min, then 2 cycles (denaturation 94ºC for 30s, annealing 42ºC for 1 min; 
elongation 72 ºC for 2 min), followed by 38 cycles (denaturation 94ºC for 30s, 
annealing 55ºC for 1 min; elongation 72 ºC for 2 min) and a final elongation step 
(72 ºC for 5 min). Samples were stored at -20ºC, but were electrophoresed the next 
day to minimise loss of activity in 
33
P-labelled PCR products. 
 
2.4.12 Analysis of DDRT-PCR products 
DDRT-PCR products were analysed using polyacrylamide gel electrophoresis on a 
SequiGen GT sequencing cell (Bio-Rad Laboratories Ltd, Hemel Hempstedf, UK) 
(Figure 28). 
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Figure 28: Sequi-Gen GT System   (http://www.bio-rad.com) 
A 6% non-denaturing gel was prepared by degassing a mixture containing 6% 
(w/v) acrylamide (acrylamide;bis-acrylamid 1:19), 0.5X Tris/Borate/EDTA buffer 
TBE, 0.001% (v/v) TEMED, before addition of 0.05% (w/v) ammonium 
persulphate. A 0.4 mm thick gel was cast in the sequencing cell according to the 
manufacturer`s protocol using a 60 place comb; the setting time was 1 hour, or 
sometimes overnight. Gel running buffer for lower and upper reservoirs was 0.5X 
TBE.  PCR products (10 μl) were mixed with 2 μl of Blue/Orange loading dye and 
loaded at 3 μl/well. Electrophoresis was performed at 80 W for 2.5 hours; the 
maximum temperature was 40ºC. 
 
Following electrophoresis, gels were mounted on chromatography paper, sealed 
with a layer of Saran Wrap and dried under vacuum at 60ºC for 1.5 hr. Dried gels 
were exposed to Kodak Biomax Maximum Sensitivity film which was developed 
following the manufacturer’s recommended methods.  Auto radiograms were also 
scanned using a Typhoon FLA 7000 ™ to create digital images for easy storage 
(Figure 29). 
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2.4. 13 Isolation and re-precipitation of differentially expressed fragments   
Auto radiograms were aligned onto gels to allow the marking and excision of 
differentially expressed bands (Appendix 6) into sterile tubes using a sterile 
scalpel. Following the excision of bands, gels were re-exposed to film to compare 
with the original autoradiogram to confirm the accuracy of band excision. 
 
 
 
Figure 29: Typhoon FLA 7000™ 
(http://www.gelifesciences.com/aptrix/upp00919.nsf/Content/55DEA1D48F26687EC12577190082
8CAD/$file/28961073AB.pdf) 
 
DNA was eluted by boiling each gel fragment in 250 μl nuclease free water for 10 
min in a water bath followed by centrifugation (16,000x g for 5 min). 180 μl 
supernatant was mixed with 2 μl Pellet Paint (Novogen, Madison, USA) and 0.5 M 
ammonium acetate in a final volume of 200 μl. 630 μl of absolute ethanol was then 
added and the DNA precipitated overnight at -20 ºC. Samples were re-centrifuged 
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(16,000x g for 5 min) and pellets were washed in 75% ethanol  twice, vacuum 
dried for 30 min, then dissolved in 50 μl nuclease free water  and stored at -20 ºC.  
 
2.4.14 Amplification of recovered DNA  
DNA recovered from differentially expressed bands was subjected to PCR using 
the same ET12X and EAP primer pair used to generate it. Reactions consisted of 25 
μl  fragment DNA (generated using method 2.4.9) , I U taq DNA polymerase, 1X 
PCR  buffer , 3 mM  MgCl2 , 50 μM  dNTP, 0.5 μM ET12 X   primer and 0.5 μM  
EAP primer in a total volume of 100 μl.  Thermal conditions were 94ºC for 10 
min, followed by 38 cycles (denaturation 94ºC for 30s, annealing 55ºC for 1 min; 
elongation 72 ºC for 2 min) and a final elongation step (72 ºC for 5 min).  Samples 
were stored at -20ºC. 
In order to verify successful PCR, gel electrophoresis was carried out using 5 μl  
PCR product mixed with 2 μl DNA loading buffer on a 2% (w/v) agarose gel in 
0.5X TBE, alongside a 100bp marker ladder. Remaining products were 
reprecipitated using pellet paint. Pellets were re-dissolved in 30 μl nuclease free 
water.  
 
2.4.15 Re-purification of samples using HYBAID columns 
The amplified DNA fragments were purified using the Hybaid Recovery DNA 
Purification Kit II, a silica gel based spin prep kit for purification of DNA (200bp-
300kb) from agarose gels and solutions. The kits were used according to the 
manufacturer’s instructions.  In brief, 400 μl of binding buffer with silica gel 
suspension was added to a spin filter, and then a cDNA sample was added and 
mixed. This spin filter was then spun at maximum speed in a microfuge for 15-30 
seconds to transfer buffer to the catch tube, leaving DNA bound on the silica gel.  
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This was then washed by adding 500 μl of washing solution to the filter, and 
spinning for 30 seconds before emptying the catch tube, then spinning for 1 minute 
to dry the gel. DNA was then eluted from the gel into a clean catch tube by adding 
15 μl of elution solution and resuspending the binding matrix/DNA by flicking the 
tube. The spin filter was then centrifuged at maximum speed in a microfuge for 30 
seconds to transfer eluted DNA into the catch tube. This elution step was repeated 
to maximise recovery giving a total DNA elute of 30 μl. In order to verify 
successful purification, gel electrophoresis was carried out using 5.25 μl DNA 
mixed with 2.33 μl DNA loading buffer and 6.42 μl water on 2% (w/v) agarose gel 
in 0.5X TBE, loading 6, 4 and 2 μl from each DNA sample (i.e. equivalent to 2.25, 
1.12, 0.056 μl eluted DNA preparation) alongside a 2, 1, 0.5, 0.25 and 0.125 kb 
DNA marker ladder. 
 
2.4.16 Cloning of differentially expressed PCR fragments 
2.4.16.1 Restriction digestion of PCR products 
The purified PCR products generated above were digested with EcoRI and XhoI in 
order to facilitate sticky-ended ligation into the pBluescript II SK
+
 plasmid vector 
(Strategene) (Figure 30). Reactions contained re-purified PCR products (7 µl), 
acetylated BSA (5 µg), XhoI (24 U; Promega), EcoRI (10 U; Promega) and buffer 
H (X1; 10 mM MgCl2, 50 mM NaCl, 90 mM Tris HCL, pH 7.5; Promega) in a 
final vol. of 50 µl. After incubation at 37 C for 3 h, reactions were made up to 
200 µl with nuclease free water, before addition of an equal volume of a mixture 
containing phenol (pH 7.9):chloroform:isoamyl alcohol (PCIAA; 25:24:1). The 
tubes were mixed vigorously then centrifuged (16,000g, 10 min; 25 C). The 
aqueous layer was transferred into a fresh tube containing an equal volume of 
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PCIAA and re-centrifuged (as above). The non-aqueous layer was also mixed with 
an equal volume of water and re-centrifuged (as above). The resulting aqueous 
layers were combined and DNA re-precipitated using Pellet Paint and ammonium 
acetate as described previously. The size and concentration of re-purified 
restriction fragments was assessed by electrophoresis on a 2% (w/v) agarose gel in 
0.5X TBE alongside a 1 kb ladder (Stratagene). 
 
Figure 30: Blue script II SK (+) Multiple Cloning Site Regions 
 
2.4.16.2 Ligation of PCR fragments into cloning vector 
Digested PCR fragments were ligated into XhoI/EcoRI digested pBluescript II SK
+
 
plasmid vector (Stratagene). Ligation reactions contained digested PCR fragment 
(ca. 5 ng), plasmid vector (100 ng), T4 DNA ligase (1U; Promega), ligase buffer 
(1X; 1 mM ATP, 10 mM DTT, 10 mM MgCl2, Tris-HCL, pH 7.8; Promega) in 10 
µl with water. Reactions were left to stand at 25 C for 2 h then at 4 C overnight. 
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2.4.16. 3 Transformation of competent E.coli 
Aliquots (50 µl) of INV F  competent E.coli cells (Invitrogen Life Technologies) 
were mixed with -mercaptoethanol (2 µl) and an aliquot (4 µl) of ligation mixture 
(Section 2.10.3.2). Cells were incubated on ice for 30 min, heat-shocked for 30 s at 
42 C, then incubated on ice for a further 2 min, before addition of SOC medium 
(250 µl) and horizontal shaking (225 rpm) at 37 C for 1 h 20 min. Cells were then 
spread-plated on Petri dishes containing Lennox Luria Bertani (LB) agar 
supplemented with sodium ampicillin (75 g/ l) and 5-bromo-4-chloro-3-indolyl-
beta-D-galacto-pyranoside (X-Gal; 40 mg/ml in formamide; applied as a top coat 
onto the gel).  X-Gal allows blue-white colour selection of recombinant (white) 
clones. Plates were allowed to dry for 10 min, inverted then incubated at 37 C for 
 18 h. 
 
2.4.16.4 Cloning 
Four white colonies were picked off each plate and suspended in separate 5 ml 
aliquots of LB medium containing ampicillin (50 µg/ml) and 0.1 % (w/v) glucose. 
Colonies were grown overnight at 37 C with shaking as before, then stored in 
30% (v/v) glycerol at –20 C. 
 
2.4.16.5 Plasmid purification 
Plasmid purification was carried out using the GenElute Plasmid Mini-Prep Kit 
(Sigma), according to the manufacturer's protocol. Briefly, overnight culture (2.3 
ml) was pelleted by centrifugation (16,000 g, 1 min; 25 C) and the supernatant 
discarded. Cells were resuspended by titration in resuspension solution (200 µl), 
followed by addition of lyses solution (200 µl). The solution was mixed by 
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inversion, then allowed to clear for 5 min. Addition of neutralization solution (350 
µl) was followed by mixing, then centrifugation (16,000 g, 10 min; 25 C). The 
cleared lysate was transferred to a Mini Spin Column, then centrifuged (16,000 g, 
1 min; 25 C). Columns were washed with wash solution (750 µl) by 
centrifugation (as above), then dried by re-centrifugation. Elution solution (100 µl) 
was added to columns and the purified plasmid DNA was collected by 
centrifugation (as above). 
 
2.4.16.6 Sequencing and identification of plasmids 
Recovered plasmids were linearised with EcoR1 and the DNA concentration in 
digests was estimated by agarose gel electrophoresis alongside a 1 kb ladder. 
Samples were adjusted to 150 ng DNA/6 µl with nuclease-free water before 
sequencing was carried out with T7 primer using a Beckman Coulter CEQ 
2000XL DNA analysis system in a local facility. The Blast  programme 
(www.ncbi.nlm.nih.gov) was used to compare insert sequences with entries in the 
GenBank database. Primers were designed to amplify regions within the identified 
genes and semi-quantitative RT-PCR was used to screen ovarian RNA samples to 
verify differential expression of target genes. 
 
 
 
 
 
 
 
111 
 
2.5 Statistical analysis 
2.5.1 Family history in patients with PCOS 
The programme G. Power 2 for Macintosh was used to perform a power analysis 
using 2 tailed T test. This provided the number of samples required for testing, 
with certain power, the null hypothesis, the means of two independent sets of 
normally distributed data of defined homogenous variance are equivalent at a 
defined level of significant (normally P < 0.05). An estimated sample size of 53 
PCOS women and 53 controls, assuming a prevalence of x and y in the two groups 
respectively, with a power of 80% and significance of P<0.05. Categorical 
variables were summarized as proportions and differences among groups were 
assessed using the chi-square test and T test.  
 
2.5.2 Ovarian surface epithelial morphology 
All statistical analyses were performed using the SPSS programme version 10.0 
for Windows. The main outcome measure for histological assessment of the 
ovarian epithelium study was the total dysplasia score for each subject or the 
highest score where more than one section was available from the same ovary. The 
score for each subject was based on the eight histological features. The a priori 
hypothesis tested in this thesis was that PCOS was associated with higher 
dysplasia scores. Student’s t-test analysis was repeated using non-parametric tests 
(Kruskal-Wallis or Mann Whitney U test, as appropriate). In cases where there 
was departure from assumptions required for parametric testing, multiple 
regression analysis, using the general linear model (GLM in SPSS®) procedure 
was used to obtain adjusted mean dysplasia scores. The dysplasia scores were 
arbitrarily classified as ‘zero’ in cases where there was no abnormality detected, 
‘one’ in cases with slight changes and ‘two’ when significant changes were seen.  
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 2.5.3 Cell cycle and apoptotic protein expression 
The Mann-Whitney U test was used to measure the associations between the 
groups with regards to their immunohistochemical expressions and assess their 
significance. A value of P<0.05 was considered statistically significant. 
The proportion of subjects whose ovaries expressed each of the cell cycle proteins 
studied was compared to those with dysplasia scores, using the chi-square test. 
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Chapter Three 
 
Results 
 
3.1 Family history in patients with PCOS  
The total number of responses after sending two reminders was 134 (response rate 
60%). 52 (38.8%) women were diagnosed with PCOS and 82 (61.2%) were 
controls. From table 11 and figure 31, it is evident that with the controls, fewer 
women are presenting in the younger age groups and with increasing years, more 
women are presenting. There could be some possible reasons for this increasing 
trend.  Younger women tend to have fewer problems with fertility compared to 
older women. Also, social trends are changing and some women in the pursuit of 
having a career defer starting their families and as a consequence, tend to present 
later with fertility problems. A similar trend can be seen in patients with PCOS, 
particularly in the 26 to 34 years age groups. A possible explanation for the 
reduced number in the 35 to 40 years age group could be that they have already 
had their fertility treatment or they have presented with different symptoms of 
PCOS. 
 
The difference and variation in the sample population mean between PCOS and 
the control group in respect of age or ethnicity (p value 0.419 and 0.0635) which is 
statistically insignificant (Table 12). Meanwhile at 95% confidence interval for the 
difference in age is (-28.66, 13.66) and (-0.33 to 8.90) in case of ethnicity. 
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Age  ( Years) PCOS (%) Controls (%) 
19 and less 1.56 0.82 
20-25 2.08 8.2   
26-29 8.32 10.66 
30-34 10.92 33.62 
35-40 1.92 18.04 
Mean 6.76 20.2 
St Dev 13.34 11 
Minimum 1 11 
P value  0.419  
 
Table 11: Age in PCOS cases and controls  
Ethnic group Control (%) PCOS (%) 
Caucasian 28.7 16.64 
Black  18.86 5.72 
Asian 10.66 4.16 
Didn’t answer 9.02 5.52 
Mean 11.71 7.43 
 P value   0.0635  
 
Table 12:  Ethnicity in PCOS cases and controls 
 
.Figure 31: Histogram with normal curve of PCOS and controls by age 
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From Tables 13&14 there was a significantly higher proportion of women in the 
PCOS group who had a first degree relative affected with breast cancer than in the 
control (non PCOS) women (P=.0.0066 ). The difference between the relatives in 
both groups is statistically insignificant (P=0.1563). However grandmother is the 
highest percentage in both groups (Figure 32) which could be explained by 
knowing that breast cancer tends to affect older women. 
 
The proportion with a family history of myocardial infarction shows borderline 
significance in the PCOS women compared to the controls (P=0.0583). However 
there was no significant association between family history of thromboembolism 
(P> 0.9999) and ovarian cancer (P > 0.9999) was also not statistically significant 
(Table 13). 
 
 PCOS (%)  Controls 
(%) 
P value 
Family history of breast cancer 
 
23 7 0.0066 
Family history of ovarian cancer 
 
4 4 > 0.9999 
Family history of myocardial 
infarction  
 
 
infarction  
 
31 11.7 0.0583 
Family history of DVT 
 
15 15 > 0.9999 
Family history of DM 
 
 
131 40  0.3575 
Table 13: Family history in PCOS and controls 
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Controls 
(%) PCOS (%)  
Mother 0 
 
1.56 
Sister   0.82 
 
0 
Grandmother 1.64 
 
2.6 
Aunt      1.64 
 
0.52 
Grandmother   & mother                                                                                                    0 
 
0.52
 Grandmother & sister 
0 
 
0.52 
Aunt & grandmother                           0 
 
0.52 
Mean 
0.71 
 1.71 
P value    
0.1563 
  
 
Table 14: Family history of Breast Cancer in PCOS and controls 
 
Figure 32: Family history of Breast Cancer in PCOS and controls with regards to 
family members.  
 
Personal past medical history of DVT is statistically insignificant (P=0.2014) 
(Table 15). None of the candidates for the study experienced   breast cancer,   
ovarian cancer or myocardial infarction. 
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 PCOS (%) Controls (%) P value 
Live birth                 52   55  0.8590 
Fertility treatment  54   57  0.7237 
History of DVT  4%   11  0.2014 
Table 15: Past medical history in PCOS and Controls 
 
3.2 Ovarian surface epithelial morphology 
3.2.1 Subject characteristics 
All subjects in both groups had been previously exposed to ovulation induction 
therapy .The most common drug used was clomiphene citrate (CC), followed by 
human menopausal gonadotropins (hMG) and gonadotropin -releasing hormone 
(GnRH). The subjects had different exposures to these drugs with regards to the 
combination and duration of use. The difference in duration of CC use was not 
statistically different between PCOS subjects and controls (P 0.9395). 95% 
confidence interval of this difference was -4.27 to 4.56 (Table 16). 
 
  Control (n = 20) PCOS  (n = 21) 
1 month 5 0 
2 months 3 2 
3 months 12 6 
4 months 0 5 
5 months 0 0 
6 months 0 7 
More than 6 months 0 1  
Mean  2.86 3 
P value  0.9395  
 
Table 16: Duration of exposure to clomiphene citrate in control and PCOS subjects 
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With regards to hMG and GnRH use alone or in combination again it was also 
statistically insignificant (P= 0.1478). 95% confidence interval of this difference 
from -4.73 to 21 (Table 17). 
 
Drug Cycle Control PCOS   
GnRH 1 14 1 
hMG 1 29 4 
CC + GnRH 2 1 1 
CC + hMG 2 2 3 
GnRH + hMG 2 6 0  
Mean   10.4 1.8 
P value  0.1478   
 
 
Table 17: Duration of exposure to GnRH, hMG and CC in control and PCOS   
 
3.2.2 Morphology of the ovarian surface epithelium 
Psammoma bodies (Figure 33) and mitoses (Figures 38&39) were found to be 
statistically more common in PCOS (p value 0.0011 and 0.0065 respectively) 
(Table 18).  The prevalence of other features assessed did not differ significantly 
between the PCOS and controls (Figures 34, 35, 36, 37, 38& 40). The results were 
also analysed according to whether the particular morphological abnormality was 
present or absent i.e. disregarding whether or not there was dysplasia, likewise the 
degree of dysplasia (Tables 18&19). Following the analysis of the data the 
presence of only two factors (as above) is statistically higher in PCOS.  
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 Control  72  PCOS 30 P 
Score  0 1 2 0 1 2  
Surface tufting 53 8 11 27 1 2 0.1819 
Psammoma  bodies 68 0 4 22 5 3 0.0011 
Epithelial stratification 68 3 1 30 0 0 0.4201 
Mitoses 72 0 0 27 3 0 0.0065 
Surface nucleoli 72 0 0 30 0 0 Na 
Nuclear pleomorphism 66 6 0 30 0 0 0.1031 
Chromatin pattern 68 4 0 26 4 0 0.1831 
Nuclear cytoplasm ratio 50 14 8 19 8 3 0.7213 
 
Table 18: Dysplasia scoring in PCOS and controls  
 
 
 
 Control 72 PCOS 30 P 
Score  -ve + ve -ve +ve  
Surface tufting 53 19 27 3 0.1108 
Psammoma  bodies 68 4 22 8 0.0058 
Epithelial stratification 68 4 30 0 0.3173 
Mitoses 72 0 27 3 0.0236 
Surface nucleoli 72 0 30 0 Na 
Nuclear pleomorphism 66 6 30 0 0.1761 
Chromatin pattern 68 4 26 4 0.2295 
Nuclear cytoplasm ratio 50 22 19 11 0.6434 
 
Table 19: Dysplasia in PCOS and controls (Analysis in view of  negative or 
positive presence of Dysplasia) 
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Figure 33:  Psammoma Body  
 
 
 
Figure 34: Presence of tufting on surface epithelium of ovary 
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Figure 35: Cellular pleomorphism in epithelial surface of ovary 
 
 
 
 
Figure 36: Multilayering in epithelial ovarian surface 
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Figure 37: Normal nuclear cytoplasmic ratio. The nucleus (1) in the centre 
bounded by a cell membrane. The nucleus contains nucleolus (2). The cytoplasm 
(3).Note that adjacent cells are connected to each other by intercellular junctions 
(4) http://www.pathpedia.com/Education/eAtlas/Histology/cells_and_epithelia/Images.aspx 
 
 
Figure 38: Normal mitosis .The arrow indicates a cell in late prophase. All other 
cells in the surrounding are in interphase.  
 
 
Figure 39:  Mitosis: (A) score one, (B) score Two. Alkaline Phosphatase staining 
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Figure 40: Nuclear cytoplasic ratio. (A) Score one, (B) Score Two 
 
3.3 Cell cycle and apoptotic protein expression 
I examined all the sections after being trained by Dr. El Sheikh, Consultant 
Histopathologist at the Royal Free Hospital.  To test for consistency and efficacy 
in the results, 20% of the samples I examined were re-examined by Dr El Sheikh. 
In 87.5 % of these cases, the Kappa test was used and identified that the difference 
between the scores calculated by myself and Dr. El Sheikh was less than 10% 
(2.15) which was not significant and demonstrated a high level of consistency. 
(Table 20) (Figures 41 to 47).  
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No Essam El Mahdi % Dr El Sheikh % Difference  % Difference 
 
1 
0 0 0 0 
 
2 
0 0 0 0 
 
3 
1.40 1.29 0.11 2.5 
 
4 
0.94 0.86 0.08 8.51 
 
5 
9.85 9.75 7.29 1.01 
 
6 
0 0 0 0 
 
7 
2.0 1.89 0.11 5.5 
 
8 
0 0 0 0 
 
9 
0 0 0 0 
 
10 
10.9 9.8 1.1 10 
 
11 
1.94 1.9 0.04 2.06 
 
12 
0 0 0 0 
 
13 
27.4 27.39 0.01 0.04 
 
14 
14.99 14.87 0.12 0.80 
 
15 
74.94 74.74 0.2 0.26 
 
16 
26.89 26.31 0.58 2.16 
 
17 
93.14 93.45 3.69 3.79 
 
18 
3.1 3.03 0.07 2.25 
 
19 
100 100 0 0 
 
20 
98.75 93.75 5 5.06 
 
21 
85.14 84.78 0.36 0.42 
 
22 
100 98.36 1.64 1.64 
Mean 15.55 15.43 0.78 2.15 
 
Table 20: Reproducibility immunohistochemistry scoring  
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Figure 41: Cyclin D1 positively stained cell 
 
 
 
Figure 42: No Cyclin D1 staining is seen in surface epithelial cells 
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Figure 43: BCL-2 positively stains the cytoplasm of surface epithelial cells and 
some stromal cells 
 
 
 
 
Figure 44: Ki-67 positively stained nuclei. 
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Figure 45: All surface epithelial cells lack ki-67 expression denoting quiescent G0 
state. 
 
 
Figure 46: The brown nuclei (arrows) are p53 positively stained surface epithelial 
cells. 
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Figure 47: Surface epithelium showing no p53 staining. 
The percentage cells staining positive for p53 expression in the ovarian surface 
epithelium of PCOS women and infertile controls is significant compared to mib 
and bcl; P value for p53 is 0.0025. However Cyclin D is marginally significant 
(P=0.0536) (Table 21).  
 
  p53 Cyclin D mib bcl TDS 
Control Mean 13.1 2.2 8.9 78.9 2.3 
PCOS Mean 39.8 7.3 9.9 85.1 1.5 
 P Value 0.002545 0.053672 0.897063 0.579269 0.225025 
Table 21: Mean percentage cells stained positive for Cyclin D1, mib, p53 and bcl 
in the ovarian surface epithelium of PCOS subjects and controls 
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The effect of clomiphene citrate ovulation induction therapy on p53, Cyclin D, 
mib and bcl expression (% positive cells) and total dysplasia score was not 
significant (Table 22). 
 
   
p53 Cyclin D mib bcl 
Clomiphene 
exposed 
Control Mean 70.2 62.6 58.2 81.1 
PCOS Mean 70.9 46.2 54.3 91.8 
Clomiphene 
unexposed 
Control Mean 79.5 63.6 62.1 87.8 
PCOS Mean 73.9 70.4 66.2 91.7 
  P Value 0.329502 0.138404 0.290241 0.505528 
 
 
Table 22: Cell cycle protein expression (% positive cells) in relation to exposure to 
clomiphene citrate 
 
 
Similarly, the expression of cell cycle proteins was not significantly affected by 
prior exposure to human menopausal gonadotropins or gonadotropin-releasing 
hormone (Tables 23 and 24).  
 
   
p53 Cyclin D mib bcl 
hMG exposed Control Mean 69.8 60.4 56.1 78.7 
PCOS Mean 87.0 44.0 80.0 73.0 
hMG unexposed Control Mean 63.8 64.7 53.2 82.7 
PCOS Mean 74.5 69.1 68.2 91.2 
 
 
P Value 
0.049974 0.781109 0.43099 0.508516 
 
 
 
Table 23: Cell cycle protein expression (% positive cells) and total dysplasia score 
in exposed subjects to human menopausal gonadtrophins staining for cell cycle 
proteins.     
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p53 Cyclin D mib bcl 
GnRH exposed Control Mean 79.1 60.2 64.0 80.1 
PCOS Mean 74.5 69.1 68.2 91.2 
GnRH unexposed Control Mean 63.8 64.7 53.2 82.7 
PCOS Mean 0 0 0 0 
 
 
P Value 0.327579 0.91277 0.524073 0.238233 
 
 
Table 24: Cell cycle protein expression (% positive cells) and total dysplasia score 
in exposed subjects to gonadotrophin releasing hormone. 
 
 
 
Previous ovulation induction exposure to any treatment did not significantly affect 
the total dysplasia score or percentage cells staining for cell cycle proteins (Table 
25).  
 
   
p53 Cyclin D mib bcl 
Any treatment 
exposed 
Control Mean 70.1 65.7 60.0 88.3 
PCOS Mean 66.5 23.0 51.0 93.5 
Any treatment 
unexposed 
Control Mean 87 66 51.5 85 
PCOS Mean 73.9 70.4 66.2 91.7 
 
 
P Value 
0.067483 0.147673 0.566064 0.853533 
 
Table 25: Cell cycle protein expression (% positive cells) and total dysplasia score 
in exposed subjects to any ovulation induction treatment 
 
 
The total dysplasia score was compared in relation to each of cell cycle elements 
(p53, Cyclin D, mib and bcl) in PCOS and control group. However, the results did 
not show any statistically significant difference (Figure 48 to 56). 
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Figure 48: Mean of percentage of p53 positive stained cells in relation to total 
dysplasia score in control group 
 
 
Figure 49: Mean of percentage of positive p53 stained cells in relation to total 
dysplasia score in PCOS 
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Figure 50: Mean of percentage of positive p53 stained cells in relation to total 
dysplasia score in PCOS subjects and controls  
 
 
 
 
Figure 51: Mean of percentage of positive Cyclin D stained cells in relation total 
dysplasia score to control group 
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Figure 52: Mean of percentage of positive Cyclin D stained cells in relation to total 
dysplasia score in PCOS group 
 
 
 
 
Figure 53: Mean of percentage of positive Cyclin D stained cells in relation to total 
dysplasia score in both groups 
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Figure 54: Mean of percentage of positive mib stained cells in relation to total 
dysplasia score in control group  
 
 
 
 
Figure 55: Mean of percentage of positive mib stained cells in relation to total 
dysplasia score in PCOS group 
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Figure 56: Mean of percentage of positive mib stained cells in relation to total 
dysplasia score in both groups 
 
 
3.4 Gene expression  
 
Although RNA extraction was initially carried out using 23 normal ovaries, 19 
ovarian cancer (papillary serous adenocarcinoma) and 7 PCOS ovaries. RNA 
quantities and quality have been tested using the previously described methods 
chapter. Only three samples from each group were used for the study as the rest of 
the ovarian RNA samples were degraded evidenced by a lack of bands at 18s and 
28s. 
 
Spectrophotometeric determination of RNA concentration using A260 /A 280 ratio 
of 1.6-2.0 indicated reasonably pure RNA, relatively free of protein contamination 
Yang et al., (2012). RNA integrity was confirmed by agarose gel electrophoresis. 
RNA samples were treated by DNase successfully from traces of contaminating 
genomic DNA.  
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The extracted RNA has been purified and the concentration has been calculated 
subsequently (Appendix 6). After extracting the total RNA, Reverse transcription 
for both general PCR and Differential display was performed as described 
previously. This was followed by PCR amplification with arbitrary primers.   
 
The Analysis of DDRT-PCR products using polyacrylamide gel electrophoresis 
was done. A total of 1700 PCR products (fragments) (Figure 57) were identified, 
isolated (Figure 58) and re-precipitated. Only 34products (2%) consistently varied 
in abundance between normal and PCOS samples. 12 products were over 
expressed in PCOS and 22 under expressed. Subsequently, cloning of these 
differentially expressed PCR fragments was carried out as described earlier by 
ligation of PCR fragments into cloning vector followed by Plasmid purification. 
 
Provided that the expected fragment T3-T7 from BSII is 130 bp, when plasmid 
ligates closed with insert at the XhoI/EcoRI junction with fragment ligated the size 
of the fragment is 130 bp. Some PCR products indicated they contained plasmid 
i.e. P1.1, P2.1, P2.3, P2.5 and P4.1. P1.1, P2.1 and P2.5 PCR products suggest 
inserts of ca 130 bp which is what we expected. P2.3 products suggest this is not a 
pure clone, and those of P2.6 indicate no insert. P4.1 product suggests a larger 
insert of 180bp. Following plasmid purification plasmids were isolated 
successfully followed by sequencing of plasmids to identify the genes. A summary 
of clone sequences and related genes are in table 26. 
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No differentially expressed bands 
 
Over expressed bands 
 
Under expressed bands 
Figure 57: Polyacrylamide gel electrophoresis for DD PCR shows the 
differentially expressed bands. 
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Figure 58: Polyacrylamide gel electrophoresis for DD PCR showing where 
differentially expressed bands are extracted. 
 
One of the over expressed products was identified as being derived from the 3` 
terminal of the mRNA for human alpha 2 smooth muscle actin. RT-PCR analysis 
of alpha 2 actin mRNA abundance detected the expected 970 bp product, at levels 
calculated 15-fold higher in PCOS ovary than in normal ovary p< 0.001. 
 
Western blotting of protein extracts from another set of normal and PCOS ovaries 
was performed (Figures 59&60). The alpha 2 actin antibody detected a protein of 
the expected size, the abundance of which was elevated approximately four fold in 
PCOS ovary compared to controls (p<0.05).  
 
 
Figure 59: Western blot of 2µg protein from normal (N) and PCOS ovaries 
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Figure 60: Alpha 2 actin mRNA abundance in normal and PCOS ovary  
This preliminary differential display analysis indicates that ovarian gene 
expression is modified in PCOS. The abundance of 2% of PCR products was 
disturbed, thus up to 2% of expressed gene transcripts in the ovary may be altered 
in PCOS, and since several PCR products may be derived from a single transcript. 
Ovarian alpha 2 actin mRNA expressions were considerably up-regulated in 
PCOS, as was alpha 2 actin protein abundance. 
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Table 26: Summary of clone sequencing data with identities 
Clones Gene Entrez Gene Number: 
P1-1; P1-12; P1-13, P1-14 Human smooth muscle alpha2 actin NM_001613.1 
P2 PCR frag; P2-1; P2-5 Human actin, alpha2, SM, cds BC017554 
P3-21 Human mRNA VSM alpha2 actin  X13839.31/HSACTA 
143 bases Human DNA seq clone RP11-399019 AL157394.15 
  Human aortic SM alpha2 actin M33216.1/HUMSMAAA 
  Human cDNA FLJ36021 fis AK093340.1 
   
P1-14 Human clone RP11-155N3, chr 13 AL161420.1 
P3-13; P3-14     
147 bases     
   
   
P3-23 Human BAC RP11-736E3 from 7 AC073346.12 
143 bases Human BAC RP11-599B13 from 17 AC129492.6 
  Human chr 17, clone CTD-3051C7 AC107913.7 
  Human chr 17, clone RP11-769H22  AC104762.7 
  Human clone RP4 HSJ543J19 
   
P4-1 Human clone BAC 82621, chr19 AC007193 
156 bases Human BAC RP11-450E9, chr2 AC062029.7 
   
P4.2 Human BAC RP11-461L13, chr 4 AC080078.7 
158 bases Human chr? (1e1-36) AC010409 
  Human clone RP11-169K16, chr1 AL450998.19 
  Human clone D47-S479, chr21q22.2 AP000153.1 
   
P4.4 
Human clone FLB4816, 
PRO1252mRNA AF130054 
157 bases Human clone RP11-497D24, chr2 AC012076.5 
  Human clone RP11-255C15, chr3 AC007823.38 
   
   
P5-1; P5-3; P5-5 Human clone RP13-98N21, chr 15 AC126339.6 
P7-1 Human clone RP13-996F3, chr 15 AC139425.3 
106 bases Human clone RP13-262C2, chr 15 AC136698.6 
  Human clone RP11-561C5, chr15 AC044860.11 
  Human clone RP11-606M5, chr 15 AC126605.4 
  Human PAC RP5-1129D5, chr15 AC005630.1 
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P6-1; P6-2; P6-3 Human genomic DNA, chr22q11.2 AP000344.1 
P7-2; P7-3 Human hypothetical protein FLJ31568  NM_152509.1 
100 bases except P7-3  Human cDNA FLJ35262 fis AK092581.1 
(102, CT insert) Human cDNA FLJ35211 fis  AK092530.1 
   
P8.2 
Human clone RP1-34B21, chr6p12.1-
21.1 AL031778.1 
134 bases Human clone RP11-57G22, chr 18 AC012123.8 
  Human clone RP11-386P4, chr18?  AC025887 
   
P8.3 TPA human chr 7 BL000001.1 
136 bases human chr 14 clone AC025594 
  human chr 7 clone AC018639 
   
P8.4 Human clone RP11-387M24,  AL355385.15 
104 bases     
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Chapter four 
 
Discussion 
 
The studies described in this thesis were designed to test the hypothesis that 
women with PCOS are not at increased risk of developing epithelial ovarian 
cancer compared to controls that do not have PCOS. 
4.1 The aims of the studies were to: 
1. Assess the history of ovarian cancer in first degree relatives of PCOS women. 
2. Assess the degree of morphological abnormality in the ovarian epithelium of 
women with PCOS. 
3. Assess cell cycle and apoptotic protein expression in the ovarian surface 
epithelium of women with PCOS and healthy controls. 
4. Assess gene expression in the ovaries of women with PCOS, healthy controls  
 
and women with serous epithelial ovarian cancer  
 
4. 2 Questionnaire study 
The results of this questionnaire study showed women with PCOS were more 
likely to have a first degree relative with a family history of breast cancer and heart 
disease. However, there was no increase in the family history of ovarian cancer in 
this group when compared to women without PCOS. 
Conversely, Moni et al, (2009) conducted a similar study in 549 infertile Iranian 
women (273 with PCOS and 276 controls). A significantly higher proportion of 
the PCOS subjects reported a family history of breast cancer compared to the 
controls (4.35% vs. 1.30%, p=0.02).  A possible explanation for the difference in 
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the results of our study compared to Moni et al’s, (2009) could be that in my study 
the subjects were from different ethnic background. Likewise, the ages of the 
relatives in both studies were not considered as some women develop cancers at 
different stages of their lives. 
 
The finding of an increased prevalence of breast cancer in the relatives of PCOS 
women is therefore rather surprising. This association could theoretically result 
from some genetic predisposition to breast cancer in PCOS women. The most well 
known genetic factors conferring an inherited susceptibility to breast and ovarian 
cancers are mutations of BRCA1 and BRCA2 genes (Brody et al, 1998). However, 
there is no available study to assess mutations of BRCA1 and BRCA2 genes in 
PCOS. 
Although the genetics of PCOS have not yet been elucidated, studies of first-
degree relatives of women diagnosed with PCOS reveal familial clustering of the 
disease, particularly hyperandrogenaemia. A prospective study (Strauss et al, 
2003) of first-degree female relatives of PCOS women found that 46% of 
ascertainable sisters of PCOS women were hyperandrogenaemic. The serum 
bioavailable testosterone in the cohort of sisters showed a bimodal distribution. 
These observations suggest a dominantly inherited trait controlling androgen 
levels.  
Nicolás Díaz-Chico et al., 2007 and Travis et al, 2003 studies have found elevated 
blood concentrations of androgens were associated with increased risk of breast 
cancer in both pre and post-menopausal women and thus, androgens may be 
potential factors linking obesity and breast cancer (Travis et al, 2003).  
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An alternative explanation for the finding of breast cancer in relatives of PCOS 
women is that there is some predisposing familial endocrine or metabolic 
disturbance in women with PCOS.  Liede et al, 2000, reported two families 
sharing an unusual clustering of pyloric stenosis, endometriosis, and breast cancer 
and that one of these families contained nine women with PCOS. They 
hypothesized that there could be a common genetic basis for these conditions and 
highlighted that pyloric stenosis has been linked to the locus of the neuronal nitric 
oxide synthase (NOS1) gene. Such a linkage could also explain the endothelial 
dysfunction identified in PCOS women (Lakhani et al, 2006). However, in the 
Baskol et al. (2012) study no significant difference was found between nitric oxide 
and thiol level activities of women with PCOS and controls (p>0.05). 
An association between PCOS and a family history of breast cancer could also be 
related to increase BMI, on the basis that relatives of women with PCOS may 
themselves be overweight or obese. These conditions are associated with 
hyperinsulinaemia, high circulating levels of serum C-peptide, which are known to 
be a risk of post-menopausal breast cancer (Schairer et al, 2004, Goodwin et al, 
2002, Yang et al, 2001, Suga et al, 2001, Toniolo et al, 2000 and Del Giudice et 
al, 1998). It is reasonable to conclude that women with PCOS might be more 
likely to develop breast cancer because obesity is more common in PCOS and 
most large epidemiological studies have found that overweight or obese women 
are at increased risk of developing postmenopausal breast cancer.  
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4. 3 Morphological assessment of ovarian surface epithelium  
In this study, the results of the detailed morphological examination of the ovarian 
surface epithelium in PCOS women revealed an increased prevalence of 
psammoma bodies and mitoses were more common compared to controls. 
These findings could have been the early morphological changes leading to 
ovarian cancer as Ferenczy et al, (1977) observed the formation of PBs which was 
initiated intracellulary in neoplastic epithelial cells and they concluded that PBs in 
ovarian papillary serous neoplasm was a consequence of dysmorphic calcification 
associated with cellular degeneration. 
Kozlovskii et al, (1978) followed all stages of PBs formation and observed that it 
is formed as a result of continuous deposition of micro crystals of oxyapatites on 
accumulations of protein substances in ergastoplasma cisterns and on the 
mitochondrial cristae giving rise to intracytoplasmic inclusions. After 
convergence, these inclusions fill the cell resulting in cell death and liberation of 
small PBs (Das et al, 2009).  
All women in this study were complaining of infertility and for this reason ovarian 
biopsy was performed and subsequently they were exposed to ovulation induction 
drugs.  This allowed a comparison of these morphological changes in PCOS and 
controls. The findings of no significant difference in total dysplasia score suggest 
that these drugs were not responsible for these subtle, but potentially premalignant 
changes.  This is in accordance with results of a study published by Dos Santos 
Silva et al, (2009).  In that retrospective study to assess long-term health effects of 
ovarian-stimulation drugs, 7355 woman were  followed up for over 20 years; 43% 
were prescribed ovarian-stimulation drugs, and 367 incident cancers and 274 
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deaths were identified. There were no significant differences in the risk of cancer 
of the ovary between women who had been prescribed ovarian-stimulation drugs 
and those who had not. It should be noted however, that the subjects for the studies 
in this thesis were also included in the cohort of women with ovulatory disorders 
studied by Dos Santos Silva et al, (2009). Histological examinations for early 
dysplasia changes were examined only in our study.  
Like the Dos Santos Silva et al, (2009) study, studies conducted by Ness et al, 
(2002), Potashnik et al (1999), Modan et al (1998), and Mosgaard et al (1997) 
concluded that treatment with ovulation-inducing drugs did not appear to increase 
the risk for ovarian cancer. Conversely, Ness et al (2002) and Rossing et al (1994) 
noticed that fertility drug use was associated with a significantly increased risk of 
borderline serous ovarian tumours when analysed by histological subtypes of 
cancer. 
4. 4 Cell cycle and apoptotic protein expression  
The finding of this study demonstrated an increased p53 expression in PCOS 
ovaries which suggested that those lesions identified using morphological criteria, 
may have increased malignant potential.  
Increased expression of p53 protein was found in approximately 50% of invasive 
epithelial ovarian tumours and in inclusion cysts and endometriosis adjacent to 
invasive tumours (Kihana et al, 1992). Although positive immunostaining can 
result from increased expression of wild-type p53, it usually reflects mutation of 
the p53 tumour suppressor gene resulting in abnormal protein expression which 
accumulates in the nucleus.  Such mutations, which are very uncommon in normal 
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ovarian epithelium, are believed to be a crucial step in the development of ovarian 
malignancy.  
In the light of the results, future work will be required to sequence p53 in these 
ovaries to obtain evidence of gene mutation. It can be hypothesized that such 
mutations will be more prevalent in ovarian epithelial cells which exhibit signs of 
dysplasia.  Confirmation of p53 mutations in p53 positive ovarian epithelium 
would challenge the ethics of any future prospective study on the progression and 
behaviour of ovarian epithelial dysplasia, if a method was available to diagnose 
dysplasia in vivo. 
It is perhaps surprising that there was no significant difference in expression of 
proliferation marker, Ki-67 and the anti-apoptotic protein, bcl-2 in control and 
PCOS ovaries (p= 0.89 and 0.57 respectively).  
The expression of the human protein Ki-67 is associated with cell proliferation. 
During interphase, the antigen can only be detected within the nucleus, whereas in 
mitosis, the majority of the protein is trans-located to the surface of the 
chromosomes. The fact that Ki-67 protein is present during all the active phases of 
the cell cycle (G1, S, G2 and mitosis), and absent from the G0 phase, has made it 
an excellent marker for determining the growth fraction of a determined cell 
population (normal or tumoural) (Scholzen et al, 2000). 
The results did show marginally increased expression of Cyclin in the surface 
ovarian epithelium of PCOS women. The D type Cyclins are a family of proteins 
which regulate the activity of Cyclin dependent kinases.  These phosphorylate the 
retinoblastoma protein, which undergoes conformational change to release 
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transcription factors which coordinate expression of G1 and early S phase genes 
required for cell cycle progression.  
In summary, the results suggest that there is an abnormality of cell cycle regulation 
in ovarian epithelial dysplasia.  In view of these results, it would be important to 
study later ovarian cancer incidence in these women.  
 
4.5 Gene expression  
In the RT-PCR DD study, smooth muscle α2-actin (αSMA) was found to be over 
expressed in PCOS which is a novel finding.  α-SMA is one of three actin isoforms 
expressed in fibroblast cells and is also expressed in vascular smooth muscle cells. 
Its expression is regulated by hormones, cell proliferation and pathological 
conditions including oncogenic transformation (Bushel et al, 1995, Kumar et al, 
1992, Owens et al, 1986 & Leavitt et al, 1985). The αSMA promoter is highly 
conserved between human, mouse and chicken genes (Reddy et al, 1990). αSMA 
promoter activity is represented in transformed cell lines (Bushel et al, 1995 and 
Kumar et al, 1992). Its activity is regulated by cell proliferation. Actively 
proliferating fibroblast cells and smooth muscle cells have low levels of αSMA; 
inhibition of cell proliferation, by density arrest or treatment with antimitotic 
agents has been found to induce αSMA promoter activity (Kumar et al, 1995, 
Owen et al, 1986 & Leavitt et al, 1985).  
Increased stromal blood flow was observed in the PCOS group by transvaginal 
colour Doppler evaluation (Abd El Aal et al., 2005 and Loverro et al., 2001). In 
the Abd El Aal study serum levels of vascular endothelial growth factor (VEGF), 
insulin-like growth factor-1 (IGF-1) and hormonal profile were measured in fifty 
women diagnosed with PCOS compared with twenty healthy and fertile women 
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with regular menstrual cycles (Abd El Aal et al., 2005). Significantly higher serum 
levels of VEGF and IGF-1 in PCOS women (P <0.001 and P <0.01, respectively) 
were noted. This may be related to the increased vascularity that underlies the 
increased blood flow demonstrated by Doppler blood flow measurements in these 
women. 
Czernobilsky et al (1989) conducted an immunohistochemical investigation of 
alpha-smooth muscle actin (α -SMA) using the monoclonal anti α -SMA -1 
antibody in 15 normal ovaries in three ovaries with stromal hyperplasia and in 27 
neoplastic ovaries. The pattern of actin isoforms was examined by using 2 D-gel 
electrophoresis. In normal ovaries, α -SMA was found in the inner cortex and in 
the theca externa. In ovarian stromal hyperplasia expression of α -SMA was 
minimal or absent. In primary and metastatic epithelial tumours there was positive 
stromal staining for α -SMA, especially in the vicinity of epithelial elements which 
was more widespread in malignant neoplasm. Thecomas did not express α -SMA 
and could be differentiated from leiomyomas which stained intensely for α -SMA. 
Only focal stromal staining of α -SMA was observed in granulosa and germ cell 
tumours. 
In all the tissues studied blood vessels were strongly positive for α -SMA. Desmin, 
although present in the stroma of most of the specimens, was less abundant than   
α –SMA. Therefore, it was concluded that α -SMA is a component of the normal 
human ovary and contributes to the contractility of its stroma. Its absence in the 
normal outer cortex, theca interna and in stromal hyperplasia and thecoma 
suggests that sex hormones do not stimulate α -SMA production in the ovary. 
Among neoplasm it is most widely represented in the stroma of epithelial tumours 
reflecting stromal stimulation mediated by neoplastic epithelium. 
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Cortón et al, (2007) carried out a similar case-control study to examine gene 
expression profiles of omental fat. Biopsy samples obtained from morbidly obese 
women with or without PCOS at the time of bariatric surgery. Eight PCOS patients 
and seven controls were recruited for the study. Cortón et al, (2007) identified 
changes in the expression patterns of 63 genes between PCOS and control 
samples. α -SMA was found to be a down-regulated gene in PCOS. The 
disagreement in findings could be due to the nature of the samples used as in this 
study, ovarian samples were used compared to omental fat in Cortón et al’s (2007) 
study.  
Kobayashi et al, (1993) compared the expression of α -SMA between benign and 
malignant human ovarian tissues by immunohistochemical staining and Western 
blot analysis using the monoclonal antibody specific to α -SMA. In normal human 
ovaries, α -SMA was found in the blood vessel walls, muscle fibres, and stromal 
cells surrounding the follicles. The main source of α -SMA in the benign ovarian 
tumours was the blood vessel walls which highly expressed α -SMA throughout 
the tumour. In malignant tumour tissues, however, the vessels located in or close 
to the cluster of cancer cells did not express α -SMA. It corresponded with the 
results of the Western blot analysis, indicating the amount of α -SMA in malignant 
ovarian tumour tissues was less than that in benign tumour tissues. Ther alteration 
in α -SMA expression may reflects the qualitative difference in vessels between 
benign and malignant ovarian tissues and therefore α -SMA could be a 
histopathologically useful marker for indicating the malignant potential of ovarian 
tumours. 
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4.6 Conclusion 
The hypothesis of this study was to establish whether or not there is an association 
between PCOS and ovarian cancer. Having reviewed the finding of all four areas 
(family history in patients with PCOS, ovarian surface epithelial morphology, cell 
cycle and apoptotic protein expression and gene expression), the evidence is not 
strong enough to link PCOS to ovarian cancer, directly or indirectly. In the 
questionnaire study, the relationship between the familiar association and PCOS 
and breast cancer could be incidental or due to other factors, such as raised BMI or 
genetic predisposition, which may have no direct link to PCOS. In the second area 
of this study which examined the ovarian epithelial changes, only two of eight 
features of the dysplasia criteria were identified.  Consequently, there is inadequate 
evidence to make a link to ovarian cancer and therefore the findings are 
inconclusive.  In the cell cycle changes study only p53 expression was a 
statistically significant finding which could be explained as due to the nature of 
PCOS and hyper androgenic state of the syndrome. This finding was also 
inconclusive as other parameters did not reveal any significant alterations in the 
cell cycle. Lastly, in the RT-PCR DD study, α-SMA was one of the genes traced 
but this gene is a normal component of the ovary and its high expression is due to 
the nature of the syndrome.  
Therefore, in conclusion, there is no direct link between PCOS and cancer of the 
ovaries. The association that Fthalla (1971) made between anovulation and ovarian 
cancer may be outdated, and newer theories linking infertility, tubal changes with 
ovarian cancer may be the direction to investigate. 
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4.7 Suggestions for future work 
1. Follow up of the biopsy patients who have been flagged on the NHS Central 
Register (as part of CR UK funded study published by Dos Santos Silva et 
al, (2009) to assess the incidence of ovarian cancer in relation to the degree 
of morphology abnormality and cell cycle/ apoptotic protein expression 
data. 
2. To micro dissect and laser capture p53 positive cells from the ovarian 
biopsies, extract and sequence the DNA. 
3. Quantitative study (using an ELISA) of α smooth muscle actin in serum of 
PCOS women and healthy controls, to investigate a possible role as a 
biomarker for PCOS. 
4. To test the hypothesis that NOS1 is a susceptibility locus for PCOS, 
perform linkage analysis and the transmission disequilibrium test using 
NOS single nucleotide polymorphisms in PCOS subjects and first degree 
relatives. 
5. Immunohistochemistry using antibody to alpha smooth actin or in FISH to 
identify anatomical site of increased expression of this protein. 
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Appendices  
 
Appendix 1: Invitation letter to the family history study 
_____________________________________________________________ 
Royal Free & University College Medical School 
UNIVERSITY COLLEGE LONDON     
DEPARTMENT OF OBSTETRICS & GYNAECOLOGY 
Royal Free Campus 
Rowland Hill Street 
London NW3 2PF 
Tel: (020) 7794 0500 
Fax: (020) 7830 2261 
Head of Department  Professor A B MacLean (3736) 
 
Patient`s address 
Date:  
Dear  Patient`s name 
According to my records you were attending my Gynaecology clinic at the North Middlesex 
Hospital, and I am writing to you to ask for your help in a research project which has been designed 
to investigate a possible association between some hormonal conditions and certain health 
problems. This project has been approved by Enfield and Haringay Health Authority, Local 
Research Ethics Committee 
I would be very grateful if you could fill in the short form attached, and return to us in the envelope 
provided. Your participation in this project is voluntary and your care will not be affected if you 
decide not to take part.  However your reply will be treated in the strictest confidence, and will 
provide important information which will help us to improve treatment for women with fertility 
problems. 
Yours Sincerely 
 
Mr Paul Hardiman MD FRCOG 
Senior Lecturer, Honorary Consultant in Obstetrics and Gynaecology 
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Appendix 2: Reminder letter to the invitation to the family history study 
__________________________________________________________________ 
Royal Free & University College Medical School 
UNIVERSITY COLLEGE LONDON     
DEPARTMENT OF OBSTETRICS & GYNAECOLOGY 
Royal Free Campus 
Rowland Hill Street 
London NW3 2PF 
Tel: (020) 7794 0500 
Fax: (020) 7830 2261 
Head of Department  Professor A B MacLean (3736) 
Patient`s address 
 
Date:  
Dear  Patient`s name 
At the end of January, I wrote to you asking for your help in a research project designed to 
investigate a possible association between some hormonal conditions and certain health problems. 
According to my records I have not received a reply to this letter and I am concerned that you may 
not have received it. I therefore enclose a copy of the original questionnaire and I would be very 
grateful if you could complete it and return to me in the postage-paid envelope provided. 
 
As mentioned in the previous letter; your participation in this project which has been approved by 
Enfield and Haringey Health authority, local research ethics Committee,  is voluntary and your care 
will not be affected if you decide not to take part. The information, which you give, will be treated 
confidentially; and will help us to improve treatment for women with fertility problems. 
Your participation in this project will be much appreciated. 
Yours Sincerely 
 
P Hardiman MD FRCOG 
Senior lecturer,  
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Appendix 3: Immunohistochemistry protocols  
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Appendix 4: Immunohistochemistry statistics  
__________________________________________________________________ 
 
  p53 Cyclin D mib bcl TDS 
N 1.94 1.53 1.18 96.21 1 
N 31.63 0 15.21 89.24 1 
N 0 0 0 44.02 3 
N 30.23 0 9.67 72.61 1 
N 0 0 94.02 100 6 
N 0 0 1.68 0 3 
N 2.4   0.03 0 2 
N 20.4 0   100 5 
N 0 0.68 0 100 3 
N 21.14 0 2.12 100 1 
N 12.44 3.25 0 98.24 1 
N 38 1.01 0 100 1 
N 14.12 21.97 0 82.52 1 
N 11.11   0 100 1 
N 13.33 0 0 100 4 
Mean  13.1 2.2 8.9 78.9 2.3 
      
PCOS 44.12 1.08 1.42 78.75 1 
PCOS 19.23 3.78 5 98.75 1 
PCOS 20.48 3.03 23.17 30.61 1 
PCOS 77.44 0 9.16 100 5 
PCOS 84.94 10.4 6.89 85.14 4 
PCOS 0 14.67 0 92.63 1 
PCOS 77.06 3.02 40.91 92.76 1 
PCOS 7.35 0 8.2 76.4 1 
PCOS 57.59 17.04 25.75 100 1 
PCOS 28.26 20 4.35 96.07 1 
PCOS 35.3 9.56 3.26 62.66 1 
PCOS 19.04 2.7 0 92.45 0 
PCOS 46.31 9.25 0 100 2 
Mean  39.8 7.3 9.9 85.1 1.5 
T test 0.002545 0.053672 0.897063 0.579269 0.225025 
Mean percentage cells stained positive for cyclin D1, mib, p53 and bcl in the 
ovarian surface epithelium of PCOS subjects and controls 
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  p53 Cyclin D mib bcl Clomid TDS 
N 1.94 1.53 1.18 96.21 NO 1 
N 31.63 0 15.21 89.24 NO 1 
N 0 0 94.02 100 NO 6 
N 20.4 0   100 NO 5 
N 0 0.68 0 100 NO 3 
PCOS 20.48 3.03 23.17 30.61 NO 1 
PCOS 77.44 0 9.16 100 NO 5 
PCOS 57.59 17.04 25.75 100 NO 1 
PCOS 28.26 20 4.35 96.07 NO 1 
PCOS 35.3 9.56 3.26 62.66 NO 1 
Mean 27.3 5.2 19.6 87.5   2.5 
        
N 0 0 0 44.02 YES 3 
N 30.23 0 9.67 72.61 YES 1 
N 0 0 1.68 0 YES 3 
N 2.4   0.03 0 YES 2 
N 21.14 0 2.12 100 YES 1 
N 12.44 3.25 0 98.24 YES 1 
N 38 1.01 0 100 YES 1 
N 14.12 21.97 0 82.52 YES 1 
N 11.11   0 100 YES 1 
N 13.33 0 0 100 YES 4 
PCOS 44.12 1.08 1.42 78.75 YES 1 
PCOS 19.23 3.78 5 98.75 YES 1 
PCOS 84.94 10.4 6.89 85.14 YES 4 
PCOS 0 14.67 0 92.63 YES 1 
PCOS 77.06 3.02 40.91 92.76 YES 1 
PCOS 7.35 0 8.2 76.4 YES 1 
PCOS 19.04 2.7 0 92.45 YES 0 
PCOS 46.31 9.25 0 100 YES 2 
Mean 24.5 4.4 4.2 78.6   1.6 
        
T test 0.778883 0.793027 0.052621 0.445574  0.152468 
 
 
Cell cycle protein expression (% positive cells) and total dysplasia score in subject 
expose according to previous exposure to clomiphene citrate 
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  p53 Cyclin D mib bcl hMG TDS 
N 31.63 0 15.21 89.24 NO 1 
PCOS 20.48 3.03 23.17 30.61 NO 1 
PCOS 77.44 0 9.16 100 NO 5 
PCOS 57.59 17.04 25.75 100 NO 1 
PCOS 28.26 20 4.35 96.07 NO 1 
PCOS 35.3 9.56 3.26 62.66 NO 1 
N 0 0 0 44.02 NO 3 
N 0 0 1.68 0 NO 3 
N 21.14 0 2.12 100 NO 1 
N 12.44 3.25 0 98.24 NO 1 
N 38 1.01 0 100 NO 1 
N 14.12 21.97 0 82.52 NO 1 
N 11.11   0 100 NO 1 
N 13.33 0 0 100 NO 4 
PCOS 44.12 1.08 1.42 78.75 NO 1 
PCOS 19.23 3.78 5 98.75 NO 1 
PCOS 84.94 10.4 6.89 85.14 NO 4 
PCOS 77.06 3.02 40.91 92.76 NO 1 
PCOS 19.04 2.7 0 92.45 NO 0 
PCOS 46.31 9.25 0 100 NO 2 
N 1.94 1.53 1.18 96.21 NO 1 
N 0 0 94.02 100 NO 6 
N 30.23 0 9.67 72.61 NO 1 
Mean 29.7 4.9 10.6 83.5   1.8 
        
N 2.4   0.03 0 YES 2 
PCOS 0 14.67 0 92.63 YES 1 
PCOS 7.35 0 8.2 76.4 YES 1 
N 20.4 0   100 YES 5 
N 0 0.68 0 100 YES 3 
Mean 15.6 1.6 28.6 64.0   2.7 
       
T test 0.049974 0.781109 0.43099 0.508516  0.466868 
 
 
 
Cell cycle protein expression (% positive cells) and total dysplasia score in subject 
expose according to previous exposure to human menopausal gonadtrophins 
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  p53 Cyclin D mib bcl GnRH TDS 
N 31.63 0 15.21 89.24 NO 1 
PCOS 20.48 3.03 23.17 30.61 NO 1 
PCOS 77.44 0 9.16 100 NO 5 
PCOS 57.59 17.04 25.75 100 NO 1 
PCOS 28.26 20 4.35 96.07 NO 1 
PCOS 35.3 9.56 3.26 62.66 NO 1 
N 0 0 0 44.02 NO 3 
N 0 0 1.68 0 NO 3 
N 2.4   0.03 0 NO 2 
N 21.14 0 2.12 100 NO 1 
N 12.44 3.25 0 98.24 NO 1 
N 38 1.01 0 100 NO 1 
N 14.12 21.97 0 82.52 NO 1 
N 11.11   0 100 NO 1 
N 13.33 0 0 100 NO 4 
PCOS 44.12 1.08 1.42 78.75 NO 1 
PCOS 19.23 3.78 5 98.75 NO 1 
PCOS 84.94 10.4 6.89 85.14 NO 4 
PCOS 0 14.67 0 92.63 NO 1 
PCOS 77.06 3.02 40.91 92.76 NO 1 
PCOS 7.35 0 8.2 76.4 NO 1 
PCOS 19.04 2.7 0 92.45 NO 0 
PCOS 46.31 9.25 0 100 NO 2 
Mean  28.8 5.8 6.4 79.1   1.7 
        
N 1.94 1.53 1.18 96.21 YES 1 
N 0 0 94.02 100 YES 6 
N 20.4 0   100 YES 5 
N 0 0.68 0 100 YES 3 
N 30.23 0 9.67 72.61 YES 1 
Mean 10.5 0.4 26.2 93.8   3.2 
       
T test 0.137539 0.117067 0.059857 0.314871  0.042168 
 
 
 
Cell cycle protein expression (% positive cells) and total dysplasia score in subject 
expose according to previous exposure to gonadotrophin releasing hormone. 
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  p53 Cyclin D mib bcl 
Any 
treatment 
TDS 
N 31.63 0 15.21 89.24 NO 1 
PCOS 20.48 3.03 23.17 30.61 NO 1 
PCOS 77.44 0 9.16 100 NO 5 
PCOS 57.59 17.04 25.75 100 NO 1 
PCOS 28.26 20 4.35 96.07 NO 1 
PCOS 35.3 9.56 3.26 62.66 NO 1 
Mean 41.8 8.3 13.5 79.8   1.7 
        
N 0 0 0 44.02 YES 3 
N 0 0 1.68 0 YES 3 
N 21.14 0 2.12 100 YES 1 
N 12.44 3.25 0 98.24 YES 1 
N 38 1.01 0 100 YES 1 
N 14.12 21.97 0 82.52 YES 1 
N 11.11   0 100 YES 1 
N 13.33 0 0 100 YES 4 
PCOS 44.12 1.08 1.42 78.75 YES 1 
PCOS 19.23 3.78 5 98.75 YES 1 
PCOS 84.94 10.4 6.89 85.14 YES 4 
PCOS 77.06 3.02 40.91 92.76 YES 1 
PCOS 19.04 2.7 0 92.45 YES 0 
PCOS 46.31 9.25 0 100 YES 2 
N 1.94 1.53 1.18 96.21 YES 1 
N 0 0 94.02 100 YES 6 
N 30.23 0 9.67 72.61 YES 1 
N 2.4   0.03 0 YES 2 
PCOS 0 14.67 0 92.63 YES 1 
PCOS 7.35 0 8.2 76.4 YES 1 
N 20.4 0   100 YES 5 
N 0 0.68 0 100 YES 3 
Mean  22.1 3.9 8.6 84.1   2.0 
       
T test 0.067483 0.147673 0.566064 0.853533  0.651773 
 
 
Cell cycle protein expression (% positive cells) and total dysplasia score in subject 
expose according to previously exposure to any ovulation induction treatment 
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Appendix5: Ethical Approval 
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Appendix 6: Differential Display  
 
 
 
 
 
 
 
Extracted RNA: (A) intact RNA, S18 and 28S are clearly seen (B&C) degraded 
RNA. 
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Polyacrylamide gel electrophoresis for DD PCR (after 18 exposure).  Upstream 
primers EPA 1 and 2. Arbitrary primer ET 12. After 18 hours exposure. Showing 
where differentially expressed bands 
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Polyacrylamide gel electrophoresis for DD PCR (after 18 exposure).  Upstream 
primers EPA 1 and 2. Arbitrary primer ET 12. After 18 hours exposure. Showing 
where differentially expressed bands are extracted. 
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CODE RNA DiffD 
N1 NO  
N2 NO  
N3 NO  
N4 NO  
N5 YES YES 
N6 NO  
N7 YES YES 
N8 NO  
N9 YES YES 
N10 NO  
N11 YES  
N12 YES  
N14 YES  
N15 NO  
N17 YES  
N18 YES  
N20 NO  
N21 NO  
N23 NO  
C1 NO  
C2 YES  
C3 NO  
C4 NO  
C5 YES YES 
C6 YES YES 
C7 NO  
C8 NO  
C9 YES YES 
C11 YES  
C12 YES  
C13 YES  
C14 NO  
C15 YES  
C16 YES  
C18 YES  
C19 YES  
P5 YES  
P5 YES  
P1 YES YES 
P2 YES YES 
P2/B YES YES 
P4 NO  
P6 NO  
P7 NOT USED  
 
Ovarian samples used in the study ;( N) Normal, (C) cancer, (P) PCOS 
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Un purified 
 
     Purified   
CODE Date.pro ul vol ug/ul tot ug µl vol µg/µl total µg 
C2 13.02.03 27 3.08 86.24       
C5 19.11.02       178 6.92 1231.76 
C11 13.02.03 45 12.64 44.82       
C12 13.02.03 43 1.06 12.92       
C15 13.02.03 77 9.57 746.4       
C18 13.02.03 77 9.269 723       
C6 19.11.02       402 2.42 972.84 
C9 02.12.02       8.46 1.8 15.228 
C16 10.03.03 26 9.560 248.56       
C13 10.03.03 26 12.36 321.4       
C20 13.02.03 17 0.76 12.92       
C19 10.03.03 26 1.18 30.68       
                
N5 19.11.02       20 5.04 100.8 
N9 02.12.02       4.56 1.2 5.472 
N14 10.03.03 26 2.02 52.52       
N18 13.02.03 43.8 1.42 62.2       
N11  08.02.03 22.2 1.02 55.68       
N12 13.02.03 43.1 1.04 44.82       
N17 13.02.03 43.5 1.28 55.68       
N7 02.12.02 24 3.24 44.82 9.5 2.98 28.31 
N21 10.03.03 26 2.46 63.96       
                
P1 02.12.02 14 1.72 12.92 9 0.96 8.64 
P2 02.12.02 19 1.6 55.68 11.35 1.74 19.749 
P2/B 02.12.02 24 2.96 62.2 8.8 2.5 22 
P5 10.03.03 26 4.72 122.7       
P5/B 10.03.03 26 6.02 156.5       
 
RNA extracted quantification.  (N) Normal, (C) cancer, (P) PCOS 
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Spectrophotometeric determination of RNA concentration 
 
 
 
 
 
µl 
vol RNA diluent diln x 
280 
nm 
260 
nm 
280 
nm 
260 
nm 260/280 µg/µl 260/280 µg/µl 
total 
µg 
N3 9 1 999 1000 0.069 0.088 0.069 0.088 1.28 3.52 1.48 3.440 30.96 
  1 999 1000 0.050 0.084 0.050 0.084 1.68 3.36    
N5 22 1 999 1000 0.102 0.177 0.102 0.177 1.74 7.08 1.31 5.900 129.80 
  1 999 1000 0.134 0.118 0.134 0.118 0.88 4.72    
N9 9 1 999 1000 0.035 0.056 0.035 0.056 1.60 2.24 1.64 2.640 23.76 
  1 999 1000 0.045 0.076 0.045 0.076 1.69 3.04    
C4/A 9 1 999 1000 0.150 0.207 0.150 0.207 1.38 8.28 1.37 8.120 73.08 
  1 999 1000 0.147 0.199 0.147 0.199 1.35 7.96    
C6/A 44 1 999 1000 0.232 0.344 0.232 0.344 1.48 13.76 1.63 13.620 599.28 
  1 999 1000 0.189 0.337 0.189 0.337 1.78 13.48    
C4/B 24 1 999 1000 0.042 0.060 0.042 0.060 1.43 2.40 1.43 2.320 55.68 
  1 999 1000 0.039 0.056 0.039 0.056 1.44 2.24    
C5 44 1 999 1000 0.141 0.208 0.141 0.208 1.48 8.32 1.47 8.540 375.76 
  1 999 1000 0.129 0.219 0.150 0.219 1.46 8.76    
C6/B 94 1 999 1000 0.152 0.217 0.152 0.217 1.43 8.68 1.44 8.800 827.20 
  1 999 1000 0.153 0.223 0.153 0.223 1.46 8.92    
 P1 9 1 999 1000 0.035 0.043 0.035 0.043 1.23 1.72 1.22 2.580 23.22 
  1 999 1000 0.071 0.086 0.071 0.086 1.21 3.44    
P2 24 1 999 1000 0.071 0.086 0.071 0.086 1.21 3.44 1.26 3.580 85.92 
  1 999 1000 0.071 0.09 0.071 0.093 1.31 3.72    
P2/B 24 1 999 1000 0.181 0.266 0.181 0.266 1.47 10.64 1.45 9.840 236.16 
  1 999 1000 0.159 0.226 0.159 0.226 1.42 9.04    
P4 40 1 999 1000 0.022 0.026 0.022 0.026 1.18 1.04 1.18 1.200 48.00 
  1 999 1000 0.029 0.034 0.029 0.034 1.17 1.36    
N5\B 8 1 999 1000 0.123 0.18 0.123 0.177 1.44 7.08 1.16 5.900 47.20 
  1 999  0.134 0.118 0.134 0.118 0.88 4.72    
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PCR of cDNA used in DD: (1-3) Cancer (4-6) Normal and (7-9) PCOS  using 
1.5µl/15µl reaction at x10, x20, x40 and x80 dilution 
 
. 
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PCR 
NO. BAND effect 
PCR 
NO. BAND effect 
PCR 
NO. BAND effect 
1 C1 C>N 62 C31 1C>N 13 P8 P<N 
2 C2 C>N 71 C32 2C>N 14 P9 P<N 
3 C3 C>N 72 C33 2C>N 32 P10 P<N 
4 C4 C>N 73 C34 1C>N 33 P11 P<N 
5 C5 1C>N 75 C35 3C<N 34 P12 P<N 
21 C6 1C>N 76 C36 2C>N 35 P13 P<N 
22 C7 2C>N 77 C37 1C>N 36 P14 P>N 
23 C8 1C>N 79 C38 2C>N 37 P15 P<N 
24 C9 1C>N 80 C39 1C>N 38 P16 P<N 
25 C10 1C>N 81 C40 2C>N 43 P17 P>N 
26 C11 1C>N 82 C41 2C>N 44 P18 P<N 
27 C12 1C>N 83 C42 1C>N 45 P19 P<N 
28 C13 2C>N 84 C43 1C>N 49 P19 P<N 
29 C14 2C>N 86 C44 3C>N 50 P20 P<N 
30 C15 1C>N 88 C45 2C>N 51 P21 P<N 
31 C16 1C>N 89 C46 2C>N 55 P22 P>N 
41 C17 1C>N 90 C47 1C>N 56 P23 P<N 
42 C18 1C>N 91 C48 2C>N 63 P24 P>N 
46 C20 1C>N 95 C49 1C>N 74 P25 P>N 
47 C21 1C>N 96 C50 1C>N 78 P26 P<N 
48 C22 1C>N 6 P1 P>N 85 P27 P>N 
52 C23 2C>N 7 P2 P>N 87 P28 P>N 
53 C24 1C>N 8 P3 P>N 92 P29 P<N 
54 C25 1C>N 9 P4 P>N 93 P30 P<N 
57 C26 1C>N 10 P5 P<N 94 P31 P>N 
58 C27 2C>N 11 P6 P<N 97 P32 P<N 
59 C28 1C>N 12 P7 P<N 98 P33 P<N 
60 C29 1C>N             
61 C30 1C>N             
Summary of gene expression of the DDRT-PCR products 
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Quantitative gel electrophoresis of re purified PCR products which shows only 
single bands with few primer dimmers. All run at 8, 4, and 2 µl. 
Cancer C, P Polycystic ovary, N Normal ovaries. 
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corr. for 
200 bp 
sample aka 
µl 
load 
µl 
DNA peak peak/µl fmol/µl av sd cv 
vs 250 bp 
stan 
DNA 
µl H2Oµl fmol/6µl 
6 P1 8 2 75.74 37.87 47.47 56.99 10.8 18.9 71.24 3.0 33.0 35.6 
  4 1 43.76 43.76 54.85        
  2 0.5 27.39 54.78 68.66        
7 P2 8 2 70.87 35.44 44.42 55.27 11.2 20.2 69.08 3.0 33.0 34.5 
  4 1 43.62 43.62 54.67        
  2 0.5 26.61 53.22 66.71        
8 P3 8 2 67.90 33.95 42.55 47.51 4.4 9.4 59.39 3.0 33.0 29.7 
  4 1 40.80 40.80 51.14        
  2 0.5 19.48 38.96 48.83        
9 P4 8 2 80.61 40.31 50.52 56.18 5.0 8.9 70.23 3.0 33.0 35.1 
  4 1 47.86 47.86 59.99        
  2 0.5 23.15 46.30 58.03        
10 P5 8 2 74.75 37.38 46.85 50.71 3.7 7.2 63.39 3.0 33.0 31.7 
  4 1 43.20 43.20 54.15        
  2 0.5 20.40 40.80 51.14        
11 P6 8 2 71.72 35.86 44.95 51.40 5.6 10.9 64.25 3.0 33.0 32.1 
  4 1 43.41 43.41 54.41        
  2 0.5 21.88 43.76 54.85        
12 P7 8 2 55.76 27.88 34.95 36.27 4.0 11.1 45.34 4.5 31.5 34.0 
  4 1 32.54 32.54 40.79        
  2 0.5 13.20 26.40 33.09        
              
Band intensity quantitation for single PCR products after purification (continued). 
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13 P8 8 2 55.13 27.57 34.55 32.81 3.3 10.0 41.02 4.5 31.5 30.8 
  4 1 27.81 27.81 34.86        
  2 0.5 11.58 23.16 29.03        
14 P9 8 2 80.12 40.06 50.21 57.60 6.4 11.1 71.99 3.0 33.0 36.0 
  4 1 48.93 48.93 61.33        
  2 0.5 24.43 48.86 61.24        
28 C13 8 2 68.67 34.34 43.04 47.79 4.3 8.9 59.74 3.0 33.0 29.9 
  4 1 40.87 40.87 51.23        
  2 0.5 19.59 39.18 49.11        
30 C15 8 2 54.92 27.46 34.42        
31 C16 4 1 28.96 28.96 36.30        
31 C16 2 0.5 17.36 34.72 43.52        
37 P15 8 2 47.86 23.93 29.99 26.59 3.0 11.2 33.24 6.0 30.0 33.2 
  4 1 20.13 20.13 25.23        
  2 0.5 9.79 19.58 24.54        
38 P16 8 2 64.22 32.11 40.25 40.57 0.9 2.2 50.71 4.5 31.5 38.0 
  4 1 31.80 31.80 39.86        
  2 0.5 16.59 33.18 41.59        
75 C35 8 2 30.11 15.06 18.87 18.93 0.8 4.3 23.66 9.0 27.0 35.5 
  4 1 14.47 14.47 18.14        
  2 0.5 7.89 15.78 19.78        
              
 
Band intensity quantitation for single PCR products after purification (continued). 
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77 C37 8 2 14.90 7.45 9.34 10.39 1.0 9.6 12.98 18.0 18.0 39.0 
  4 1 8.37 8.37 10.49        
  2 0.5 4.52 9.04 11.33        
78 P26 8 2 13.06 6.53 8.18 8.45 0.8 8.9 10.57 18.0 18.0 31.7 
  4 1 7.42 7.42 9.30        
  2 0.5 3.14 6.28 7.87        
83 C42 8 2 33.77 16.89 21.16 19.95 1.1 5.3 24.94 9.0 27.0 37.4 
  4 1 15.37 15.37 19.27        
  2 0.5 7.75 15.50 19.43        
97 P32 8 2 34.88 17.44 21.86 19.62 2.0 10.2 24.52 9.0 27.0 36.8 
  4 1 15.11 15.11 18.94        
  2 0.5 7.20 14.40 18.05        
98 P33 8 2 37.91 18.96 23.76 21.59 2.6 11.8 26.99 9.0 27.0 40.5 
  4 1 14.98 14.98 18.78        
  2 0.5 8.87 17.74 22.24        
30 C15 6 1.5 44.72 29.81 37.37 37.34 3.4 9.1 46.67 4.5 31.5 35.0 
  4 1 33.60 33.60 42.12        
  2 0.5 14.14 28.28 35.45        
31 C16 8 2 64.35 32.18 40.33 38.60 3.8 9.8 48.25 4.5 31.5 36.2 
  4 1 31.23 31.23 39.14        
  2 0.5 13.44 26.88 33.69        
              
 
 (continued) Band intensity quantitation for single PCR products after purification. 
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   corr       3x12 µl sequencing rxn (36 µl)   
sample aka fmol/µl fmol/µl 
DNA 
µl H2Oµl fmol/6µl  Up Lp DNA µl H2Oµl fmol/6µl    
6 P1 56.99 71.24 3.00 33.00 35.62114829 *P+ 1 A 3.0 33.0 35.6    
7 P2 55.27 69.08 3.00 33.00 34.541363 ***P+ 1 A 3.0 33.0 34.5    
8 P3 47.51 59.39 3.00 33 29.69343 *P+ 1 A 3.0 33.0 29.7    
9 P4 56.18 70.23 3.00 33 35.11324466 *P+ 1 A 3.0 33.0 35.1    
10 P5 50.71 63.39 3.00 33.00 31.6950141 **P- 1 C 3.0 33.0 31.7    
11 P6 51.40 64.25 3.00 33.00 32.12718916 **P- 1 C 3.0 33.0 32.1    
12 P7 36.27 45.34 4.50 31.50 34.00734654 **P- 1 C 4.5 31.5 34.0    
13 P8 32.81 41.02 4.50 31.50 30.76211657 *P- 1 C 4.5 31.5 30.8 =P16   
14 P9 57.60 71.99 3.00 33.00 35.99718 **P- 2 A 3.0 33.0 36.0    
28 C13 47.79 59.74 3.00 33.00 29.86969465 ***C+(2) 2 C 3.0 33.0 29.9    
30 C15 37.33783643 46.6723 4.50 31.50 35.00 *C+(1) 2 C 4.5 31.5 35.0    
31 C16 38.59712406 48.2464 4.50 31.50 36.18 ***C+(1) 2 C 4.5 31.5 36.2 =P9   
37 P15 26.58960343 33.237 6.00 30.00 33.24 *P- 2 C 6.0 30.0 33.2    
38 P16 40.56543992 50.7068 4.50 31.50 38.03 **P- 2 A 4.5 31.5 38.0    
75 C35 18.92900665 23.66 9.00 27.00 35.49 ***C- 5 C 9.0 27.0 35.5 tumour suppressor? 
77 C37 10.38682497 12.9835 18.00 18.00 38.95 *C+(1) 5 C 18.0 18.0 39.0    
78 P26 8.452351938 10.5654 18.00 18.00 31.70 *P- 5 C 18.0 18.0 31.7    
83 C42 19.95264789 24.9408 9.00 27.00 37.41 ***C+(3),*P+ 5 G 9.0 27.0 37.4    
97 P32 19.61630862 24.52 9.00 27.00 36.78 *P+ 6 G 9.0 27.0 36.8    
98 P33 21.59047387 26.9881 9.00 27.00 40.48 **P- 6 G 9.0 27.0 40.5    
                
Differential displayfragments characterisation 
. 
.  
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DNA quantitation in Hybaid column purified samples (30µl elutes) each loaded at 2.25, 1.5 
and 0.75 µl.  
7=P2 8=P3 14=P9   75=C35  97=P32. P(  PCOS), C(Cancer) 
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2% agrose electrophoresis of hybaid purified EcoRI and XhoI  cleaved differentially displayed 
fragments (P1-P33). 
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2% agrose electrophoresis of hybaid purified EcoRI and XhoI  cleaved differentially displayed 
fragments (C13-C42). S (Standred). 
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Estimation of DNA content in re purified restriction enzyme digested PCR fragment 
preparations. 100bp marker on the left side for size estimation. 
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T3-T7 PCR of plasmid preparations. 
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PvuII digest of plasmid DNA isolated from first set of clones 
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T3-T7 PCR products  from the first plasmid batch and also PvuII digest and PCR controls. 
BS=blue script II SK+ and fos-BSII is same plasmid with the 1-1349 fos cDNA insert in the 
XhoI/EcoRI . 
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T3-T7 PCR of plasmid second transformation and plasmid isolation using P1, P2, P3 DD 
fragments ligated in bluescript II.  
T3-T7 PCR product in XhoI/EcoRI linearised ligated bluscript is from bases 791-626 in vector 
without the 33 bp XhoI/EcoRI fragment ie 133bp. 
 
 
 
 
Pvu II digest of plasmids, second transformation and plasmid isolation using P1, P2, P3 and P4 
DD fragments ligated in bluscript II . Expected Pvu II fragments without fragment insert are 
2513 and 415, the area photographed shows only 415 bp area. 
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  undigested plasmid from second transformation and plasmid isolation  
Using P1, P2, P3 and P4 DD fragments ligated in bluscript II.  
 
 
 
 
  PvuII digests of plasmid products from second transformation and plasmid isolation using 
P5.1, P5.4, P6.1, P6.4, P7.1, P7.4, P7.6 and P8.4  DD fragments ligated in bluscript II . 
Expected product 133bp: insert in P5.1,P6.1, P7.1, P7.6, P8.4. F1 shows the expected 1500 bp 
product, F2 no insert. Clone P5.4 appears to be a mixed up clone. 
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  PCR detection of differential display targets using designed primers(1). 
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  PCR detection of differential display targets using designed primers (2) 
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  PCR for cDNA used in DD using α actin. Good products in cancer and PCOS at 28 and 32 
cycles (CYC)  
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  Designed Primers used for the study. Upper and lower primer sequences, expected product size, and annealing temperature for 
housekeeping genes and target gene fragments. Primers were designed using Oligo 5.0 software and synthesized by Sigma Genosys 
Ltd. NCBI Genbank accession numbers for target gene sequences have been indicated, as have the sequence for upper (U) and lower 
(L) primers. 
Clone Target Gene Primer sequences (5' - 3') Nucleotides from 
start of coding 
sequence 
Expected product size 
(bp) 
Annealing 
temperature (°C) 
P1-1,  
P1-12, P1-
13, P1-14, 
P2-1,  
P2-5,  
P3-21:  
Human alpha2 
smooth muscle 
actin mRNA 
 
U: CTCCAGCTATGTGTGAAGAAGAGG  
L: CCGTGATCTCCTTCTGCATT 
59-82 
1008-1028 
970 bp  58 
P1-14, P3-
13, P3-14 
Chr 13, BAC RP11-
155N3, AL161420.1 
U:CATGGGGGATCGTTTGTAT   
L:TCACAGGTGTATGCGTGTCT 
884-902 
1291-1310 
427 61 
  
U:TTGGGAGGCTGAGGAAC  
L:TCACAGGTGTATGCGTGTCT 
1147-1163 
1291-1310 
164 61 
  
U:AGAGCAGACACGCATACA   
L:AAAACATGTTAGTTGCCT 
1286-1303 
1482-1500 
216 61 
214 
 
  
U:AGAGCAGACACGCATACA   
L:GGTTCTGAAGCCAAATCTAT 
1286-1303 
1586-1605 
320 57 
P3-23 
Chr 7, BAC RP11-
736E3, 
AC073346.12 
U: AAATGGCAACAAACATACA 
L: ATATTAACTTGGGAGACAACA  
 
973-992 
1253-1273 
301 55 
  
 
U: AAAGGCCTACTGAGTCAAA  
L: ATATTAACTTGGGAGACAACA  
 
             845-864 
1253-1273 
421 56 
  
U:TGTTTTGTTGTCTCCCAAGT  
L:CCTTAATGCTGCCCAGTT  
 
1247-1266 
1644-1661 
415 59 
P4-1: 
P4-2 
P4-4 
Chr 19 BAC82621 
AC007193, 
Chr 4 BAC RP11-
461L13 
Human clone 
FLB4816 PRO1252 
mRNA 
 
U: CCTGGCCTCAAGCAA  
L: GCCAAATAGCAAATAGGTCA  
 
101-115 
795-814 
714 57 
  
U: CTATTTGCTATTTGGCTGTT  
L: TCAGTGTGAAGGGGTCTTT  
 
799-819 
1272-1290 
493 59 
215 
 
P4-4: 
Compilation of 
AC012076 genomic 
complementary 
sequence and 
AF130054 1653 
L:CTTGAGGCCAGGAGTT  
U:GATATTTTCTTCAGGCAGAT  
 
719-734 
405-424 
330 55 
  
U:TGGGACATAACAAATGAAAA  
 
U:GATATTTTCTTCAGGCAGAT  
 
455-474 
405-424 
281 58 
P5-1,  
P5-3, 
P5-5,  
P7-1: 
Chr 15 AC005630.1 
and others 
U: CTGCCTTCCCCTCCACTT  
  
L: GGCATGATCTTGGCTCACTAA  
 
98-115 
790-810 
713 63 
  
U: CATTTCATTGCACGCTTTCTA  
L: GGCATGATCTTGGCTCACTAA  
 
499-520 
790-810 
312 62 
P5-1, 
 P5-3, 
 P5-5,  
P7-1: 
Chr 15 AC005630.1 
and others 
 
U:ATATAAAAGGGCCAGGCACA  
L: TGGGCATTTTCACAGTCGT  
 
1720-1739 
482-500 
 
1598 63 
  
U:CACCTGAGTCCCCAGAGAAT  
L: TGGGCATTTTCACAGTCGT  
 
 
2449-2468 
482-500 
 
869 63 
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U: CTGCCTTCCCCTCCACTT  
L: TGGGCATTTTCACAGTCGT  
 
 
98-115 
482-500 
 
403 63 
  
U: AGGCCAGTTTTGCTACCTCT 
 L: TGGGCATTTTCACAGTCGT  
 
 
191-210 
482-500 
 
310 63 
P6-1,  
P6-2,  
P6-3,  
P7-2,  
P7-3 
Chr 22q11 
U: CCACCCCTGCGATGAAGA  
L: TGTAGGACAGGCTGCGATTGT  
 
175-192 
731-751 
577 66 
  
U: GAGACCTGGCATTTCTTTGAT  
L: CTGTCACCAGGCTGGAGTA  
 
1881-1901 
2309-2327 
447 61 
  
U: TCCAGCCTGGTGACAG  
 
L: GATTCGCCTTCCTCCAA  
15-32 
181-197 
183 62 
  
U: TCCAGCCTGGTGACAG  
 
L: GTCCCGGCTGCTCAG  
 
15-32 
416-431 
416 62 
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Appendix 7: Summary of clone sequencing data 
__________________________________________________________________ 
 
Analysis for clones P1-1, P1-12, P1-13, P2-1, P2-5, P3-21 
P1.1 
GAATTCACACGACTGTGAATGTCCTGTGGAATTATGCCTTCAGTTCTTTTCCAAATCATTCCTAG
CCAAAGCTCTGACTCGTTACCTATGTGTTTTTTAATAAATCTGAAATAGGCTACTGGTAAAAAAA
AAAAACTCGAG 
P1.12 
GAATTCACACGACTGTGAATGTCCTGTGGAATTATGCCTTCAGTTCTTTTCCAAATCATTCCTAG
CCAAAGCTCTGACTCGTTACCTATGTGTTTTTTAATAAATCTGAAATAGGCTACTGGTAAAAAAA
AAAAACTCGAG 
P1.13 
GAATTCACACGACTGTGAATGTCCTGTGGAATTATGCCTTCAGTTCTTTTCCAAATCATTCCTAG
CCAAAGCTCTGACTCGTTACCTATGTGTTTTTTAATAAATCTGAAATAGGCTACTGGTAAAAAAA
AAAAACTCGAG 
P2.1 
GAATTCACACGACTGTGAATGTCCTGTGGAATTATGCCTTCAGTTCTTTTCCAAATCATTCCTAG
CCAAAGCTCTGACTCGTTACCTATGTGTTTTTTAATAAATCTGAAATAGGCTACTGGTAAAAAAA
AAAAACTCGAG 
P2.5 
GAATTCACACGACTGTGAATGTCCTGTGGAATTATGCCTTCAGTTCTTTTCCAAATCATTCCTAG
CCAAAGCTCTGACTCGTTACCTATGTGTTTTTTAATAAATCTGAAATAGGCTACTGGTAAAAAAA
AAAAACTCGAG 
P3-21 
GAATTCACACGACTGTGAATGTCCTGTGGAATTATGCCTTCAGTTCTTTTCCAAATCATTCCTAG
CCAAAGCTCTGACTCGTTACCTATGTGTTTTTTAATAAATCTGAAATAGGCTACTGGTAAAAAAA
AAAAACTCGAG 
 
Homology with several entries for human alpha2 actin from smooth muscle 
mRNA (NM-00163.1; X138389,HSACTA; AL157394.15; M33216.1, 
HUMSMAAA; AK093340.1; BC017554). 119/120 fit with most, though 
occasionally the insert sequence was a couple of bases shorter. 
 
BC017554, human alpha2 actin, smooth muscle, aorta, clone MGC:9221. Sub 
21/11/01 
CCCACGCGTCCGGTGTGGAGCAGCCCAGCCAAGCACTGTCAGGAATCCTGTGAAGCAGC59TCCAG
CTATGTGTGAAGAAGAGGACAGCACTGCCTTGGTGTGTGACAATGGCTCTGGGCTCTGTAAGGCCG
GCTTTGCTGGGGACGATGCTCCCAGGGCTGTTTTCCCATCCATTGTGGGACGTCCCAGACATCAGG
GGGTGATGGTGGGAATGGGACAAAAAGACAGCTACGTGGGTGACGAAGCACAGAGCAAAAGAGGAA
TCCTGACCCTGAAGTACCCGATAGAACATGGCATCATCACCAACTGGGACGACATGGAAAAGATCT
GGCACCACTCTTTCTACAATGAGCTTCGTGTTGCCCCTGAAGAGCATCCCACCCTGCTCACGGAGG
CACCCCTGAACCCCAAGGCCAACCGGGAGAAAATGACTCAAATTATGTTTGAGACTTTCAATGTCC
CAGCCATGTATGTGGCTATCCAGGCGGTGCTGTCTCTCTATGCCTCTGGACGCACAACTGGCATCG
TGCTGGACTCTGGAGATGGTGTCACCCACAATGTCCCCATCTATGAGGGCTATGCCTTGCCCCATG
CCATCATGCGTCTGGATCTGGCTGGCCGAGATCTCACTGACTACCTCATGAAGATCCTGACTGAGC
GTGGCTATTCCTTCGTTACTACTGCTGAGCGTGAGATTGTCCGGGACATCAAGGAGAAACTGTGTT
ATGTAGCTCTGGACTTTGAAAATGAGATGGCCACTGCCGCATCCTCATCCTCCCTTGAGAAGAGTT
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ACGAGTTGCCTGATGGGCAAGTGATCACCATCGGAAATGAACGTTTCCGCTGCCCAGAGACCCTGT
TCCAGCCATCCTTCATCGGGATGGAGTCTGCTGGCATCCATGAAACCACCTACAACAGCATCATGA
AGTGTGATATTGACATCAGGAAGGACCTCTATGCTAACAATGTCCTATCAGGGGGCACCACTATGT
ACCCTGGCATTGCCGACCGA1008ATGCAGAAGGAGATCACGGCCCTAGCACCCAGCACCATGAAGA
TCAAGATCATTGCCCCTCCGGAGCGCAAATACTCTGTCTGGATCGGTGGCTCCATCCTGGCCTCTC
TGTCCACCTTCCAGCAGATGTGGATCAGCAAACAGGAATACGATGAAGCCGGGCCTTCCATTGTCC
ACCGCAAATGCTTCTAAAACACTTTCCTGCTCCTCTCTGTCTCTAGCACACAACTGTGAATGTCCT
GTGGAATTATGCCTTCAGTTCTTTTCCAAATCATTCCTAGCCAAAGCTCTGACTCGTTACCTATGT
GTTTTTTAATAAATCTGAAATAGGCTACTGGTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
Italics shows insert. Bold shows variance between insert and published sequence. 
Note that this fit was 109/110. All other fits were 119/120 with 10 bases more 
(italics-shadow box; 2 are as in the polyA tail) in the clones fitting with the inserts, 
these being 3’ before the polyA tail (ie ATAGG-CTACTGGTAA-
AAAAAAAAAACTCGAG). BC017554 is probably a splice variant featuring 
premature polyA tail formation. All other clones are for the longer, probably more 
common, mRNA species. 
The alpha2 mRNA differs at 29 bases from the alpha1 form, in the first 120 bases 
of the cds (67.1200). This leads to 6 residue differences, 4 in the first 7 residues. 
The ordered primers are boxed - CTCCAGCTATGTGTGAAGAAGAG (23 mer,  
59-82) and CCGTGATCTCCTTCTGCATT (20 mer, 1008-1028) – and differ 
slightly from published primer sequences (underlined), to ensure primer 
comparability of Tm. The Lp complimentary sequence is: 
AATGCAGAAGGAGATCACGG. 
 
Up:  CTCCAGCTATGTGTGAAGAAGAGG (23mer, 59-82)  970 bp 
 58C  
Lp:  CCGTGATCTCCTTCTGCATT (20mer, 1008-1028) 
19/3/3: Full quantitative PCR analysis performed, P>>>>N 
22/5/3: N and P pools, 32-50 cyc @60C. P>>>N 
27/5/3: N and P pools, 32,35 cyc @60C. No N products 
24/6/3: N/P pool, 22-32 cyc @55C. Product at 32 cyc only and this was ca 500bp. 18S 
failed 
4/7/3: N/P pool, 30-55 cyc @57C. Products from 35 cyc 
10/7/3: 32,34,36 cycles @59C, N and P pools, a2actin failed in P 
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15/7/3: 32,34,36 cycles @59C, N and P pools, a2actin P>N, 18S N just above P as 
expected 
 
Analysis of P1-14 clone, also P3-13 and P3-14  
P1.14 
GAATTCACACGACTGTACTCCAGCCTAGGTGACAAGTGAGACTCTGTCTCAAAAAATAATAATAA
TGTATACAATTTGATGAGAGCAGACACGCATACACCTGTGATACCATCACCACAACTGAGGTAAA
AAAAAAAAACTCGAG 
P3.13 
GAATTCACACGACTGTACTCCAGCCTAGGTGACAAGTGAGACTCTGTCTCAAAAAATAATAATAA
TGTATACAATTTGATGAGAGCAGACACGCATACACCTGTGATACCATCACCACAACTGAGGTAAA
AAAAAAAAACTCGAG 
P3.14 
GAATTCACACGACTGTACTCCAGCCTAGGTGACAAGTGAGACTCTGTCTCAAAAAATAATAATAA
TGTATACAATTTGATGAGAGCAGACACGCATACACCTGTGATACCATCACCACAACTGAGGTAAA
AAAAAAAAACTCGAG 
 
AL161420. 120/121 +/- fit. Human DNA clone RP11-155N3 from chr 13. Sub 
1/2/1. The NCBI report talks about genes and expressed sequences in this clone 
but not involving the sequence corresponding to the insert in P1-14 - nuc 14337 – 
14456. 
CCCTGTGTGTCATGGAGAATTGGTAGGTAGAGTCAGAGGCTTGATCTGAGTCAGATGCAAGTTTTT
GGCAAGACTACTTCATAGGTGGTGGTGTGTACTTCTACCAGGAGACACGAGAACGCTTTGTCTTTT
TTGATAATATCAACTCCTTCAATGGTTACCAAGCAGTTTTCCTTTCATTATGAACTCATAGACTTA
ATTACATACTTTCAGTCCGTTGCAATTATTCTTTTTTTTTTTTTTTTTTTTTTTTTTGAGATGGGG
TCTGGCTCTGTCACCCAGGCTGGAGTGCAGTGGCATGATTACTGCTCACTGCATTGCAATTATTCT
TACTGATGCCCATCCTGCACCTTGCTAGTGGGAGCTTCTTTAAAATCCTTCTCACACGACCCCAGA
GTGTTTTAATTTAACCCTGCTGGTCTCATAGACACATCTTTTCCTCTCCCATGTAAGAACCTGGTT
CCCGATGATACCAACATAAATACTCATTTACTCTCTGGCAATAAACATAAAACAGTCTCAGAATAA
AAACCAATGCAACACTTAAACAAAACAATTACTGAAACTAGTTTTTGTCAATAAACCACTAATAAA
TAAGTGGTTGCCACTTATTTGGCTGGGCGTGGTGGTTCACACCTGTAATCCCAGCACTTTGGGAGG
CCGAGGTGGGCAGATCACTTGAGGTCAGAAGTTTGAGACCAGCCTGGCCAACATGGTGGAATTCTG
TCTCTACCAAAAATTCAAAAATTAATAAATAATAAATAATTGATTGCCACTCTTCTTGACCTGAGG
GCATATCACACTAAGAAAGCACAGTAAAACTGCTGTAGTTTAAACTTGTTTGAAATAATTCCTTTC
TGTATGTTGCCAACATAATATTATATGGTTAGGTTCATTTATCACATTTTGCCTTCAATTTCTTAG
AAATTTAAAAATTCATTTGCTAATGATGTAAATATTTGCATGGTTCTGAAGCCAAATCTATAAAGC
AAATGATATTAGACAAGTTTATCTTCTAACCCTGTCCCCTGCACGTCATTCCCTCTCCCTTGCTGT
AGGTAACAACTATAAAACATGTTAGTTGCCTATATACGTTACTGTTATTGTGCACTTACAAATTTG
TTAAGAGGGTTGATCTCGTGTTAAATGTCCTTACCACAAAACAAGAGGGGAGCACGAGGAAACTTC
TGGAAGTGGTGGATATATTTTACTGTCCTTTTTTTTTTTTTTTTTTTTTTTACCTCAGTTGTGGTG
ATGGTATCACAGGTGTATGCGTGTCTGCTCTCATCAAATTGTATACATTATTATTATTTTTTGAGA
CAGAGTCTCACTTGTCACCTAGGCTGGAGTACAGTGGTGTGATTTCGGCTCACTGCAACCTCTGCT
TCCCGGGTTCAAGCGATTCTAGTTCCTCAGCCTCCCAAGTGGCTGGGATTACAGGCGCCCGCCAGC
ATGCCTGGCTAATTTTTGAATTTTTGGTAGAGACAGAATTCCACCATGTTGGCCAGGCTGGTCTCA
AACTTCTGACCTCAAGTGATCTGCCCACCTCGGCCTCCCAAAGTGCTGGGATTACAGGTGTGCGCC
ACCGCGCCCAGCCAAATTGTATACATTAAATGAGCAGATTTTTACAGCTGCACAGTATTCCACTGT
GTGGATGTACCATGGTTTATACAAACGATCCCCCATGGATGGAGATCACATTTTCTTGGAACGGAG
TCACTGCTTTGAGTTATATGATGAAACCATTCTGGATGGCTGCTTCTCGTCACTCAGGTTACCTTG
CCATCCTGCAGTCCTGCTCTCAGCAGCTGTCCTCTGTGCAAGGGTCTGGCTCTATTTGTTCCCACC
TGGCTAATATCCAGGACAAGGTCTTAACTAGAGTTTTAATTCCAGTGTTGCCTCAAAAGCAGTGTT
GTGAGGGGGAAGTAGGGAGTTCCTGTTTAATGAGTACTGAGTGTGAGTTTGGGAAGATGAGTATCT
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GGAGATGGAGGGTGGCGATGGTTGCACAATGAGAATCTACTTGATGCCAATGAACCTTACACTTAA
AAATGGTTAAACTGGTACATTTTAGGCATATTTTACCTCAATTAAAAGAAAGAATAAGTAGGACCT
ATGGGAAAAAAAACCCCACATTTACTGCAGAATAGCAATACGAATTCCCAAGAAAATGCTCCACCT
GGCTTTGTACATAACGAAGGGAAGATTTAATTGATACGGATGTTTCCCTGCAGGATGTTCCCAACT
TAGAGATGGCTCCTCTCTCCACTCCTGTCATAAGCAAGGCTTGGTCGCCTTCCAAACTTACCTTTA
TCTGACATGGGCTCTTTCTAGACTTCTATTTATCTTACTACATGGTGACTTGAGTTTTATGGTTTC
TGGATGAGGCATTTATGACTAGACGATCCAGCTCAGCGCCAGGCTCTTCTCCCAGACATGCTGATG
TTTGCCTTAAGGTTTATTAGCCCCGGCTGGGATGTCAGCGACATGGAACAAACGTATGCTGGGTAA
GTCCCAATGGCGTCATGAGTGCATAAGTGGGCTGTGGATTCTGGTGGGTCGTGGCGACCCTT 
 
Complementary strand with ca 500 bp surround. Insert italicised. 
AAGGGTCGCCACGACCCACCAGAATCCACAGCCCACTTATGCACTCATGACGCCATTGGGACTTAC
CCAGCATACGTTTGTTCCATGTCGCTGACATCCCAGCCGGGGCTAATAAACCTTAAGGCAAACATC
AGCATGTCTGGGAGAAGAGCCTGGCGCTGAGCTGGATCGTCTAGTCATAAATGCCTCATCCAGAAA
CCATAAAACTCAAGTCACCATGTAGTAAGATAAATAGAAGTCTAGAAAGAGCCCATGTCAGATAAA
GGTAAGTTTGGAAGGCGACCAAGCCTTGCTTATGACAGGAGTGGAGAGAGGAGCCATCTCTAAGTT
GGGAACATCCTGCAGGGAAACATCCGTATCAATTAAATCTTCCCTTCGTTATGTACAAAGCCAGGT
GGAGCATTTTCTTGGGAATTCGTATTGCTATTCTGCAGTAAATGTGGGGTTTTTTTTCCCATAGGT
CCTACTTATTCTTTCTTTTAATTGAGGTAAAATATGCCTAAAATGTACCAGTTTAACCATTTTTAA
GTGTAAGGTTCATTGGCATCAAGTAGATTCTCATTGTGCAACCATCGCCACCCTCCATCTCCAGAT
ACTCATCTTCCCAAACTCACACTCAGTACTCATTAAACAGGAACTCCCTACTTCCCCCTCACAACA
CTGCTTTTGAGGCAACACTGGAATTAAAACTCTAGTTAAGACCTTGTCCTGGATATTAGCCAGGTG
GGAACAAATAGAGCCAGACCCTTGCACAGAGGACAGCTGCTGAGAGCAGGACTGCAGGATGGCAAG
GTAACCTGAGTGACGAGAAGCAGCCATCCAGAATGGTTTCATCATATAACTCAAAGCAGTGACTCC
GTTCCAAGAAAATGTGATCTCCATCCATGGGGGATCGTTTGTATAAACCATGGTACATCCACACAG
TGGAATACTGTGCAGCTGTAAAAATCTGCTCATTTAATGTATACAATTTGGCTGGGCGCGGTGGCG
CACACCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACTTGAGGTCAGAAGTTTGAG
ACCAGCCTGGCCAACATGGTGGAATTCTGTCTCTACCAAAAATTCAAAAATTAGCCAGGCATGCTG
GCGGGCGCCTGTAATCCCAGCCACT1147TGGGAGGCTGAGGAACTAGAATCGCTTGAACCCGGGAA
GCAGAGGTTGCAGTGAGCCGAAATCACACCACTGTACTCCAGCCTAGGTGACAAGTGAGACTCTGT
CTCAAAAAATAATAATAATGTATACAATTTGATGAGAGCA1291GACACGCATACACCTGTGATACC
ATCACCACAACTGAGGTAAAAAAAAAAAAAAAAAAAAAAAGGACAGTAAAATATATCCACCACTTC
CAGAAGTTTCCTCGTGCTCCCCTCTTGTTTTGTGGTAAGGACATTTAACACGAGATCAACCCTCTT
AACAAATTTGTAAGTGCACAATAACAGTAACGTATATAGGCAACTAACATGTTTTATAGTTGTTAC
CTACAGCAAGGGAGAGGGAATGACGTGCAGGGGACAGGGTTAGAAGATAAACTTGTCTAATATCAT
TTGCTTTATAGATTTGGCTTCAGAACCATGCAAATATTTACATCATTAGCAAATGAATTTTTAAAT
TTCTAAGAAATTGAAGGCAAAATGTGATAAATGAACCTAACCATATAATATTATGTTGGCAACATA
CAGAAAGGAATTATTTCAAACAAGTTTAAACTACAGCAGTTTTACTGTGCTTTCTTAGTGTGATAT
GCCCTCAGGTCAAGAAGAGTGGCAATCAATTATTTATTATTTATTAATTTTTGAATTTTTGGTAGA
GACAGAATTCCACCATGTTGGCCAGGCTGGTCTCAAACTTCTGACCTCAAGTGATCTGCCCACCTC
GGCCTCCCAAAGTGCTGGGATTACAGGTGTGAACCACCACGCCCAGCCAAATAAGTGGCAACCACT
TATTTATTAGTGGTTTATTGACAAAAACTAGTTTCAGTAATTGTTTTGTTTAAGTGTTGCATTGGT
TTTTATTCTGAGACTGTTTTATGTTTATTGCCAGAGAGTAAATGAGTATTTATGTTGGTATCATCG
GGAACCAGGTTCTTACATGGGAGAGGAAAAGATGTGTCTATGAGACCAGCAGGGTTAAATTAAAAC
ACTCTGGGGTCGTGTGAGAAGGATTTTAAAGAAGCTCCCACTAGCAAGGTGCAGGATGGGCATCAG
TAAGAATAATTGCAATGCAGTGAGCAGTAATCATGCCACTGCACTCCAGCCTGGGTGACAGAGCCA
GACCCCATCTCAAAAAAAAAAAAAAAAAAAAAAAAAAGAATAATTGCAACGGACTGAAAGTATGTA
ATTAAGTCTATGAGTTCATAATGAAAGGAAAACTGCTTGGTAACCATTGAAGGAGTTGATATTATC
AAAAAAGACAAAGCGTTCTCGTGTCTCCTGGTAGAAGTACACACCACCACCTATGAAGTAGTCTTG
CCAAAAACTTGCATCTGACTCAGATCAAGCCTCTGACTCTACCTACCAATTCTCCATGACACACAG
GG 
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Italics shows insert. Bold shows variance between insert and published sequence. 
Primers (10/6/03) shown in boxes, Lps shaded (884,1291; 1147,1291; 1286, 1482; 
1286,1586) 
 
P1-14, P3-13, P3-14: Chr 13, BAC RP11-155N3, AL161420.1; No EST 
+/- hit, primers designed to complementary strand 
No first look, Second phase of investigation 
Lp: TCACAGGTGTATGCGTGTCT (20mer, 1291-1310) 
 
Up: CATGGGGGATCGTTTGTAT (19mer, 884-902)  427 bp  61C 
16/6/3: 40,50 cyc @55C, N and P pools. No products, though a2 actin was low 
4/7/03: 30,35..50,55 cyc@61C, NP pool. No product though controls relatively unproductive 
3/10/03: 48,50,52 cyc@59C N/P pool, No product, controls good 
No products with these primers 
 
Up: TTGGGAGGCTGAGGAAC (17mer, 1147-1163)  164 bp  61C 
16/6/3: 40,50 cyc @55C, N and P pools. No products, though a2 actin was low 
4/7/03: 30-55 cyc@61C, NP pool, 170bp 55cyc only 
10/7/3: 36,38,40 cycles @59C, N and P pools, variable output 170bp, a2actin failed in P 
3/10/03: 36,38,40cyc@59C N/P pool, No product, controls good 
Uncertain whether 170 bp product is consistent and quantitative 
 
Up: AGAGCAGACACGCATACA (18mer, 1286-1303) 
 
Lp: AAAACATGTTAGTTGCCT (20mer, 1482-1500)  216 bp  53C 
16/6/3: 40,50 cyc @55C, N and P pools. No products, though a2 actin was low 
3/7/03: 30-55 cyc@59C, NP pool, No product though Ta was high 
4/7/3: N/P pool, 30-55 cyc @57C. No products, though 18S and a2 actin are lower than 
normal 
No products (should check once more) 
 
Lp: GGTTCTGAAGCCAAATCTAT (20mer, 1586-1605) 320 bp  57C 
16/6/3: 40,50 cyc @55C, N and P pools. No products, though a2 actin was low 
4/7/03: 30-55 cyc@57C, NP pool, No product though Ta was high and 18S and a2 actin are 
lower than normal 
No products (should check once more) 
 
Analysis of P3-23 clone  
P3-23 
GAATTCACACGACTGTTCGGTTATAATCACTGCCTCCTGAATCGTTGAGGAGTCT
TTTAAATTAGATTTTTGTTTTGTTGTCTCCCAAGTTAATATTATATTTAGATATCA
GAGAGTCAGGTAAAAAAAAAAAACTCGAG 
 
AC073346.12, +/- fit, Submitted 01/03/02. 
115/116 hit with clone carrying human male DNA (clone RP11-736E3) from chr 7 
GATGCTTCTTCACTCCTTGTACACTTTAACCAAAACTTTCATGCAAGCCAAGTCAGCTCACTCTAG
AATTACACCATAAACAGGACTTTAGGTTGCTAGTGCCTGTTTTTGGATAAAAAATGAGGCTCCCAA
TGTCATCTGGAGAGCTACAGATTGGAAAATGCATTTTAGGAAAAAATTTCACTACTTACCTCCAGT
GTGACCCTAAAGTTTGATTTCCTTAGACTACTTTATGCTGGCTACAACTTGAGAATCAAATGAATC
ACTGAGGACCCTTGTTAGACATGGAGTTCCAGGCCCCATCTCACAGCTATACAACCAGGAGAAAGA
CCAGGGAATCAAAAAGTCTTATCAAGTGCCTGGAATGATTCTTGGGCTCAAGCAAGTTGGCAGTCT
TCTTAAATTTGTAATGTGCATACAAATTAACTTGGGCTTTGGAAACGAATGCTGTTCCTGATCCAA
TTGGTCTGGGTGGGGCCTGAGATTCTGCATTTCTAACAAGCCCCAGGTGATGTTGCTGGCTTGAAG
ACACTTTAAGTAGCTAGGCCAGAGAGGATATTTCGTTTGGCTGGCGTACAAATCAGTTTAAGCCAT
TTCATTTTCCTTCTATATTTCTAGATTTTCTATCAGGGGCTTCTCTGACCTTAATGCTGCCCAGTT
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CTCATTATGTCTCTTCAAGCTACCGCAATCAGTTAACACAAGGCATCCTGCCCTTCTCCACTTAGC
TCATATAAAAATCCACAATGGATACAAACAGCCCCAAATAAGAAATGGACACGAAACATTAACTTA
TAACATAATGGGTTTATATTTAATATAGTACTTCTCATCAGGAGGATGTTACTCAGTTAATATAAA
GTTTTTTTTCAAAACATTAAATCTCTTTTCCATGTCAATGTCTATAGTTTTTTTTTAACATTAAAT
TTTTTTCCGCATTTCAGTATTAGATACACTGAATACATTTTTCTAAATGTTTTTTCCCTAGAGATA
AAAGTTTTCCTTTTTGCCTGACTCTCTGATATCTAAATATAATATTAACTTGGGAGACAACAAAAC
AAAAATCTAATTTAAAAGACTCCTCAACGATTCAGGAGGCAGTGATTATAACCGAACAGTGGTGAT
TTCCTAAGATTCTGGGCAAGAACTTCCTTCTTCCTATTTCACATGCTTTGAGAGAATTCTAAGATT
ATGAAATATTACTTATGTAAATTTCAGCCATCTTACTTCTTTGACTACCTAACTAGCAAATTATAG
GCTGCATTTTTCTGTGCATTATTTGTTGTAAAGAAAACATTTTTTTTTCAATTTATAAATGTATGT
TTGTTGCCATTTCATGGAAACAATGAAAAATGTGAAACTCCCTTATTTACTGATTCTTGGAACCTT
TCACACACCAAATCTCAGGTTTAGCCTCTAAAGCGCAAAGGTTTTCAGGGTGAGGTTTGACTCAGT
AGGCCTTTCAAAGTCACATCTGTCCATTTCTTTTTCGTGCATATACCCCCAAGCAGGCACAAATGC
CTGTAATGCTGAGAACCACACCTAACAAAAGGGCGATTGCATCACCGGCTTCTACTGCTTCCACAA
CAGGCAGCACCAAAAGCAGTGACATGAGGACTAAGGACAACTGTGTTGAAACTGAGGTCATGATGT
TGGAATCTTGAGGGCTGAAGGTTCCTAGAAATTAAACATGGAAACAAAAAGGAACCATTAAAAATT
CCTCCCTTTTCAAATGACAAAATGAACACATGACAAATAACAGGCCAGCCAATCTTTTGGATACTT
TATGAATCATTTCCAATCCATCTCCTCATCTTATAGGTGGAAAAACAGAGGGACGTTAAAGACAGT
AATTTGAGGTTCATCTCCCTATCTCGTGATAACACTCTAAACCCAGGAATTTTCCACGATAATGCC
AACACCTCGTGCATCAACCAAACAAAAATTGAACAGGAGTTCATAATTAAGAACAAACAGAAAAAA
AGCACGAGCCACTAACTTGGAAACTTAAAATATCCTAGTGGGTAAAAATTGTACATTTTCTTAGGG
TCTCTCCCATCCAAGAAATGCAGACAAATTTGGCAAAAGTCACACAACATATAACTCTGCGAAGTT
GTGG 
Insert comprises nuc 48282-48397 of this clone and several notes for ESTs were 
described in the NCBI report 
  misc_feature 48066..48496 
   /note="match to EST AI061282 (NID:g3336650) an25g11.x1" 
  misc_feature 48071..48705 
   /note="match to EST AV753297 (NID:g10911145)" 
  misc_feature 48073..48295 
   /note="match to EST BG054805 (NID:g12511889)" 
  misc_feature 48074..48754 
   /note="match to EST AV700969 (NID:g10302940)" 
  misc_feature 48074..48507 
   /note="match to EST R26096 (NID:g782231) yh49a02.s1" 
  misc_feature 48139..48476 
   /note="match to EST AA248757 (NID:g1880196)" 
  misc_feature 48200..48955 
   /note="match to EST BG619963 (NID:g13671334)" 
  misc_feature 48240..48950 
      /note="match to EST BG030299 (NID:g12419442)" 
  misc_feature 48246..48273 
      /note="match to EST BG289755 (NID:g13045863)" 
  misc_feature 48277..48955 
      /note="match to EST BG501943 (NID:g13463460)" 
  misc_feature 48291..48844 
      /note="match to EST BF921100 (NID:g12316988)" 
  misc_feature 48352..48961 
      /note="match to EST BE568947 (NID:g9812667)" 
  misc_feature 48367..48955 
      /note="match to EST BG289755 (NID:g13045863)" 
  misc_feature 48384..48955 
      /note="match to EST BF247603 (NID:g11163210)" 
  misc_feature 48386..48955 
      /note="match to EST BF028861 (NID:g10736573)" 
  misc_feature 48393..48955 
      /note="match to EST BF215712 (NID:g11109298)" 
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Note other fits (AC129492.6; AC107913.7; AC104762.7, from chr 17) are very 
similar but likely to be gene duplications or pseudogenes. AC010102 from chr 2 is 
slightly less similar than these. 
 
Complementary strand of AC073346.12 with fragment (italics) and surrounding ca 
1000 bp 5’ and 500 bp 3’. This should match the + mRNA strand, assuming RT 
from ET12X worked on ssRNAs, giving (-) cDNA in a 5’ direction up the mRNA. 
AAAATAATAATAGTAATAATAATTAATTTTTAAATCCTTCTCTCCGCCCCCTCCCCACCCCCCATG
CTAATAATAGGTCGTGTCACGTGGAACCTCTTAATCTCAGCATCCGGAGCTCCAGGAAGGGAAAAT
TTCAAGTCAGATAGAATTCTATATATACCATTTCTTTGGTAAGTCTTATTAATTCCCCACAACTTC
GCAGAGTTATATGTTGTGTGACTTTTGCCAAATTTGTCTGCATTTCTTGGATGGGAGAGACCCTAA
GAAAATGTACAATTTTTACCCACTAGGATATTTTAAGTTTCCAAGTTAGTGGCTCGTGCTTTTTTT
CTGTTTGTTCTTAATTATGAACTCCTGTTCAATTTTTGTTTGGTTGATGCACGAGGTGTTGGCATT
ATCGTGGAAAATTCCTGGGTTTAGAGTGTTATCACGAGATAGGGAGATGAACCTCAAATTACTGTC
TTTAACGTCCCTCTGTTTTTCCACCTATAAGATGAGGAGATGGATTGGAAATGATTCATAAAGTAT
CCAAAAGATTGGCTGGCCTGTTATTTGTCATGTGTTCATTTTGTCATTTGAAAAGGGAGGAATTTT
TAATGGTTCCTTTTTGTTTCCATGTTTAATTTCTAGGAACCTTCAGCCCTCAAGATTCCAACATCA
TGACCTCAGTTTCAACACAGTTGTCCTTAGTCCTCATGTCACTGCTTTTGGTGCTGCCTGTTGTGG
AAGCAGTAGAAGCCGGTGATGCAATCGCCCTTTTGTTAGGTGTGGTTCTCAGCATTACAGGCATTT
GTGCCTGCTTGGGGGTATATGCACGAAAAAGAAATGGACAGATGTGACTTTGA845AAGGCCTACTG
AGTCAAACCTCACCCTGAAAACCTTTGCGCTTTAGAGGCTAAACCTGAGATTTGGTGTGTGAAAGG
TTCCAAGAATCAGTAAATAAGGGAGTTTCACATTTTTCATTGTTTCCATG973AAATGGCAACAAAC
ATACATTTATAAATTGAAAAAAAAATGTTTTCTTTACAACAAATAATGCACAGAAAAATGCAGCCT
ATAATTTGCTAGTTAGGTAGTCAAAGAAGTAAGATGGCTGAAATTTACATAAGTAATATTTCATAA
TCTTAGAATTCTCTCAAAGCATGTGAAATAGGAAGAAGGAAGTTCTTGCCCAGAATCTTAGGAAAT
CACACTGTTCGGTTATAATCACTGCCTCCTGAATCGTTGAGGAGTCTTTTAAATTAGATTTTT1247
GTTT1253TGTTGTCTCCCAAGTTAATATTATATTTAGATATCAGAGAGTCAGGCAAAAAGGAAAAC
TTTTATCTCTAGGGAAAAAACATTTAGAAAAATGTATTCAGTGTATCTAATACTGAAATGCGGAAA
AAAATTTAATGTTAAAAAAAAACTATAGACATTGACATGGAAAAGAGATTTAATGTTTTGAAAAAA
AACTTTATATTAACTGAGTAACATCCTCCTGATGAGAAGTACTATATTAAATATAAACCCATTATG
TTATAAGTTAATGTTTCGTGTCCATTTCTTATTTGGGGCTGTTTGTATCCATTGTGGATTTTTATA
TGAGCTAAGTGGAGAAGGGCAGGATGCCTTGTGTTAACTGATTGCGGTAGCTTGAAGAGACATAAT
GAGA1644ACTGGGCAGCATTAAGGTCAGAGAAGCCCCTGATAGAAAATCTAGAAATATAGAAGGAA
AATGAAATGGCTTAAACTGATTTGTACGCCAGCCAAACGAAATATCCTCTCTGGCCTAGCTACTTA
AAGTGTCTTCAAGCCAGCAACATCACCTGGGGCTTGTTAGAAATGCAGAATCTCAGGCCCCACCCA
GACCAATTGGATCAGGAACAGCATTCGTTTCCAAAGCCCAAGTTAATTTGTATGCACATTACAAAT
TTAAGAAGACTGCCAACTTGCTTGAGCCCAAGAATCATTCCAGGCACTTGATAAGACTTTTTGATT
CCCTGGTCTTTCTCCTGGTTGTATAGCTGTGAGATGGGGCCTGGAACTCCATGTCTAACAAGGGTC
CTCAGTGATTCATTTGATTCTCAAGT 
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Primers are shown in boxes, lower primers shaded (188, 1253 - not ordered; 845, 
1253; 973, 1253; newer set = 1247, 1644). Note misc_feature 48200.48955. Match 
to EST BG619963 NID: g13671334, sequence shown underlined 
 
Up:  AAATGGCAACAAACATACA (19mer, 973-992)  301 bp 
 55C  
Lp:  ATATTAACTTGGGAGACAACA (21mer, 1253-1273) 
10/6/3: P pool, 30,35,40,45, then further 20,30,40,50 cyc @53C. No products. Sigma 
said primers dodgy  
24/6/3: N/P pool, 24-50 cyc @55C. No products. 18S and a2actin very poor. Fresh 
primers though  
4/7/3: N/P pool, 30-55 cyc @57C. No products, though 18S and a2 actin are lower 
than normal 
17/9/03: N and P pools, 40,45,50,55cyc @57C. From 40 cyc 300bp product, P>N ?? 
Recommend 40 cyc (??check signal at 40 cyc), 57C for x10-x80 cDNA dilutions 
 
Up:  AAAGGCCTACTGAGTCAAA (19mer, 845-864)  421 bp 
 56C  
Lp:  ATATTAACTTGGGAGACAACA (21mer, 1253-1273) 
10/6/3: P pool, 30,35,40,45, then further 20,30,40,50 cyc @53C. No products. Sigma 
said primers dodgy  
24/6/3: N/P pool, 24-50 cyc @55C. No products. 18S and a2actin very poor. Fresh 
primers though  
4/7/3: N/P pool, 30-55 cyc @57C. Product from 35 cyc 
17/9/03: N and P pools, 32,34,36,38 cyc @57C. From 36 cyc 420bp product, N>P?? 
Recommend 38 cyc,56C for x10-x80 cDNA dilutions 
 
Second phase 
Up: TGTTTTGTTGTCTCCCAAGT (20mer, 1247-1266) 
Lp: CCTTAATGCTGCCCAGTT (18mer, 1644-1661)  415 bp 
 59C 
16/6/3: 40,50 cyc @55C, N and P pools. No products, though a2 actin was low 
4/7/3: N/P pool, 30-55 cyc @57C. Products from 35 cyc onwards 
10/7/3: 36,38,40 cyc @59C, N and P pools, No products, a2actin failed in P 
17/9/03: 32,34,36,38cyc @57C. Product in N pool at 38cyc only, not in P pool, a2a 
OK 
Recommend 40 cyc,57C for x10-x80 cDNA dilutions 
 
P3-23: AC129492.6 CLONE RP11-599B13 FROM HUMAN MALE, CHR 17. +/- fit 
58/60 and 47/47 broken by a 10 base insert (shadow box) which replaces TT in the 
dd cloned sequence (in this – strand) and in AC073346.12 from chr 7. Also CA 
(bold) differs. 
TGTATTAGGTAATCTAGAAAAGATTTAAGGTACACAAGAGTTTGTACTTAGGTTACACACAAATAC
TTCTGCACCATTTTATATCAGGAACTTGAGCATCCTCAGATTTTGGTATCCAAGGGGGTCCCGGAA
CCAATCCCCTAAGGATACCCAAGGATAACTGTCTATTACACTTCTGTTTTACAGATGTTAACACTG
AGGCTTAGAAAGGTCGTTTGGACTGCCCAAGGTCACAAAAGCTACTAAATGAGCACTGGGACTCTA
CTTTTCCAAAGTCTTAAACTCTACACTATTTTTTTAATAACACAATGGGTTTATATTTAATATAGT
ACTTCTCATCAGGAGGATGTTACTCAGTTAATATAAAGTTTTTTTCAAAACACTAAATCTCTTTTC
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CATGTCGATGTCAATAGTTTTTTTTTTTAACATTAAATTTTTTTCCGCATTTCAGTATTAGATACA
CTGAATACATTTTTCTAAATGTTTTTTCCCCAGAGATAAAAGTTTTCCTTTTTGGCTGACTCTCCA
ATATCTAAATATAATA 
TGTATTAGGTAATCTAGAAAAGATTTAAGGTACACAAGAGTTTGTACTTAGGTTACACACAAATAC
TTCTGCACCATTTTATATCAGGAACTTGAGCATCCTCAGATTTTGGTATCCAAGGGGGTCCCGGAA
CCAATCCCCTAAGGATACCCAAGGATAACTGTCTATTACACTTCTGTTTTACAGATGTTAACACTG
AGGCTTAGAAAGGTCGTTTGGACTGCCCAAGGTCACAAAAGCTACTAAATGAGCACTGGGACTCTA
CTTTTCCAAAGTCTTAAACTCTACACTATTTTTTTAATAACACAATGGGTTTATATTTAATATAGT
ACTTCTCATCAGGAGGATGTTACTCAGTTAATATAAAGTTTTTTTCAAAACACTAAATCTCTTTTC
CATGTCGATGTCAATAGTTTTTTTTTTTAACATTAAATTTTTTTCCGCATTTCAGTATTAGATACA
CTGAATACATTTTTCTAAATGTTTTTTCCCCAGAGATAAAAGTTTTCCTTTTTGGCTGACTCTCCA
ATATCTAAATATAATATTAACTTGGGAGACAACAAAACAAAAATCTAATAAAGGAATGGAGAAAA
GACTCCTCAACGATTCAGGAGGCAGTGATTATAACCGAACAGTGGTGATTTCCTAAGATTCTGGGC
AAGAACTTCCTTCTTCCTATTTCACATGCTTTGAGAGAATTCTAAGATTATGAAATATTACTTATG
TAAATTTCAGCCATCTTACTTCTTTGACCGCCTTTCTAACTAGCAAATTATAGGCTGCATTTTTCT
GTGCATTATTTGTTGTAAAGAAAACATTTTTTTTTCTATTTATAAATGTATGTTTGTTCCCATTTC
ATGGAAACAATGAAAAATGTGAAACTCCCTTATTTACTGATTCTTGGAACCTTTCACACACCAAAG
CTCAGGTTTAGCCTCTATAGCACAAAGGTTTTCAGGGTGAGGTTTGACTCAGTAGGCCTTTCAAAG
TCACATCTGTCCATTTCTTTTTCATGCGTATACCCCCGGGCGATTGCATCACCGCCTTCTACTGCT
TCCACAACAGGCAGCACCAAAAGCAGTGACATGAGGACTAAGCACAACTGTGTTGAAACTGAGGTC
ATGATATTGGAATCTTGAGGGCTGAAGGTTCCAAAGAAATGGTATATATAGAATTCTATCTGACTT
GAAATTTTCCCTTCCTGGAGCTCCGGATGCTGAGATTAAGAGGTTCCACGTGACATGACCTTCCAG
GAAGCAG 
 
Insert comprises nucleotides 18698-18757 and 18770-18816 in this clone 
AC129492.6 and AC104762.7 are identical in this region. AC129492.6 shows 
very close homology (>95%) with AC073346.12 (above) for the 220 bases 5’ to 
the insert area in sequence above and for 400 base 3’. Outside of this range little 
homology. The boundaries are discrete. This chr 17 gene is probably a gene 
duplication from the chr 7 form found in AC073346.12, though the latter is 
probably the gene related to P3-23 
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Appendix 8: Analysis of clones sequences 
 
Analysis of P4 clones 
All P4 clones (P4.1, .2, .4) contained a unique sequence 
 
Clone P4.1 
P4.1 
GAATTCACACGACTGTAATCCCAGCTGCCTGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGC
ACATGTTGCAATGAGCCGAGATTGCGCCACTGCACTCCAGCCTAGTCGATAGAGTGAGACTCAGTCTAA
AAAAAAAAAACTCGAG 
 
AC007193  146180 bp  PRI 17-JUN-1999 Homo sapiens chromosome 19, 
BAC 82621 (CIT-B-139a18). +/+ fit 129/130. 
GGATTAGAAACCCAGATCCCTTGAGCCCTGCCAAGTCCTCACTCCCTGGGAGGTGCTGACAGGAGG
CTTGAGGCCAGGCAGGAGCAGCCCATCTGGCCCATCTTCTGCCACCACCCCCAACCCCACCGCACC
GCACCCTTCCCCTCCACGCTTGCCATGTTTTCCTCAGCAGGACAGATATTTAATGGTGACTTTGTG
GACCGAGGCTCCTTCTCTGTAGAAGTGATCCTCACCCTTTTCGGCTTCAAGCTCCTGTACCCAGAT
CACTTTCACCTCCTTCGAGGTGAGCTGGGAAGTGACAAGGTTTGGGTTCATTGTGGGGTCCTGAGT
GGGGCACTCACTCTGCAAGGATAATAGTTGCAGCTGTATTTATTTTGTGGACTCGGAGATCATGCA
CAGGGCGACCTTTTAAGATTGAGTATGTAGTGCACTGCACAAAAGCATCACACCAAAGGACGCGTT
TACATCATAGATAGTGTAGAAATGGATGTTTACTCTGACCATTTTTCAGCAGATGGCAAACAAGGG
TGTGAGGATGGGCCCCTTATTCTAATTTGCACAAGGGCATGAAACAGGCTCCTGGGTGGCCCTAAA
TCTGGCACTAAAGCTGAGTGACTGAGTGAACAGACCAGGGCTCGAGGGTGGGAGTAAGGAGACTGT
TGACGAGGCAGTTGTGCCCCCTCAGATTCAGGCTTGGTGTCAGATTTGGGTTCTCTTGATTGAAGT
AGAGCCCGGAGCTGAGTGTGCTGGTTCACACCTGTAATCCCAGCACTTTGGAAGGCCCAGGTAGGA
GGATCACTTCAGCCCAGGAGTTTGAGACCAGCCTGGGCAACACAGTGAGACTTTGTCTCCAGTAAA
CATTTTTTAAAAAGGCCAGGCGCAGTGGCTCATGCCTGTAATCCCAGCATTTTGGGAGGCCAAGGC
AGGTGGATCATCTGAGGTCAAGAGTTCGAAACCAGCCTGTCCAATGTGGTGAAACCCCGTCTCTAC
TAAAAATACAAAAATTAGCCGGGCATGGTGGTACACGCCTGTAATCCCAGCTGCCTGGGAGGCTGA
GGCAGGAGAATCGCTTGAACCCAGGAGGCACATGTTGCAATGAGCCGAGATTGCGCCACTGCACTC
CAGCCTAGTCGATAGAGTGAGACTCAGTCTAAAAAAAAAAAAAAAAGCCAGGCATGGTGGCACCGT
GCACCCGTAGTCCCAGCTTCTTGGGTGGCCAAAGTGGAAGGATTGCTTGAGCCCAGGAGTGTAAGG
CTGCAGTGAGCCATGATCACACCGCTGCACTCCAGCGTGGGCAACAGAGCAAGACCCTGTCTCTTT
GAAAAAAAAAAAAAAAGTAAGAAACTTGGAAGTAGAGCCCAGAGTATTTGCTGGAGGAACAGACAC
AGGTGTGAGACAAAGAGGGAACGAAAGGGGCCCTCTAGGGTTTTGGCCGGAGTATCTGGAGGGCTA
TGGCTGCCAGTGACGAAGACGGGAACATGTAGAGCAGGGTGTGGCCAGGAGCTGAGGAGCTCCCCT
TTGGATGTGGCTGAGACTCAGGAGACATGGGATGTGGGTGGGGTTCCAAGGGGTGTTGAAAATGTA
GGTTTCTTGGTGTCCAGATGAGATTAGACAAGAGGAGCTCACTGGGATGTGAGGGCCACACAGGGG
AGGCCCTGCCCATGGCGGGGCCGGGGTGAGTTGGGAGGTGAGTGATAGGCTGGGGCGAAGCCTGCA
TGCCCGTGTCCCTGGGCTCACAGGGTTCACGCAGCAGTGTCCAGCACAGGGTCAAAGCTCAGGAAG
CCCGACTGTGGGCCTCGTTGCAGGAGGCAACAAGTGCTCAGGCCGAGAAGTCAGACAAGCAGAGTC
TGAGCAGATGCGAGACTGGGCAGCCTTCTCCTTGCCCCCAAGCTCTGGAAGGGAAGAAGGAGGCCG
GGTGCTTGTGTCTGAGACAGAAGGATGGAGCTCAGGGTGGGGTGGGCTGGGGCACATGTTCTGTAG
ATGGGCCTACTTTTTGGTTTTGAGACGGTCTTGCTTTGCTCTGTTGCCCAGGCTGGAGTGCAGTAG
CATGAGCATAGCTCACTGCAGCCTCTGCTTCGTGGGCTCAAGTGATCCTCTGGCCTCAGCCTCCCA
AGTAGCTGGCACTATAGGCACGCACCACCATGCCCAGCTAATTTTTAA 
Insert sequence is 130863 – 130992 and in italics. Bold is different in insert (A). 
NCBI Note: 
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gene  92311..135795 /gene="PPP5C" "protein phosphatase 5, catalytic 
subunit" 
mRNA join(92311..92431, 98962..99203, 120818..120965, 121667..121788, 
128625..128690, 128994..129092, 130018..130123, 132307..132449, 
132580..132667,  133622..133662,133767..133945, 135265..135346, 
135498..135795) 
CDS  join(92311..92431,98962..99203,120818..120965, 121667..121788, 
128625..128690, 128994..129092, 130018..130123, 132307..132449, 
132580..132667,  133622..133662,133767..133945,135265..135346, 
135498..135560) /codon_start=1 /product="PPP5_HUMAN"/ 
protein_id="AAD22669.1" /db_xref="GI:4558638" 
 
This fragment appears to be primed from a stretch of 16As within the gene here 
but it does not arise from within the coding sequence or mature transcript, as 
detailed above. It may arise from an mRNA precursor. It may arise from a 
transcript within a transcript (cf rev-erbA) It may also arise from genomic DNA, 
though this is unlikely hopefully. 
 
 
 
Clone P4.2 
P4.2 
GAATTCACACGACTGTAATCCCAGCTACTTGGGAGGCTGAGTCATGAGAACCTCTTGAACCCGGGAAGT
GGAGGTTGCAATGAGCCGAGATTGCGCCACTGCACTCTAGCATGGGCAACAGAGTATGACTATGTCTTT
AAAAAAAAAAAACTCGAG 
 
AC080078.7 150567 bp PRI 16-APR-2002 Homo sapiens BAC clone RP11-
461L13 from chr 4. +/- fit 131/132 
ACAATCAGTACTAAAAAGTTTAACTCAACTAAAAAGTTTATAATTAGTGGAAAATACTATGAATAC
TATTAGTTCTTTTCTTTACCTTGCTAACATTTAAAAATACACTTCCATTTTATAATAGTAGGAGAA
TGTGTTTATATTCCTATGTCAGTGATTTTATTATTATCATGACAACACTTTGTACTCTAGAAAGGA
CTAGGAAACCACCACAGTTAGCTGTCTTGCCCTGAGCACAGAATTTAGATTACAGACAGTTCAAAA
TTACAGACAGTTCAAAATTTCAACATCAATGAAAGGAATGCCAAGCATGTTGAGACTGAAATACTT
TTTGAAATTTCACTAACTCACTGTCATTAACTTTCTGGGATGTGAGTGCTTATTAAAAGGTTTGCT
TATTAAAACTGGCAAACTAATAAACCTGTTCTATTACAGATATCAACTGGAATAGTATATATGCCC
AGCATTTACATTTTCACTAACACAAATAGGTGGCAGTATTGGCCAATAAGCAATTTTCCATATTTA
TTCATTCAGTAAGCATTTGTTTAGCACCTACTTTGTGTTGGGCACAGAATATTATATACATCAATT
GAAACTTTGTTCTTTCTCCATTGGAAATACAGTCAATTAACACAAGAGCATAGTGTAACGTAATAT
ACACAAACATCTGACTGTTAGAACTCATACTGAAATTAGTTCTAAAAAATTTTTGAGAACATGTAA
AATAAAACAAGATGAGCCAGCTTTAGTTCAAAACTACCATCTAAGTAAACAAATACTGTGACACTA
GTGCCTTAGAAAAAAATCCCAAACACTAAACACTGTAATAGATAATCTTACTTTACTTAAACTTAT
TTTTTGGGGGGAAGGGGATGTTTATAATATATATAATCCAAACCTTTGTAAATCAAGCTGCAAATC
AAAATGTTATAGCTGACTGCTTTTAAATAAATTTTAATATAATTACAGAAGTAGTAGTTTTTTCTT
TTTTTTTTTTAAAGACATAGTCATACTCTGTTGCCCATGCTAGAGTGCAGTGGCGCAATCTCGGCT
CATTGCAACCTCCACTTCCTGGGTTCAAGAGGTTCTCATGACTCAGCCTCCCAAGTAGCTGGGATT
ACAGTCGTGTGCCACCACACCCCACTAATTTTTCTATTTTTAGTAGAGATGGGGTTTCACCATGTT
GGCCAGGCTAGTCTCGAACTCCTGGCCTCAAGTAATCCGCCCGCCTCAGCCTCCCAAGGTGCTGGG
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ATTACAGGGGTAAGCCACCGTGCCTGGCCAGAAGTTTTAATTCTTGAAGTTTAAGCTATTTAAAAC
TCTCCTTACAAAGACACAGCCTCTGATTAGTGTGACACACTAATCAACTGCAGTATTAGTTCCAAC
AGTGTAAGTTTTTTCATTCCTTCAGATTGGGCCAAATTAGTCATCTGATGGACACATGCACAAATG
TATTTATCTACAAATATATAAATATACACACATACATAATTCATACCCAATAGTGCAAGTTAAGAG
TTCTATTTATGCCAGCCACAGAATAAAATAATATGGGGGTTTTATTCGCTCCTCTAAAATTTATAT
TGTTACAGAGCTGTCAGACTAATACTAAGTCAACATCCTCTACTTTTTCACAGACAGCCGGCATCA
GTGCAATAATTTGACAACAAAGTTAGCAAGTCACCCTGGAGTTTACTGATTTATCCAGAAAGCAAT
GAATCTTTCATGCTTAAAATCCAAAATAAACTACCAATAAGCATTTGGAATTCATAAGTTTCCTCT
CAAAATTTTATTGTGAATTTCTTATAGTAATACCTTCAGTAAAGTAAGACAGATATCATGGAAAAA
AAGTATAAAATGTAAGTTTGACTTCAAGAAAAATGAAACCACAAATATGACCCAGGAAAGAATTTA
ACATGGAGAAAGAATGAAATCAAATTTCCCTCAATATAAGGCCTAAACCCTATTCACTCTTCTGCT
TTCTTTACACAAATCCATATTTATTGCTGCTGTTTGTGATTTTCAAATATATTTGCCTGACTTGAG
AAGAATTTCCCATAGGTGTGATATATTAATCTTGTATTCATTTCAAGAACTGTTTAAAATTCTGGG
ATTAATTTCCTAAATTAGTGATTAGTCATGATAAAAAAGTTTTGAGAA 
 
Insert sequence is 83681 - 83812 and in italics. Bold is different in insert (C) 
 
Complementary strand  
AAAAAGTAGAGGATGTTGACTTAGTATTAGTCTGACAGCTCTGTAACAATATAAATTTTAGAGGAG
CGAATAAAACCCCCATATTATTTTATTCTGTGGCTGGCATAAATAGAACTCTTAACTTGCACTATT
GGGTATGAATTATGTATGTGTGTATATTTATATATTTGTAGATAAATACATTTGTGCATGTGTCCA
TCAGATGACTAATTTGGCCCAATCTGAAGGAATGAAAAAACTTACACTGTTGGAACTAATACTGCA
GTTGATTAGTGTGTCACACTAATCAGAGGCTGTGTCTTTGTAAGGAGAGTTTTAAATAGCTTAAAC
TTCAAGAATTAAAACTTCTGGCCAGGCACGGTGGCTTACCCCTGTAATCCCAGCACCTTGGGAGGC
TGAGGCGGGCGGATTACTTGAGGCCAGGAGTTCGAGACTAGCCTGGCCAACATGGTGAAACCCCAT
CTCTACTAAAAATAGAAAAATTAGTGGGGTGTGGTGGCACACGACTGTAATCCCAGCTACTTGGGA
GGCTGAGTCATGAGAACCTCTTGAACCCAGGAAGTGGAGGTTGCAATGAGCCGAGATTGCGCCACT
GCACTCTAGCATGGGCAACAGAGTATGACTATGTCTTTAAAAAAAAAAAAGAAAAAACTACTACTT
CTGTAATTATATTAAAATTTATTTAAAAGCAGTCAGCTATAACATTTTGATTTGCAGCTTGATTTA
CAAAGGTTTGGATTATATATATTATAAACATCCCCTTCCCCCCAAAAAATAAGTTTAAGTAAAGTA
AGATTATCTATTACAGTGTTTAGTGTTTGGGATTTTTTTCTAAGGCACTAGTGTCACAGTATTTGT
TTACTTAGATGGTAGTTTTGAACTAAAGCTGGCTCATCTTGTTTTATTTTACATGTTCTCAAAAAT
TTTTTAGAACTAATTTCAGTATGAGTTCTAACAGTCAGATGTTTGTGTATATTACGTTACACTATG
CTCTTGTGTTAATTGACTGTATTTCCAATGGAGAAAGAACAAAGTTTCAATTGATGTATATAATAT
TCTGTGCCCAACACAAAGTAGGTGCTAAACAAATGCTTACTGAATGAATAAATATGGAAAATTGCT
TATTGGCCAATACTGCCA 
 
This fragment appears to be primed from a stretch of 16As within the genomic 
sequence (underlined) but it does not arise from within the coding sequence or 
mature transcript, as detailed in the NCBI notes. It may arise from an mRNA 
precursor. It may arise from a transcript within a transcript (cf rev-erbA) It may 
also arise from genomic DNA, though this is unlikely hopefully!. 
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Clone P4.4 
P4.4 
GAATTCACACGACTGTAGTCCTAGCACATTGGGAAGCCAAGGTGGGAGGATTGCTTGAGGCCAGGAGTT
CAAGGCTGCAGTGAGCTATGATTGCACACTGTACTCTAGCCTGGGAGACAGAGTGAGACACTGTCTCTA
AAAAAAAAAAACTCGAG 
 
AF130054 1653 bp mRNA 08-MAY-2001, Homo sapiens clone FLB4816 
PRO1252 mRNA, complete cds. Expressed in human fetal liver. +/- fit (should be 
+/+ if the hit is an mRNA sequence given the direction of sequencing ie seq end in 
poly A from ET12C primer) 
GCTTTTTTTTTTTTTTTTTTTTTTTTTTAGAGACAGTGTCTCACTCTGTCTCCCAGGCTAGAGTAC
AGTGTGCAATCATAGCTCACTGCAGCCTTGAACTCCTGGCCTCAAGCAATCCTCCCACCTTGGCTT
CCCAATGTGCTAGGTTTACAGGCGTGAAAACATTGTGTTGTGTGTGTGTGTGTTTTTTTTTTTTTT
TTTTTTAGACAGAGTTTCGCTCTTGTTGTCCAGGCTGGAGTACAATGGCTTGATCTTGGCTCACTG
CAATCTCTGCCTCGCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCTGGAGTGGCTGGGATTACAGG
CGCCCACCATCACGCCCGGCCAATTTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCC
AGGCTGGCCTCGAACTCTTGACCTCAGGTGATCCACCTGCCTTGGCCTCCCAATGTACTGAGATTA
CAGGCATGAGCCACCACGCCCGGCCAAAAACATTTAAAAAATGACTGTCCCTGCTCAAATACTGCA
GTAGGAAATGTAATTTGACATATATCACTTCCAGAAAAAAACTTTAAATCTTTCTATAAAATGAAT
TTGATACATCATCAGCATGAAGTGAAGTTAAAATCTCTTACAAAGTAAATTCAGGTATATCAACAA
TGAGATCCAAAAGTATCGGTTCAAGATCAAAGACTCATATGAGGTAAAGGCAAATAAAGCCCCTCA
TGCTTTCAGACATTTACTTGTTATCCTTAAAATGATTATTGTTCTAAGGTGCAAATCTTATCATTC
AGTGACCTATTTGCTATTTGGCTGTTTATCTCCTTTAAATAAAATACCATACAGGTTATAATGTAC
ATTTTAAAATCAAATATGAAAGTACACATATGTGAACAAGACATTAATTTAAATATCAATTATATT
CATAATACAGAAGTCTAAGAATGCTATTTGGTCATTTCAATTAGATGCTGATATATTTGGTCAAGA
AAACCCACATTCCTATCAGCCTAAGGCAAATAGTAAATGCCTCTATTTTTATTAAGTGGACTATAA
ACAGTAGACATTATTGTTTGATACTACTGGAATGCTCTCAATTAGAACGTACACTGATAACAAATA
TGTCTTTCTAATCTGGGTGATAACCTCAATGATTACATGGAAATCTACAAGTAACAGTCTATAACT
TAAAGCAGTAGAGCACCTGGTAATTGTCATACAGTGCCTCTCTATGAATTTAGAACATTCTACTTA
CATTGGCAGTGGAGAGAAAAGACCCCTTCACACTGAGACTTCCTGTGCACCGCGCCTGCCGCCTGC
CTCAGCTTAGGACATGGTACAGTCTTCTTTGCTTTTGCCCTTCTCATTCCCTCCTCTGGTATCTTC
TCTGCTTTCTGGATTGAAGTGCCCTGGCTCTCTTCCTGGTGCCGACAAGTCATTGTTCTCTAGGCT
ATTGCTGTCTAAAGCTTTCCTGACGGTCTGACTTGGATGTTCTGACATCTCACACCTTTCTGTCTT
CCTCTTCTCACCCTCCTCCCTCCCCTTAGCCATCACTTCTGGGAAGTAAAGAACTTGACTTAGTGC
CGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AA 
 
Primers are indicated in boxes, lower primer shaded (ie 101,795; 798,1272)  
 
AC012076 212275 bp; PRI 01-MAR-2002; Homo sapiens BAC clone RP11-
497D24 from chr2, complete sequence. +/+ fit 118/118 
GAGGTTATCACCCAGATTAGAAAGACATATTTGTTATCAGTGTACGTTCTAATTGAGAGCATTCCA
GTAGTATCAAACAATAATGTCTACTGTTTATAGTCCACTTAATAAAAATAGAGGCATTTACTATTT
GCCTTAGGCTGATAGGAATGTGGGTTTTCTTGACCAAATATATCAGCATCTAATTGAAATGACCAA
ATAGCATTCTTAGACTTCTGTATTATGAATATAATTGATATTTAAATTAATGTCTTGTTCACATAT
GTGTACTTTCATATTTGATTTTAAAATGTACATTATAACCTGTATGGTATTTTATTTAAAGGAGAT
AAACAGCCAAATAGCAAATAGGTCACTGAATGATAAGATTTGCACCTTAGAACAATAATCATTTTA
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AGGATAACAAGTAAATGTCTGAAAGCATGAGGGGCTTTATTTGCCTTTACCTCATATGAGTCTTTG
ATCTTGAACCGATACTTTTGGATCTCATTGTTGATATACCTGAATTTACTTTGTAAGAGATTTTAA
CTTCACTTCATGCTGATGATGTATCAAATTCATTTTATAGAAAGATTTAAAGTTTTTTTCTGGAAG
TGATATATGTCAAATTACATTTCCTACTGCAGTATTTGAGCAGGGACAGTCATTTTTTAAATGTTT
TTGGCCGGGCGTGGTGGCTCATGCCTGTAATCTCAGTACATTGGGAGGCCAAGGCAGGTGGATCAC
CTGAGGTCAAGAGTTCGAGGCCAGCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAAATACAA
AAAATTGGCCGGGCGTGATGGTGGGCGCCTGTAATCCCAGCCACTCCAGAGGCTGAGGCAGGAGAA
TCGCTTGAACCTGCGAGGCAGAGATTGCAGTGAGCCAAGATCAAGCCATTGTACTCCAGCCTGGAC
AACAAGAGCGAAACTCTGTCTAAAAAAAAAAAAAAAAACACACACACACACAACACAATGTTTTCA
CGCCTGTAAACCTAGCACATTGGGAAGCCAAGGTGGGAGGATTGCTTGAGGCCAGGAGTTCAAGGC
TGCAGTGAGCTATGATTGCACACTGTACTCTAGCCTGGGAGACAGAGTGAGACACTGTCTCTAAAA
AAAAAAAAAAAAAAAAAAAAAGTTTTTGAACCTTAAAATACTTTGTTTGAATTTCTAATCATCATT
CAAAAGAGCAGTAAAAAATGGTTACTTGTTCTTGTACAAGCTACTAATTAGACTATAGTAGGATAT
TTTAAAGAGCTGAATCACTTTTGGTATTTTGGTATAAATATTTTCATTTGTTATGTCCCAGTATAT
TCTTACTGGAAAATTCTTGTTTTGATCTGCCTGAAGAAAATATCTGTTTTCTATATAAAAAAATTT
TTTAAAATAATTGTAAAGTTAGATTTAAAATTGTAAAATATAAAATCACAAAGGAATGTACCTTAT
GAATGTTGTTGACATTTTATGAAATTATGTGGATTCATATTACTGTTACAAGATAGAATTGAATGC
AAAAAGACCAAAACCTCAATAAAATTTGAGGAAAACGTGTTATTATGTAATTGAAATAAAAACATT
TTATAATTGTGCAAGCCTGTGGTTCCACTCTTTGGGCTGCTTGAAGTCTGAGTCTGACTACTGTTG
TATGTAATACCACCTTTGAGTAATATCTGCTTGGGGGTTGCTGATTCCTATTGGGGTTCCGTGGAA
GACCCACGCCTGATGCCCTCCCTCAGTAAGGAATGCACTTCCCTCCTGGCATCGAGCCTGGGGCTA
GCATGGGCATTACTGGGAGAACTGAGACGATTGTCACGCACCATCCCCTGTGATCTGTGGTTCTGA
TGTGCAGCCTCAGCTGAAAACGGTCTTCACCTGTGGCTGTGCTTACCTGCGCCACTACTTACAGTG
TTTTGAAGAGCAGGATGAAAACGGCAAAAACCTTGACTGTTTCTGCTCAAGTGTCCTGAAGTAGAG
GATGGTGGGGATGATAAATGCTTGCTAGGAAATAAGTCCAAGGGCTCTATAGGACTTCACAGGGTT
TTAGTTTATGTCTCTAACTTTAGCAAAGCTGCATTCCTATTGGAATGCATACTGGAAACAGCTCTC
ATTCCT 
Insert fit is to nuc 87039 – 87156; underlined area is EST BE674143 match 
NCBI notes 
misc_feature 86584..87233/note="similar to EST BG286780 (NID:g13039960)" 
repeat_region 86701..87000/rpt_family="Alu" 
misc_feature 87005..87632/note="match to EST AW976721 (NID:g8167954)" 
repeat_region 87027..87181/rpt_family="Alu" 
misc_feature 87040..87638/note="match to EST BE674143 (NID:g10034684)" 
misc_feature 87075..87633/note="match to EST AI091818 (NID:g3430877) 
qa58b09.s1" 
 
Complementary sequence for 500 bp each side of insert – note sequence is the 
same as for AF130054 1653 bp mRNA for the first 540 bp of the mRNA (ie 3’ to 
fragment in this sequence). Italics = P4.4 insert, underlined = EST BE674143 
ATGCCAGGAGGGAAGTGCATTCCTTACTGAGGGAGGGCATCAGGCGTGGGTCTTCCACGGAACCCC
AATAGGAATCAGCAACCCCCAAGCAGATATTACTCAAAGGTGGTATTACATACAACAGTAGTCAGA
CTCAGACTTCAAGCAGCCCAAAGAGTGGAACCACAGGCTTGCACAATTATAAAATGTTTTTATTTC
AATTACATAATAACACGTTTTCCTCAAATTTTATTGAGGTTTTGGTCTTTTTGCATTCAATTCTAT
CTTGTAACAGTAATATGAATCCACATAATTTCATAAAATGTCAACAACATTCATAAGGTACATTCC
TTTGTGATTTTATATTTTACAATTTTAAATCTAACTTTACAATTATTTTAAAAAATTTTTTTATAT
AGAAAACAGATATTTTCTTCAGGCAGATCAAAACAAGAATTTTCCAGTAAGAATATACTGGGACAT
AACAAATGAAAATATTTATACCAAAATACCAAAAGTGATTCAGCTCTTTAAAATATCCTACTATAG
TCTAATTAGTAGCTTGTACAAGAACAAGTAACCATTTTTTACTGCTCTTTTGAATGATGATTAGAA
ATTCAAACAAAGTATTTTAAGGTTCAAAAACTTTTTTTTTTTTTTTTTTTTTTTTTAGAGACAGTG
TCTCACTCTGTCTCCCAGGCTAGAGTACAGTGTGCAATCATAGCTCACTGCAGCCTTGAACTCCTG
GCCTCAAGCAATCCTCCCACCTTGGCTTCCCAATGTGCTAGGTTTACAGGCGTGAAAACATTGTGT
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TGTGTGTGTGTGTGTTTTTTTTTTTTTTTTTAGACAGAGTTTCGCTCTTGTTGTCCAGGCTGGAGT
ACAATGGCTTGATCTTGGCTCACTGCAATCTCTGCCTCGCAGGTTCAAGCGATTCTCCTGCCTCAG
CCTCTGGAGTGGCTGGGATTACAGGCGCCCACCATCACGCCCGGCCAATTTTTTGTATTTTTAGTA
GAGACAGGGTTTCACCATGTTGGCCAGGCTGGCCTCGAACTCTTGACCTCAGGTGATCCACCTGCC
TTGGCCTCCCAATGTACTGAGATTACAGGCATGAGCCACCACGCCCGGCCAAAAACATTTAAAAAA
TGACTGTCCCTGCTCAAATACTGCAGTAGGAAATGTAATTTGACATATATCACTTCCAGAAAAAAA
CTTTAAATCTTTCTATAAAATGAATTTGATACATCATCAGCATGAAGTGAAGTTAAAATCTCTTAC
AAAGTAAATTCAGGTATATCAACAATGAGATCCAAAAGTATCGGTTCAAGATCAAAGACTCATATG
AGGTAAAGGCAAATAAAGCCCCTCATGCTTTCAGACATTTACTTGTTATCCTTAAAATGATTATTG
TTCTAAGGTGCAAATCTTATCATTCAGTGACCTATTTGCTATTTGGCTGTTTATCTCCTTTAAATA
AAATACCATACAGGTTATAATGTACATTTTAAAATCAAATATGAAAGTACACATATGTGAACAAGA
CATTAATTTAA 
 
Compilation of AC012076 complementary sequence and AF130054 1653 bp 
mRNA to give the +/- strand to the fragment (+/+ wrt mRNA), providing the 5’ 
sequence omitted from the mRNA which is an EST (underlined). This was used to 
design further primers . 
ATGCCAGGAGGGAAGTGCATTCCTTACTGAGGGAGGGCATCAGGCGTGGGTCTTCCACGGAACCCC
AATAGGAATCAGCAACCCCCAAGCAGATATTACTCAAAGGTGGTATTACATACAACAGTAGTCAGA
CTCAGACTTCAAGCAGCCCAAAGAGTGGAACCACAGGCTTGCACAATTATAAAATGTTTTTATTTC
AATTACATAATAACACGTTTTCCTCAAATTTTATTGAGGTTTTGGTCTTTTTGCATTCAATTCTAT
CTTGTAACAGTAATATGAATCCACATAATTTCATAAAATGTCAACAACATTCATAAGGTACATTCC
TTTGTGATTTTATATTTTACAATTTTAAATCTAACTTTACAATTATTTTAAAAAATTTTTTTATAT
AGAAAACAG405ATATTTTCTTCAGGCAGATCAAAACAAGAATTTTCCAGTAAGAATATACT455GGG
ACATAACAAATGAAAATATTTATACCAAAATACCAAAAGTGATTCAGCTCTTTAAAATATCCTAC
TATAGTCTAATTAGTAGCTTGTACAAGAACAAGTAACCATTTTTTACTGCTCTTTTGAATGATGAT
TAGAAATTCAAACAAAGTATTTTAAGGTTCAAAA(startAF130054)ACTTTTTTTTTTTTTTTT
TTTTTTTTTAGAGACAGTGTCTCACTCTGTCTCCCAGGCTAGAGTACAGTGTGCAATCATAGCTCA
CTGCAGCCTTG719AACTC101CTGGCCTCAAGCAATCCTCCCACCTTGGCTTCCCAATGTGCTAGGT
TTACAGGCGTGAAAACATTGTGTTGTGTGTGTGTGTGTTTTTTTTTTTTTTTTTTTTAGACAGAGT
TTCGCTCTTGTTGTCCAGGCTGGAGTACAATGGCTTGATCTTGGCTCACTGCAATCTCTGCCTCGC
AGGTTCAAGCGATTCTCCTGCCTCAGCCTCTGGAGTGGCTGGGATTACAGGCGCCCACCATCACGC
CCGGCCAATTTTTTGTATTTTTAGTAGAGACAGGGTTTCACCATGTTGGCCAGGCTGGCCTCGAAC
TCTTGACCTCAGGTGATCCACCTGCCTTGGCCTCCCAATGTACTGAGATTACAGGCATGAGCCACC
ACGCCCGGCCAAAAACATTTAAAAAATGACTGTCCCTGCTCAAATACTGCAGTAGGAAATGTAATT
TGACATATATCACTTCCAGAAAAAAACTTTAAATCTTTCTATAAAATGAATTTGATACATCATCAG
CATGAAGTGAAGTTAAAATCTCTTACAAAGTAAATTCAGGTATATCAACAATGAGATCCAAAAGTA
TCGGTTCAAGATCAAAGACTCATATGAGGTAAAGGCAAATAAAGCCCCTCATGCTTTCAGACATTT
ACTTGTTATCCTTAAAATGATTATTGTTCTAAGGTGCAAATCTTATCATTCAGT795GACC799TATT
TGCTATTTGGCTGTTTATCTCCTTTAAATAAAATACCATACAGGTTATAATGTACATTTTAAAATC
AAATATGAAAGTACACATATGTGAACAAGACATTAATTTAAATATCAATTATATTCATAATACAGA
AGTCTAAGAATGCTATTTGGTCATTTCAATTAGATGCTGATATATTTGGTCAAGAAAACCCACATT
CCTATCAGCCTAAGGCAAATAGTAAATGCCTCTATTTTTATTAAGTGGACTATAAACAGTAGACAT
TATTGTTTGATACTACTGGAATGCTCTCAATTAGAACGTACACTGATAACAAATATGTCTTTCTAA
TCTGGGTGATAACCTCAATGATTACATGGAAATCTACAAGTAACAGTCTATAACTTAAAGCAGTAG
AGCACCTGGTAATTGTCATACAGTGCCTCTCTATGAATTTAGAACATTCTACTTACATTGGCAGTG
GAGAGAA1272AAGACCCCTTCACACTGAGACTTCCTGTGCACCGCGCCTGCCGCCTGCCTCAGCTT
AGGACATGGTACAGTCTTCTTTGCTTTTGCCCTTCTCATTCCCTCCTCTGGTATCTTCTCTGCTTT
CTGGATTGAAGTGCCCTGGCTCTCTTCCTGGTGCCGACAAGTCATTGTTCTCTAGGCTATTGCTGT
CTAAAGCTTTCCTGACGGTCTGACTTGGATGTTCTGACATCTCACACCTTTCTGTCTTCCTCTTCT
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CACCCTCCTCCCTCCCCTTAGCCATCACTTCTGGGAAGTAAAGAACTTGACTTAGTGCCGGAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
New primers (U405, L719; U455, L719) on this compiled sequence (shadowed 
boxes), old primers (ie 101,795; 799,1272) in normal boxes. Lps are shaded, 
hatched areas are shared between Lps and Ups 
 
Up:  CCTGGCCTCAAGCAA (15mer, 101-115)   714 bp 
 59C  
Lp:  GCCAAATAGCAAATAGGTCA (20mer, 795-814) 
10/6/3: P pool, 30,35,40,45, then further 20,30,40,50 cyc @53C. No products. Sigma 
said primers dodgy  
24/6/3: N/P pool, 24-50 cyc @55C. No products. 18S and a2actin very poor. Fresh 
primers though  
4/7/3: N/P pool, 30-55 cyc @57C. No products, though 18S and a2 actin are lower 
than normal 
17/9/03: N and P pools, 40,45,50,55cyc @57C. No products, a2a/18S OK 
No Products with these primers 
 
Up:  CTATTTGCTATTTGGCTGTT (21mer, 799-819) 493 bp  59C  
Lp:  TCAGTGTGAAGGGGTCTTT (19mer, 1272-1290) 
10/6/3: P pool, 30,35,40,45, then further 20,30,40,50 cyc @53C. No products. Sigma 
said primers dodgy  
24/6/3: N/P pool, 24-50 cyc @55C. No products. 18S and a2actin very poor. Fresh 
primers though  
4/7/3: N/P pool, 30-55 cyc @57C. No products, though 18S and a2 actin are lower 
than normal 
17/9/03: N and P pools, 40,45,50,55cyc @57C. From 40 cyc 470bp product. 
Recommend 42 cyc,59C for x10-x80 cDNA dilutions 
 
Second phase 
P4-4: Compilation of AC012076 genomic complementary sequence and AF130054 
1653 bp PRO1252 mRNA to give the +/- strand to the fragment (as used for primers 
previously) but including the 5’ sequence omitted from the mRNA which is an EST. 
 
Lp: CTTGAGGCCAGGAGTT (16mer, 719-734) 
 
Up: GATATTTTCTTCAGGCAGAT (20mer, 405-424)  330 bp 
 55C 
16/6/3: 40,50 cyc @55C, N and P pools. Equal product at 50cyc- a2 actin was low 
4/7/3: N/P pool, 30-55 cyc @57C. Products from 35 cyc onwards, tends to doublet 
17/9/03: N and P pools, 32,35,39,41 cyc@57C. products at 35 cyc weak, P>N, 
a2a/18S OK 
Recommend 38 cyc (check intensity),55C for x10-x80 cDNA dilutions 
 
Up: TGGGACATAACAAATGAAAA (20mer, 455-474) 281 bp  58C 
16/6/3: 40,50 cyc @55C, N and P pools. Equal product at 50cyc- a2 actin was low 
4/7/3: N/P pool, 30-55 cyc @57C. Products from 45 cyc onwards, tends to doublet 
17/9/03: 41,44,47,50 cyc@57C. products at 41 cyc weak, P>N, a2a/18S OK; doublet 
in some 370bp/440bp 
Recommend 42 cyc (check intensity),57C for x10-x80 cDNA dilutions 
 
Analysis of P5 clones and P7-1 clone insert sequence. Homology detected with 
BAC chromosome 15 clones listed below. 
P7-1 
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GAATTCACACGACTGTGAAAATGCCCATTTCATTGCACGCTTTCTAACATTTATACCAATCTGAT
AAATAAAAGCTGGTACCTAGAAAAAAAAAAAACTCGAG 
P5-1 
GAATTCACACGACTGTGAAAATGCCCATTTCATTGCACGCTTTCTAACATTTATACCAATCTGAT
AAATAAAAGCTGGTACCTAGAAAAAAAAAAAACTCGAG 
P5-3 
GAATTCACACGACTGTGAAAATGCCCATTTCATTGCACGCTTTCTAACATTTATACCAATCTGAT
AAATAAAAGCTGGTACCTAGAAAAAAAAAAAACTCGAG 
P5-5 
GAATTCACACGACTGTGAAAATGCCCATTTCATTGCACGCTTTCTAACATTTATACCAATCTGAT
AAATAAAAGCTGGTACCTAGAAAAAAAAAAAACTCGAG 
 
Summary: The sequence AC126339.6 is probably most accurate and is exactly 
the same as AC136698.6 and AC 005630.1 except that: 1) it is sequenced in the 
opposite direction (no problem) 2) a TTTTTTT insertion in AC126339.6, though 
this is reflected as a run of 22Ts in AC126339 and 15Ts in AC136698.6 and AC 
005630.1. 
Small differences exist between AC126339.6 and AC139425.3, noted in bold 
type below, which probably represent sequence errors as the sequences were 
derived from the same group and, presumably, sampled individual. Alternatively 
it is possible each sequence is derived from a different chromasome from the 
diploid chr15 pair. 
Even more significant is that AC 005630.1 quotes the region of the insert 
homologous sequence as being similar to EST AA443771 and ESTAI338526, 
suggesting that this sequence is at least expressed at the RNA level. 
 
AC126339.6+/-, sub 8/4/03 
GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATTTTTTTTCTACCTTAACTAATGCTTTGGACA
TCATCAACAGGTAGAGCTAAATCCTTGAAACCTTCCAAGTGGTGGCTTTCAGTTATTGCTGAAT
TGGTTTTTAGAGATGGAACAAATTATATTGTATGGAAACTTTTTTTTTTTTTTTTTTTTTTGAG
ACAAAGTCTCAGCTTGTCACCCAGGCTGGAGGGCAATGGCATGATCTTGGCTCACTAAAACCTCC
ACCTCCCAGGTTCAAGTGATCCTCTTGCCTCAGCCTCCCGAGTAGTTGGGATTACAGGGGCCTGC
CACCATGCCCGGCTAATGTTTGTGTTTTTACTAGAGATGGGGTTTCATCATGTTGGCCAGGCTTG
TCTCGAACTCCTGACCTCAGGTGATCCACTCACCTTGGTCTCCCAAAGTACTGGGATTACAGGCA
TGAGCCACCATACCCAGCCTTTTTTTCTTCTAGGTACCAGCTTTTATTTATCAGATTGGTATAAA
TGTTAGAAAGCGTGCAATGAAATGGGCATTTTCACAGTCGTGGCAGAAAGTATAATTATCTTTGA
CTTTCTAGAAAGCAGTCTGGCATTCTAGAAACTTGCCTAACCTCTTCCCATTTAGACAAGATGAA
TTCTGACAGGGCCAGCCTTGTCCCTGTGATTCCGTATCTCCCAGAAAGAGAGGTCTAGTCTCAGG
GAAAACCCAGATTTTCTTGGCTTAGCCCACCTGACAGCTAATCACTGGAAATGGGGCGGGCCGGT
AGAGTCCTTTGGTCAGGTTTTGTGTCAAGAGAGGGATGTGGAAAGATGGGAGAGAGGTAGCAAAA
CTGGCCTCAATGGAACTGTGTAAGTTAACATAGAATGGCAAAGGAATGTTTCTTCCAAGGAAGAA
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ATTCTAGGGAAGGAATAAAGTAGAGGGGAAGGCAGCAGTTCTCAAAGTTTTGGGGTCAGGATTCC
TTTACACTCTTAAAAGTATATTGAGGGCCCAAGGAGCTTTTGTGTATGTGGGTTATATCTATTGG
TA 
 
Insert comprises nuc 84817 - 84896 of this clone (RP13-98N21) in +/- fit. 
Sequence  here  includes  480 bp each side of insert. Note excerpts from NCBI 
report regarding this region 
repeat_region   84331..84368 
      /rpt_family="(TG)n" 
repeat_region   complement(84505..84808) 
      /rpt_family="AluSx" 
repeat_region   complement(85277..85421) 
      /rpt_family="Charlie1" 
 
 
P5: AC139425.3+/-, sub 21/2/03 
AGAGAGAGAGAGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTATTTTTTTTCTACCTTAACTAATG
CTTTGGACATCAACAGGTAGAGCTAAATCCTTGAAACCTTCCAAGTGGTGGCTTTCAGTTATTGC
TGAATTGGTTTTTAGAGATGGAACAAATTATATTGTATGGAAACTTTTTTTTTTTTTTTTGAGAC
AAAGTCTCACCTTGTCGCCCAGGCTGGAGAGCAATGGCATGATCTTGGCTCACTGCAATCTCTGC
CTCCCAGGTTCAAGTGATTCTCTTGCCTCAGCCTCCCGAATAGTTGGGATTACAGGTGCTTGCCA
CCATGCCCGGCTAATTTTTGTCTTTTTACTAGAGATGGGGTTTCATCATGTTGGCCAGGCTTGTC
TCGAACTCCTGACCTCAGGTGATCCACTCACCTTGGCCTCCCAAACTACTGGGATTACAGGCATA
AGCCACCATACCCAGCCTTTTTTTCTTCTAGGTACCAGCTTTTATTTATCAGATTGGTATAAATG
TTAGAAAGCGTGCAATGAAATGGGCATTTTCACAGTCGTGGCAGAAAGTATAATTATCTTTGACT
TTCTAGAAAGCAGTCTGGCATTCTAGAAACTTGCCTAACCTCTTCCCATTTAGGCAAGATGAATT
CTCACTACCCGTAGGTGGCCAACCTTGTCCTTGTGATTCCGTATCTTCCAGAAAGAGAGGTCTAG
TCTCAGGGAAAACCCAGATTTTCTTGGCTTAGCCCACCTGACAGCTAATCACTGGAAATGAGGTG
GGCCGGTAGAGTCCTTTGGTCAGGTTTTGTGTCAAGAGAGGAATGTGGAAAGATGGGAGGGAGGT
AGCAAAACTGGCCTCAATGGAACTATGTAAGTTAACATAGAATGACAAAGGAATGTTTCTTCCAG
GGAAGAAATTCTAGGGAAGGAAGAAAGTGGAGGGGAAGGCAGCAGTTCTCAAAGTTTTGGGGTCA
GGATTCCTTTACACTCTTAAAAGTATATTGAGGGCCCAAGGAGCTTTTCTGTATATAGGTTATAT 
 
Italics show the –ve complement to P5 inserts, bolds the differences and shadow 
boxes the insertions, between AC139425.3 and AC126339.6. Insert comprises nuc 
114595 - 114674 of this clone (RP13-996F3) in +/- fit. Sequence here includes 480 
bp each side of insert. Note excerpts from NCBI report regarding this region. 
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repeat_region   114084..114128/rpt_family="(GA)n" 
repeat_region   114128..114155/rpt_family="(TG)n" 
repeat_region   complement(114289..114586)/rpt_family="AluSx" 
 
AC136698.6+/+, sub 8/2/02 
TACCAATAGATATAACCTACATACACAAAAGCTCCTTGGGCCCTCAATATACTTTTAAGAGTGTA
AAGGAATCCTGACCCCAAAACTTTGAGAACTGCTGCCTTCCCCTCCACTTTATTCCTTCCCTAGA
ATTTCTTCCTTGGAAGAAACATTCCTTTGCCATTCTATGTTAACTTACATAGTTCCATTGAGGCC
AGTTTTGCTACCTCTCTCCCATCTTTCCACATCCCTCTCTTGACACAAAACCTGACCAAAGGACT
CTACCGGCCCACCCCATTTCCAGTGATTAGCTGTCAGGTGGGCTAAGCCAAGAAAATCTGGGTTT
TCCCTGACACTAGACCTCTCTTTCTGGGAGATACGGAATCACAGGGACAAGGCTGGCCCTGTCAG
AACTCATCTTGTCTAAATGGGAAGAGGTTAGGCAAGTTTCTAGAATGCCAGACTGCTTTCTAGAA
AGTCAAAGATAATTATACTTTCTGCCACGACTGTGAAAATGCCCATTTCATTGCACGCTTTCTAA
CATTTATACCAATCTGATAAATAAAAGCTGGTACCTAGAAGAAAAAAAGGCTGGGTATGGTGGCT
CATGCCTGTAATCCCAGTACTTTGGGAGACCAAGGTGAGTGGATCACCTGAGGTCAGGAGTTCGA
GACAAGCCTGGCCAACATGATGAAACCCCATCTCTAGTAAAAACACAAACATTAGCCGGGCATGG
TGGCAGGCCCCTGTAATCCCAACTACTCGGGAGGCTGAGGCAAGAGAATCACTTGAACCTGGGAG
GTGGAGGTTTTAGTGAGCCAAGATCATGCCATTGCCCTCCAGCCTGGGTGACAAGGTGAGACTTT
GTCTCAAAAAAAAAAAAAAAGTTTCCATACAATATAATTTGTTCCATCTCTAAAAACCAATTCAG
CAATAACTGAAAGCCACCACTTGGAAGGTTTCAAGGATTTAGCTCTACCTGTTGATGATGTCCAA
AGCATTAGTTAAGGTAGAAAAAAAATATACACACACACACACACACACACACACACACACACACA 
 
Insert comprises nuc 110098 - 110177 of this clone (RP13-262C2). Sequence 
here includes 480 bp each side. Note excerpts from NCBI report regarding this 
region. Repeat_region   110186..110482/rpt_family="AluSx" 
repeat_region   110621..110664/rpt_family="(CA)n" 
 
AC136698.6 Complementary strand 
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTATATTTTTTTTCTACCTTAACTAATGC
TTTGGACATCATCAACAGGTAGAGCTAAATCCTTGAAACCTTCCAAGTGGTGGCTTTCAGTTATT
GCTGAATTGGTTTTTAGAGATGGAACAAATTATATTGTATGGAAACTTTTTTTTTTTTTTT(T7m
issing)GAGACAAAGTCTCACCTTGTCACCCAGGCTGGAGGGCAATGGCATGATCTTGGCTCAC
TAAAACCTCCACCTCCCAGGTTCAAGTGATTCTCTTGCCTCAGCCTCCCGAGTAGTTGGGATTAC
AGGGGCCTGCCACCATGCCCGGCTAATGTTTGTGTTTTTACTAGAGATGGGGTTTCATCATGTTG
GCCAGGCTTGTCTCGAACTCCTGACCTCAGGTGATCCACTCACCTTGGTCTCCCAAAGTACTGGG
ATTACAGGCATGAGCCACCATACCCAGCCTTTTTTTCTTCTAGGTACCAGCTTTTATTTATCAGA
TTGGTATAAATGTTAGAAAGCGTGCAATGAAATGGGCATTTTCACAGTCGTGGCAGAAAGTATAA
TTATCTTTGACTTTCTAGAAAGCAGTCTGGCATTCTAGAAACTTGCCTAACCTCTTCCCATTTAG
ACAAGATGAGTTCTGACAGGGCCAGCCTTGTCCCTGTGATTCCGTATCTCCCAGAAAGAGAGGTC
TAGTGTCAGGGAAAACCCAGATTTTCTTGGCTTAGCCCACCTGACAGCTAATCACTGGAAATGGG
GTGGGCCGGTAGAGTCCTTTGGTCAGGTTTTGTGTCAAGAGAGGGATGTGGAAAGATGGGAGAGA
GGTAGCAAAACTGGCCTCAATGGAACTATGTAAGTTAACATAGAATGGCAAAGGAATGTTTCTTC
CAAGGAAGAAATTCTAGGGAAGGAATAAAGTGGAGGGGAAGGCAGCAGTTCTCAAAGTTTTGGGG
TCAGGATTCCTTTACACTCTTAAAAGTATATTGAGGGCCCAAGGAGCTTTTGTGTATGTAGGTTA
TATCTATTGGTA 
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Comparison of AC136698.6 complementary strand with AC126339.6. Italics 
show the –ve complement to P5 inserts, bolds the differences and underlined 
the insertions, between the two sequences above 
 
AC005630.1, sub 21/2/03, +/+ fit (match to AC 136698.6) 
TACCAATAGATATAACCTACATACACAAAAGCTCCTTGGGCCCTCAATATACTTTTAAGAGTGTA
AAGGAATCCTGACCCCAAAACTTTGAGAACTGCTGCCTTCCCCTCCACTTTATTCCTTCCCTAGA
ATTTCTTCCTTGGAAGAAACATTCCTTTGCCATTCTATGTTAACTTACATAGTTCCATTGAGGC
CAGTTTTGCTACCTCTCTCCCATCTTTCCACATCCCTCTCTTGACACAAAACCTGACCAAAGGA
CTCTACCGGCCCACCCCATTTCCAGTGATTAGCTGTCAGGTGGGCTAAGCCAAGAAAATCTGGGT
TTTCCCTGACACTAGACCTCTCTTTCTGGGAGATACGGAATCACAGGGACAAGGCTGGCCCTGTC
AGAACTCATCTTGTCTAAATGGGAAGAGGTTAGGCAAGTTTCTAGAATGCCAGACTGCTTTCTAG
AAAGTCAAAGATAATTATACTTTCTGCCACGACTGTGAAAATGCCCATTTCATTGCACGCTTTC
TAACATTTATACCAATCTGATAAATAAAAGCTGGTACCTAGAAGAAAAAAAGGCTGGGTATGGTG
GCTCATGCCTGTAATCCCAGTACTTTGGGAGACCAAGGTGAGTGGATCACCTGAGGTCAGGAGTT
CGAGACAAGCCTGGCCAACATGATGAAACCCCATCTCTAGTAAAAACACAAACATTAGCCGGGCA
TGGTGGCAGGCCCCTGTAATCCCAACTACTCGGGAGGCTGAGGCAAGAGAATCACTTGAACCTGG
GAGGTGGAGGTTTTAGTGAGCCAAGATCATGCCATTGCCCTCCAGCCTGGGTGACAAGGTGAGAC
TTTGTCTCAAAAAAAAAAAAAAAGTTTCCATACAATATAATTTGTTCCATCTCTAAAAACCAATT
CAGCAATAACTGAAAGCCACCACTTGGAAGGTTTCAAGGATTTAGCTCTACCTGTTGATGATGTC
CAAAGCATTAGTTAAGGTAGAAAAAAAATATACACACACACACACACACACACACACACACACAC
ACA 
 
Insert comprises nuc 85207-85286 (ITALICS) of this clone (RP5-1129D5). 
Sequence here includes 480 bp each side. Note excerpts from NCBI report 
regarding this region misc_feature 85103.85583       /note="similar to EST 
AA443771 (NID: g2156446) zw95f08.s1" UNDERLINED 
 
Primers are indicated in boxes (first design 98, 790; 499, 790), or shadowed 
boxes (second design 191,481, successful) lower primers shaded 
 
AC136698.6+/+, sub 8/2/02; Expanded coverage 
AACTGGCAGAGGCTCTAAGAGTGGGAGGTGAGTTGTTTTCTCCTTCATGTAAATATAT
TTACCTTTTAAACACTAGGCCCAATTTTATATCCTATTTCATTTAACTTTATGAACATAT
TTATGTATGTATGCATGTATGTATGTATCTCATGTGATGTTTTAGACACTGAAAAATAA
CTCATTTCTATTATAAAACTGATATCTTTAGATGTTCAGAAGCAACTTCCTAAAAGGAG
GTAGCAGTAATGGAGCTATGTCTATCATTCTTTCCCATCAACCCCCTTGATGGAGATG
TAAACATGTGTCCATCAAGCCTTTAATTTTTACCTCTTATCTTCATGGCTCTCCATACA
AAACTTAACTCTTTTTTTTTTCTATTTGTATACGTATATTTATATGTATATCTATATCGAG
AGAGAGAGAGAGAGAAAGAGTCTTGCTGTGTTGCCCAGGCTGATCTCAAACTCCTGG
GCTCAAGCAATCCTCCCACCTTGGCCTCGCAAAGTGCTGGGATTACAGGCGTGAAC
CACTGTGCCCAGCCTCAGCCTTAACTCTTAAAATATCTTCAAACCAATATTCTTCTGTT
CTAATTTTTAAGAATAGATGTGTTTAAACCAACTAACTTATTTTGACAAAAATTGGAGTT
AAGACTCAGACTTCCTCAAATAGTTCTCCTAAAACCATTTACAGAATAATCTATCTTTT
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CAGTATTAAGTTAAAATACCACCTTTTCCTTATACTAAATTCTCGTTTGCATGACTCTG
GTTCTAAACTTCCATTGCCTTTATCTGTCTGGCCCAGGGATAGTCCACAATATTTTATT
TACTATCTGGTTGAAAGAGTCTATACTTTATTACTTTTTATTACTTATTCTTCTAAACAA
ATTTTAGAGTCGTTTTGTCAAGTGTCAAAAATAAATCTGCCAGAATTTGTACTGAAATT
TGTGTGTGTGTGTATATATATAATACACACACACTATATATAAAATATAAAATGTATATA
TACAATTTATATATATAAATATTTATAAAATATGAAATATATATATATATACACACACACA
CTTTTCTAGTTCTTTTTTTTTTTTTTGAGACAGGGTCTCACTCTGTCACCTAGGCTGGA
GTTCAGAGGCATGATCTCGGCTCACTGCAACCTCTGCCTCCCAGGCTCAAGTGCTCC
TCCCACCTCAGCCTCAGAAGTAGTTGGAAATACAAGTGTGTGCCACAGACACCCAGC
TAATTGTCATCTACCCGCCTCAGCTTCCCAAACTGTTTGGATTACAGGTATGAGCCAC
TGTGCCCAGCAGAAATTACATTTACAAATTAATATGAAGACATGGTGATAACTAACATA
TTTATAACATGAAATCTGCTCATCCAGGAACATAGAATGCAAATCTTTCATTCCACTCA
GCAAAATTTTGTCCTGTCCTTGATAAAAGTCCTGCACATCTAAGTTTATTCCTAGGTAT
TTAATTTTTGCTGAAATACCTGAAAAAATACTTCATCACTATATCTTCTACGTGATTATA
GCTAACACTGGGGAAGGCTATTGATTTTTATATAAAAGAACTTTTAACCAGTAATCTTA
AAAATTGTTTTTCTCAGTTGGTTCCTTTGGATATTTTTAGGTAAACAATCATGTCAACT
GAAAATAATGATAAATTTTCTATAAAGACTATGACATCACAGGAAAATACAGTAAATAC
TTTTTAAAAGA
1720
ATATAAAAGGGCCAGGCACAGTGGCTCACGCCTGTAATCCCAGC
ACTTTGGGAGGCCAAGGTGGGCAGACCATGAGGTCAGGAGATCGAGACCATCCTGG
CTAACACGGTGAAACCCCATCTCTACTAAAAAATACAAAAAATTAGCCGGGAATGGTG
GCGGGCGCCTGTAGTCCCAGCTACTGGGGAGGCTGAGGCAGGAGAATGGTGGGAA
CCCAGGAGGTGGAGCTTGCAGTGAGCCGAGATCACGGCACTGCACTCCAGCCTGG
GTGACAGAGCAAGACTCTGTCTCAAAAAAAAAAAAAAAAAAAAAAAGAATATAAAACT
ATAGAGAATATGACCTCAACTATTAAGCATATGTGTAAGGGTTATGTATTTTAATAGCA
AAGAAAAACTATATACTGGTAGAAAATGACCATCATGTCAACAGTCAATAGTGGTTAT
ATTAGATAGAGAAATTATGGGAGACTTTAATTTTTTTCTTTTATCTTTTCTGTACTTTAC
CAATTTTCTCAACAATGGTTGCTTATGAGTTTTAAAATTAAAAAAAGGTTTTAAAAATTT
TTCCAACATGGAAAGTTATATTTCTTTATATACTAAAACAAAAACAAAACTTTCTATTTG
AATACCTATGGCAAAACCCTATCTCTACAAAAAATACAAAAAATTAGCAAGGTGGGGT
AGTACACACCTGTAGTCCCAGCTACTCTGGAGGCTGAGGTGGGAGGATC
2449
ACCTG
AGTCCCCAGAGAATGAGGCTCCAGTGAGCCGTGATCATAGCACTGCATTCCAGCCT
GGGAGACAGAGAAAGACCCCATCTCAAAAAAAAAAAAAAGAAAGAAAGCAAAAAGAA
ATATCCATAATGATCTGAAATGCCTATCTGTATGAGACTGTCCTTTGTTCACATTTTTT
CAAGCAAATATCACACAATAAATTGAATGCAGGTACAAATGACATATCAAACATCAAA
GAAATTTGCAAAGGACGTAAGACTGTACTACCTTGGGTTTAGAAATTTTCTTATCATAA
AAGCATTTATAACAATATTTTGTGAGCTTTTAAGGAATATTTTAAGTATTTCTGATTTAA
TTTCTAGTGATAAATACCAATAGATATAACCTACATACACAAAAGCTCCTTGGGCCCT
CAATATACTTTTAAGAGTGTAAAGGAATCCTGACCCCAAAACTTTGAGAACTGC
98
CCT
TCCCCTCCACTTTATTCCTTCCCTAGAATTTCTTCCTTGGAAGAAACATTCCTTTGCCA
TTCTATGTTAACTTACATAGTTCCATTGA
191
GGCCAGTTTTGCTACCTCTCTCCCATCT
TTCCACATCCCTCTCTTGACACAAAACCTGACCAAAGGACTCTACCGGCCCACCCCA
TTTCCAGTGATTAGCTGTCAGGTGGGCTAAGCCAAGAAAATCTGGGTTTTCCCTGAC
ACTAGACCTCTCTTTCTGGGAGATACGGAATCACAGGGACAAGGCTGGCCCTGTCAG
AACTCATCTTGTCTAAATGGGAAGAGGTTAGGCAAGTTTCTAGAATGCCAGACTGCTT
TCTAGAAAGTCAAAGATAATTATACTTTCTGCCA
482
CGACTGTGAAAATGCCC
499
ATTT
CATTGCACGCTTTCTAACATTTATACCAATCTGATAAATAAAAGCTGGTACCTAGAAG
AAAAAAAGGCTGGGTATGGTGGCTCATGCCTGTAATCCCAGTACTTTGGGAGACCAA
GGTGAGTGGATCACCTGAGGTCAGGAGTTCGAGACAAGCCTGGCCAACATGATGAA
ACCCCATCTCTAGTAAAAACACAAACATTAGCCGGGCATGGTGGCAGGCCCCTGTAA
TCCCAACTACTCGGGAGGCTGAGGCAAGAGAATCACTTGAACCTGGGAGGTGGAGG
TTT
790
TGAGCCAAGATCATGCCATTGCCCTCCAGCCTGGGTGACAAGGTGAGACTTT
GTCTCAAAAAAAAAAAAAAAGTTTCCATACAATATAATTTGTTCCATCTCTAAAAACCA
ATTCAGCAATAACTGAAAGCCACCACTTGGAAGGTTTCAAGGATTTAGCTCTACCTGT
TGATGATGTCCAAAGCATTAGTTAAGGTAGAAAAAAAATATACACACACACACACACA
CACACACACACACACACACACACTCACCCCTATGTAGTCAGTACCAGGAAACACGAA
AGACTAGATGGTACAGTCATCCAACACAAAGCACACAATAACTGAAGGCACTGTAGA
GGAGTAACTTATGACACAGATCTACAATATTGAGTGAAAATGCAGATTA 
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Primers are indicated in boxes (first design 98, 790; 499, 790; second design 
1720,482 (aka3299); 2449,482; 98,482; 191,482) lower primers shaded. 
 
Up:  CTGCCTTCCCCTCCACTT (18mer, 98-115)   713 bp 
 63C  
Lp:  GGCATGATCTTGGCTCACTAA (21mer, 790-810) 
22/5/3: N and P pools, 32-50 cyc @60C. No products. Sigma said primers dodgy 
10/6/3: N pool, 30,35,40,45, then further 20,30,40,50 cyc @53C. No products. Sigma 
said primers dodgy  
24/6/3: N/P pool, 24-50 cyc @55C. No products. 18S and a2actin very poor. Fresh 
primers though  
4/7/3: N/P pool, 30-55 cyc @61C. No products 
3/10/03: N/P pool, 48,50,52 @59C. Doublet at 750bp, weak at 48 building up. 
Recommend 48 cyc (needs more optimisation – doublet??, temp),59C for x10-x80 
cDNA dilutions 
 
Up:  CATTTCATTGCACGCTTTCTA (21mer, 499-520)  312 bp 
 62C  
Lp:  GGCATGATCTTGGCTCACTAA (21mer, 790-810) 
22/5/3: N and P pools, 32-50 cyc @60C. No products. Sigma said primers dodgy 
27/5/3: N and P pools, 32-50 cyc @60C. No products even with further sub-
amplification 
24/6/3: N/P pool, 24-50 cyc @55C. No products. 18S and a2actin very poor. Fresh 
primers though  
4/7/3: N/P pool, 30-55 cyc @61C. Products 30cyc onwards 
Recommend 32 cyc (?? Check intensity),60C for x10-x80 cDNA dilutions 
 
Second phase 
Lp:  TGGGCATTTTCACAGTCGT (19mer, 482-500, aka 3299) 
 
Up: ATATAAAAGGGCCAGGCACA (20mer, 1720-1739) 1598 bp 63C 
16/6/3: 40,50 cyc @55C, N and P pools. No products, though a2 actin was low 
4/7/03: 30-55 cyc@61C, NP pool, No product 
No products 
 
Up: CACCTGAGTCCCCAGAGAAT (20mer, 2449-2468) 869 bp  63C 
16/6/3: 40,50 cyc @55C, N and P pools. No products, though a2 actin was low 
4/7/03: 30-55 cyc@61C, NP pool. Product 40cyc onwards 
10/7/3: 40,42,44 cycles @59C, N and P pools, N>P but a2actin failed in P 
15/7/3: 40,42,44 cycles @59C, N and P pools N>P, a2actin P>>N, 18S N just above P 
as expected 
Recommend 38 (check intensity, should do one more optimisation) cyc,59C for x10-
x80 cDNA dilutions 
 
Up:  CTGCCTTCCCCTCCACTT (18mer, 98-115, aka 2915) 403 bp  63C 
16/6/3: 40,50 cyc @55C, N and P pools. No products, though a2 actin was low 
4/7/03: 30-55 cyc@61C, NP pool. Product 35 cyc onwards 
10/7/3: 32,34,36 cycles @59C, N and P pools, N>P but a2actin failed in P 
15/7/3: 32,34,36 cycles @59C, N and P pools, N>P , 18S N just above P as expected 
Recommend 30 cyc (check intensity, should do one more optimisation) cyc,59C for 
x10-x80 cDNA dilutions 
 
Up:  AGGCCAGTTTTGCTACCTCT (20mer, 191-210, aka 3008) 310 bp 63C 
27/5/3: 32-50 cyc @60C. N and P pools, Products from 32 cyc, N = P? - a2actin-N 
failed 
29/5/3: No apparent difference in C,N,P expression in full quant approach 
16/6/3: 40,50 cyc @55C, N and P pools. Product at 40 cyc, P>>N 
4/7/03: 30-55 cyc@61C, NP pool. Product 30 cyc onwards 
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Recommend 30 cyc (check intensity, should do one more optimisation),59C for x10-
x80 cDNA dilutions 
 
Analysis of P6 clones and P7-2/7-3 clones insert sequence. Homology detected 
with chromosome 22g11 and expressed gene listed below. 
P6-1 
GAATTCACACGACTGTACTCCAGCCTGGTGACAGAGCCAGACTGTTTTAAAATAAATAAAAATAA
AAAATTGGTTTTGGAAAAAAAAAAAACTCGAG 
P6-2 
GAATTCACACGACTGTACTCCAGCCTGGTGACAGAGCCAGACTGTTTTAAAATAAATAAAAATAA
AAAATTGGTTTTGGAAAAAAAAAAAACTCGAG 
P6-3 
GAATTCACACGACTGTACTCCAGCCTGGTGACAGAGCCAGACTGTTTTAAAATAAATAAAAATAA
AAAATTGGTTTTGGAAAAAAAAAAAACTCGAG 
P7-2 
GAATTCACACGACTGTACTCCAGCCTGGTGACAGAGCCAGACTGTTTTAAAATAAATAAAAATAA
AAAATTGGTTTTGGAAAAAAAAAAAACTCGAG 
P7-3 
GAATTCACACGACTGTACTCCAGCCTGGTGACAGAACCAGACTCTGTTTTAAAATAAATAAAAAT
AAAAAATTGGTTTTGGAAAAAAAAAAAACTCGAG 
 
AP000344.1; +/- 
TCACGCCTGTAATCCCAGCACTTTGAGACGCAGAGGCAGGCAGATCACGAGGTCAGGAGATCGAG
ACCATCCTGGCTAATGCGGTGAAACCCCATCTCTACTAAAAATACAAAAAAATTAGCCGGGCGCG
GTGGCGGGCGCCTGTAGTCCCGGCTGCTCAGGAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGA
GGCGGAGCTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGAGCAAGACCC
CATCTCAAAAAAAAGAAAAAAAAGAAAGAAAAGCCAGACATTTGAGCACTGAGTCTCATGGGAAG
TTCCAAGACTAAATAAACAAAAAAGAACCATGAGAGAAAATGCAGAAAGCAAAAGATTCGCCTTC
CTCCAAACCCACTTTATGCCTAAGAGCAGAACTGAATTCTCTGGAACAAGAAGAGGGGAGCTCAG
GGAATGATAGAGATGTCTTGGAAATGAAAAACAGGACTGCTAAAATCCAAAACCAATTTTTTATT
TTTATTTATTTTAAAACAGTCTGGCTCTGTCACCAGGCTGGAGTACAGTGGTGTGATTTCGGCTC
ACTGCAACCTCTGCCACCCGGGTTCAAGCCAGTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATT
ACAGGTGCACACCACCACATTCAGCTACTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCATGT
TGGCCAGGCTGGTCTGGAACTCCTGACCTCAAGTGATCTGCCTGCCTCGGCCTCCCAAAGTGCCT
GGGACTACAGGTGTAAGCCACTACATCCAGCCCCAAAACTAATTTTTTAAAAAGCAGAGAGAGTG
TGTGTGTTTGGATTCAAGGAAAATCTTATCTACAAGCAAAGGTAGAAAGAAGGACTCACAGAATC
TATCCAAAAGGCCCAACATCTGACTGACAGGAGTTCCAGAATGAGCAGGAAACGAGAAGAAATGT
TATCAAAGAAATGCCAGGTCTCAAGGCAGAACGTGCTCACCAAGCGCCCAGCGTGGTGAGGAAAC
ACCCGCAGTTGGTGTGACCCCCCAGAGGTGCAGGG 
 
Insert comprises nuc 67478 - 67553 of this clone (KB1269D1 on chromosome 
22q11.2). Sequence  here  includes  480 bp each side. Insert homologous region 
in italics. 
 
Complementary strand of AP000344 with insert in italics, now +/+. 
 
CTTTCCCACTTCTATCTCCTGTCCCTGCAGCCAGGAGCCGCCTCTTTAAGCTCCTCCTGGAGGTG
GGCTGCCGTCCTCTGCCCCTCGTCCCCACGGAAGAGGTCATTCTGTAGCCCAGCTTTTATTTTCG
CCTAATGTATCTCTGAGGTTTTAAAACATTCTTTTCTAGCTATCTATTGAACATTTACTTTATGC
CAGATCCAGTACATGCCATTGTTATCCTCTGTTTACAGGTGGGGAAGCTGAGGCAGGAAGCCCTT
TAGTCACTTGCCGAAGGCCACGCTGTTACCCATGGGACCGGTTTTGGGCGGCCGAAGAGCACTCA
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TGGGGCCGGATTCACGCCCCAGGCCCGTTCCCTCCTGCTCTCTGGTGCTCCTCACGCCATTGGCC
CCACTGCCTCTCACTGCCCGTGAGTCCCTGTGCCCGTGTCCTCCTTCTTGAACCCCTCAGCCCTC
AGTTAACCCTCAGAAAGCTGGCTCGGAGAAGTCCTTGTGTGGTATCTGGGAGGCAGAGTTTGCCG
TGAGCCGAGATTGTGCCACTGCACGCACTCCAGCCTGGGCGACAGAGCGAGACCCCATCTCAAAA
AAAAAAAAAAAAAGGCCTCACGGGACTAGAAGCGTCTTACCCTGACCTCACACCTGCTGGACATC
AGGCTGGGGAGAGAATCGGGGAAGAGGGCATTTTCCAACAGGACTGGAAGGCCAGTCGTGGTCCT
TGGTGGTGAGAGCTAGCCAGGCCGCCGGCCTTCTCCCTGGAAGCCTGCAGGGTCCCCTCTGATCC
CTGCACCTCTGGGGGGTCACACCAACTGCGGGTGTTTCCTCACCACGCTGGGCGCTTGGTGAGCA
CGTTCTGCCTTG1881AGACCTGGCATTTCTTTGATAACATTTCTTCTCGTTTCCTGCTCATTCTG
GAACTCCTGTCAGTCAGATGTTGGGCCTTTTGGATAGATTCTGTGAGTCCTTCTTTCTACCTTTG
CTTGTAGATAAGATTTTCCTTGAATCCAAACACACACACTCTCTCTGCTTTTTAAAAAATTAGTT
TTGGGGCTGGATGTAGTGGCTTACACCTGTAGTCCCAGGCACTTTGGGAGGCCGAGGCAGGCAGA
TCACTTGAGGTCAGGAGTTCCAGACCAGCCTGGCCAACATGGTGAAACCCCGTCTCTACTAAAAA
TACAAAAAGTAGCTGAATGTGGTGGTGTGCACCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAG
GAGACTGGCTTGAACCCGGGTGGCAGAGGTTGCAGTGAGCCGAAATCACACCACTGT2309ACT15C
CAGCCTGGTGACAGAGCCAGACTGTTTTAAAATAAATAAAAATAAAAAATTGGTTTTGGATTTT
AGCAGTCCTGTTTTTCATTTCCAAGACATCTCTATCATTCCCTGAGCTCCCCTCTTCTTGTTCCA
GAGAATTCAGTTCTGCTCTTAGGCATAAAGTGGGTT181TGGAGGAAGGCGAATCTTTTGCTTTCT
GCATTTTCTCTCATGGTTCTTTTTTGTTTATTTAGTCTTGGAACTTCCCATGAGACTCAGTGCTC
AAATGTCTGGCTTTTCTTTCTTTTTTTTCTTTTTTTTGAGATGGGGTCTTGCTCTGTCGCCCAGG
CTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTCCGCCTCCCGGGTTCACGCCATTCTCC
TGCCTCAGCCTCC416TGAGCAGCCGGGACTACAGGCGCCCGCCACCGCGCCCGGCTAATTTTTTT
GTATTTTTAGTAGAGATGGGGTTTCACCGCATTAGCCAGGATGGTCTCGATCTCCTGACCTCGTG
ATCTGCCTGCCTCTGCGTCTCAAAGTGCTGGGATTACAGGCGTGAGCCACTGTGCCCAGCCTTTT
CTTTCTTTTTGATCCCTGTTTATAGGGGAGGCAGGCAGAGCTGCCCGGCACTCCTCTCTCCTTGT
TAACTTGAGAAAGCCGGACACCCAGGTCTTGGAAGGGAGGCCTCCTGCCTCCAGGCAGCATCTTG
GGCTGCAGGGCTGCAGTCTGGAGTGGGGACAGTCCCGGCTCCCACTCGTCTCGGGCTGCAGGGCT
GCGGTCTGGAGTGGGGGCAGTACTGGCTCCCACTCGTCTCGGGCTGCAGGGCTGCGGTCTGGAGT
GGGGGCAGTACCGGCTCCCACTCGTCTCGGGCTGCAGGGCTGCGGTCTGGAGTGGGGACAGTACC
AGCTCCCGCTGCTGTCCTGCCATGCTTGTTTGCAGCACACGTCTCCTCATACCAGTGACGAGGCT
ACTGCTTGCCAGCTGCTTGCCTTCTTCCTGCCAGGGTGTCCTGCTATGTCAGCCTCTGCTCTCCA
CTTCAAGAAGTGTCTTGAAAGATCTTGTCTGCAGAAGACCTCTCTCCTGTTCTCAGTGCCACGTG
GGGCCTCCCCAGCAGAGGCGGCTGGATACCTGGCCCTGGCTACTGGAGGCTGTCTGTTAGCTGCC
AGAGGGCGGCGGCAGCCTTCAGGAACCTCCCCTGGCCTCTGCCCTGTTCATTCCTTGCTGGAATG
TCATGGGTCTCCGGATTTGCTGAGCTCAGAGACCCCATGGGGCAACTTGGGATGGGGGCTAAGGA
AGGCCTCTTGGAGGAACCCTGAGGTGAGGTGGCCCTGGGGTGGGGTGGAGGAGGCCTTGAGCAGC
AGGGGAGGGGGCTGCCCCCTGCTCTCTGCATCCCTGAGTGAGTGGGGCGGGGCCTGCCCCCTGCT
CTCTGTGTCCCTGAGTGAGTGGGGCGGGAGGATGAACCCTGCTCTCTGTCCCTGAGTGCATGGGG
CGGGGCCTGCCCCCTGCTCTCTGCGTCCCTGAGTGAGAGGGGCGGGGGGCTGCACCCTGCTCTCT
GCGTCCCTGAGTGAGTGGGGTGGGGGGCTGCACCCTGCTCTCTGTGTCCCTGAGTGAGTGGGGCG
GGGGCTGGCCCCTGCTCTCTGCGTCCCTGAGTGAGTGGGGCGGGGGCTGGCCCCTGCTCTCTGCG
TCCCTGAGTGAGTGGGGCGGGGGGCTGCACCCTGCTCTCTGTGTCCCTGAGTGAGTGGGGCGGGG
GCTGCCTCCTGCTCTCTGTGTCCCTGAGTGGGGCGGGGCCTGCCCCCTGCTCTCTGTGTCCCTGA
GTGAGTGGGGTGGGGGCTGCAC 
 
The insert (italics) and 5’ sequence (underlined) matches NM-152509.1 and 
AK092530.1 +/+,(see below), and primers were originally designed to this 
region. This sequence also includes 3’ sequence allowing design of primers 
U15,L181 and U15,L416 numbering relative to start of fragment. 
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NM-152509.1, +/+ 
AAGACATTCATCCTCCCGGAGGCCCGCGCCGCCCTCGCCCTGCACGCCTAGCGTTGTCCCGCGGC
CAGGCCCGGCCGGAGCGGCGGCGCCTGGATGTGGACCTGGCTGCGGGGAGACGGGCGCCGGCCCC
AAAGCGACTTTCGGTCCTCGACGCGCCCCGCCCCACCCCTGCGATGAAGAGGGCGTCTGCTGGAG
GTTCCAGGCCCCGATTCCCTTATCCTGGGGGACGACAGCATCCATAGCCTGGACTTTGTGTCGAG
CCGAGCCTGGACTTCCCTGACTATGGGCCCGGGGGCCTGCACGCAGCCTACCTGCCATCCCCACC
GCTCAGCGCCTCTGATGCCTTCTCATTGCTTTGTGCTCCCTGAGCCTCAAGGCCTCAAGCCGGCA
GGGCGGGGACTACGTGGCCCTGCAGCCCCTGTGCTCCGAGGGTGGGCCTCCCATGCCCCACCGTA
GCATCTTTGCCCCCCCATGCACTGCCCAACCACAATCGCAGCCTGTCCTACAATAATGTGCTCAA
CCCTGGCTCGCCTGGTGGCCACGCCTGCCTCGCCCATCCAGCAGTTGGCGTGGCCGGATACCACT
CACCCTACCTGCACCCTGGGGCAACGGGCGACCCACCATGGCCCCTGCCCCACAGCTTCAGTCCC
GTGCTGGGCCCCCGGCCCCAGGAGCCCTCGCCTGTGCTCTACGACATCCTGTCCAGGACCATCAT
GGCATCCATCCAGGAGCGCAAGGACAGGGAGGAGCGTGAGTGCCTGCTGCGCTCCCAGGCCGACT
CACTCTTCGGCGACTCAGGCGTCTATGATGCTCCCAGCTCCTACAGCCTGCAGCAGGCCAGTGTG
CTGTCTGAGGGCTTCTGAGGTCCTACGCTGTGCTACAGCTCTACAGATGACCTTGTGGCCAGGCC
CGGCTTCGGCGGCGCCTGCAACCCTGTCCTGCAGACATCATTGTCCTCGCTTTCCAGCTCCGTGA
GCCGTGCACTGCGGACGTCGTCCTCCTCCCTGCAGGCTGATCAGGTGGGGAAGCTGAGGCAGGAA
GCCCTTTAGTCACTTGCCGAAGGCCACGCTGTTACCCATGGGACCGGTTTTGGGCGGCCGAAGAG
CACTCATGGGGCCGGATTCACGCCCCGGGCCCGTTCCCTCCTGCTCTCTGGTGCTCCTCACGCCA
TTGGCCCCACTGCCTCTCACTGCCCGTGAGTCCCTGTGCCCGTGTCCTCCTTCTTGAACCCCTCA
GCCCTCAGTTAACCCTCAGAAAGCTGGCTCGGAGAAGTCCTTGTGTGGTATCTGGGAGGCAGAGT
TTGCCGTGAGCTGAGATTGTGCCACTGCACGCACTCCAGCCTGGGCGACAGAGCGAGACCCCAT
CTCAAAAAAAAAAAAAAAGGCCTCACGGGACTAGAAGCGTCTTACCCTGACCTCACACCTGCTGG
ACATCAGGCTGGGGAGAGAATCGGGGAAGAGGGCATTTTCCAACAGGACTGGAAGGCCAGTCGTG
GTCCTTGGTGGTGAGAGCTAGCCAGGCCGCCGGCCTTCTCCCCGGAAGCCTGCAGGGTCCCCTCT
GATCCCTGCACCTCTGGGGGGTCACACCAACTGCGGGTGTTTCCTCACCACGCTGGGCGCTTGGT
GAGCACGTTCTGCCTTGAGACCTGGCATTTCTTTGATAACATTTCTTCTCGTTTCCTGCTCATTC
TGGAACTCCTGTCAGTCAGATGTTGGGCCTTTTGGATAGATTCTGTGAGTCCTTCTTTCTACCT
TTGCTTGTAGATAAGATTTTCCTTGAATCCAAACACACACACTCTCTCTGCTTTTTAAAAAATTA
GTTTTGGGGCTGGATGTAGTGGCTTACACCTGTAGTCCCAGGCACTTTGGGAGGCCGAGGCAGGC
AGATCACTTGAGGTCAGGAGTTCCAGACCAGCCTGGCCAACATGGTGAAACCCCGTCTCTACTAA
AAATACAAAAAGTAGCTGAATGTGGTGGTGTGCACCTGTAATCCCAGCTACTCAGGAGGCTGAGG
CAGGAGACTGGCTTGAACCCGGGTGGCAGAGGTTGCAGTGAGCCGAAATCACACCACTGTACTCC
AGCCTGGTGACAGAGCCAGACTGTTTTAAAATAAATAAAAATAAAAAATTGGTTTTGG 
This is a hypothetical mRNA-protein sequence of 2136 bp, insert homology is 
to 2062 – 2136. Comparison of AK092530.1 and NM-152509.1. Italics show the 
homologous sequence to clone inserts, bolds the differences and shadowed 
boxes the insertions, relative to other sequence. Underlined area shows the 
cds as predicted from comments regarding sequence AK092581.1 below 
 
AK092581.1, +/+: (exact match to NM-152509.1 above) 
Also says. 
CDS 472..975 /note="unnamed protein product" /codon_start=1 /protein_id="BAC03919.1" 
/db_xref="GI:21751207" 
MHCPTTIAACPTIMCSTLARLVATPASPIQQLAWPDTTHPTCTLGQRATHHGPCPTASVPC
WAPGPRSPRLCSTTSCPGPSWHPSRSARTGRSVSACCAPRPTHSSATQASMMLPAPTACSR
PVCCLRASEVLRCATALQMTLWPGPASAAPATLSCRHHCPRFPAP 
 
AK092530.1, +/+ 
ACCTGATTCCATAAGACATTCATCCTCCCGGAGGCCCGCGCCGCCCTCGCCCTGCACGCCTAGC
GTTGTCCCGCGGCCAGGCCCGGCCGGAGCGGCGGCGCCTGGATGTGGACCTGGCTGCGGGGAGAC
GGGCGCCGGCCCCAAAGCGACTTTCGGTCCTCGACGCGCCCCGCC175CCACCCCTGCGATGAAGA
GGGCGTCTGCTGGAGTCCAAGGGCAGCCTGGACCCGCTAGATAAGCCGCTGGACTTGGGGCCGG
CGCTGCCCCCCCAAGATGGAGGCTGGCACGTTCAGCAGTGACCTGCAGACCCCACGCCCAGGCA
GTGTTGAGAGTGCCCTGTCGGTGCAGAGGACCAGCCTCCGCCACCCCCCGACGCCTGCCATGTA
CAAGTTTAGGCCGGCTCACGGGTCCTAAGGCACCTTCTGTGGATGAGGCGAGCAGGTTCCAGGC
CCCGATTCCCTTATCCTGGGGGACGACAGCATCCATAGCCTGGACTTTGTGTCGAGCCGAGCCTG
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GACTTCCCTGACTATGGGCCCGGGGGCCTGCACGCAGCCTACCTGCCATCCCCACCGCTCAGCGC
CTCTGATGCCTTCTCATTGCTTTGTGCTCCCTGAGCCTCAAGGCCTCAAGCCGGCAGGGCGGGGA
CTACCTGGCCCTGCAGCCCCTGTGCTCCGAGGGTGGGCCTCCCATGCCCCACCGTAGCATCTTTG
CCCCCCCATGCACTGCCCAACC731ACAATCGCAGCCTGTCCTACAATAATGTGCTCAACCCTGGC
TCGCCTGGTGGCCACGCCTGCCTCGCCCATCCAGCAGTTGGCGTGGCCGGATACCACTCACCCTA
CCTGCACCCTGGGGCAACGGGCGACCCACCATGGCCCCTGCCCCACAGCTTCAGTCCCGTGCTGG
GCCCCCGGCCCCAGGAGCCCTCGCCTGTGCTCTACGACATCCTGTCCAGGACCATCATGGCATCC
ATCCAGGAGCGCAAGGACAGGGAGGAGCGTGAGTGCCTGCTGCGCTCCCAGGCCGACTCACTCTT
CGGCGACTCAGGCGTCTATGATGCTCCCAGCTCCTACAGCCTGCAGCAGGCCAGTGTGCTGTCTG
AGGGCTTCCGAGGTCCTACGCTGTGCTACAGCTCTACAGATGACCTTGTGGCCAGGCCCGGCTTC
GGCGGCGCCTGCAACCCTGTCCTGCAGACATCATTGTCCTCGCTTTCCAGCTCCGTGAGCCGTGC
ACTGCGGACGTCGTCCTCCTCCCTGCAGGCTGATCAGGTGGGGAAGCTGAGGCAGGAAGCCCTTT
AGTCACTTGCCAAAGGCCACGCTGTTACCCATGGGACCGGTTTTGGGCGGCCGAAGAGCACTCAT
CCGACAGTGGGGCCGGATTCACGCCCCGGGCCCGTTCCCTCCTGCTCTCTGGTGCTCCTCACGC
CATTGGCCCCACTGCCTCTCACTGCCCGTGAGTCCCTGTGCCCGTGTCCTCCTTCTTGAACCCCT
CAGCCCTCAGTTAACCCTCAGAAAGCTGGCTCGGAGAAGTCCTTGTGTGGTATCTGGGAGGCAGA
GTTTGCCGTAAGCCGAGATTGTGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACCCCATCTC
AAAAAAGACGCTCACGGGACTAGAAGCGTCTTACCCTGACCTCACACCTGCTGGACATCAGGCTG
GGGAGAGAATCGGGGAAGAGGGCATTTTCCAACAGGACTGGAAGGCCAGTCGTGGTCCTTGGTGG
TGAGAGTTAGCCAGGCCACCGGCCTTCTCCCCGTAAGCCTGCAGGGTCCCCTCTGATCCCTGCAC
CTCTAGGGGGTCACACCAACTGCGGGTGTTTCCTCACCACGCTGGGCGCTTGGTGAGCACGTTCT
GCCTTG1881AGACCTGGCATTTCTTTGATAACATTTCTTCTCGTTTCCTGCTCATTCTGGAACTC
CTGTCAGATGTTGGGCCTTTTGGATAGATTCTGTGAGTCCTTCTTTCTACCTTTGCTTGTAGATA
AGACTTTCCTTGAATCCAAACACACACACTCTCTCTGCTTTTTAAAAAATTAGTTTTGGGGCTGG
ATGTAGTGGCTTACACCTGTAGTCCCAGGCACTTTGGGAGGCCGAGGCAGGCAGATCACTTGAGG
TCAGGAGTTCCAGACCAGCCTGGCCAACATGGTGAAACCCTGTCTCTACTAAAAATACAAAAAGT
AGCTGAATGTGGTGGTGTGCACCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGACTGGCT
TGAACCCGGGTGGCAGAGGTTGCAGTGAGCCGAAATCACACCACTGT2309ACTCCAGCCTGGTGA
CAGAGCCAGACTCTGTTTTAAAATAAATAAAAATAAAAAATTGGTTTTGG……..ATTTTAGCAG
TCCTGTTTTTCATTTCCAAGACATCTCTATCATTCCCTGAGCTCCCCTCTTCTTGTTCCAGAGAA
TTCAGTTCTGCTCTTAGGCATAAAGTGGGTT181TGGAGGAAGGCGAATCTTTTGCTTTCTGCATT
TTCTCTCATGGTTCTTTTTTGTTTATTTAGTCTTGGAACTTCCCATGAGACTCAGTGCTCAAATG
TCTGGCTTTTCTTTCTTTTTTTTCTTTTTTTTGAGATGGGGTCTTGCTCTGTCGCCCAGGCTGGA
GTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTCCGCCTCCCGGGTTCACGCCATTCTCCTGCCT
CAGCCTCC416TGAGCAGCCGGGACTACAGGCGCCCGCCACCGCGCCCGGCTAATTTTTTTGTATT
TTTAGTAGAGATGGGGTTTCACCGCATTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCTG
CCTGCCTCTGCGTCTCAAAGTGCTGGGATTACAGGCGTGAGCCACTGTGCCCAGCCTTTTCTTTC
TTTTTGATCCCTGTTTATAGGGGAGGCAGGCAGAGCTGCCCGGCACTCCTCTCTCCTTGTTAACT
TGAGAAAGCCGGACACCCAGGTCTTGGAAGGGAGGCCTCCTGCCTCCAGGCAGCATCTTGGGCTG
CAGGGCTGCAGTCTGGAGTGGGGACAGTCCCGGCTCCCACTCGTCTCGGGCTGCAGGGCTGCGGT
CTGGAGTGGGGGCAGTACTGGCTCCCACTCGTCTCGGGCTGCAGGGCTGCGGTCTGGAGTGGGGG
CAGTACCGGCTCCCACTCGTCTCGGGCTGCAGGGCTGCGGTCTGGAGTGGGGACAGTACCAGCTC
CCGCTGCTGTCCTGCCATGCTTGTTTGCAGCACACGTCTCCTCATACCAGTGACGAGGCTACTGC
TTGCCAGCTGCTTGCCTTCTTCCTGCCAGGGTGTCCTGCTATGTCAGCCTCTGCTCTCCACTTCA
AGAAGTGTCTTGAAAGATCTTGTCTGCAGAAGACCTCTCTCCTGTTCTCAGTGCCACGTGGGGCC
TCCCCAGCAGAGGCGGCTGGATACCTGGCCCTGGCTACTGGAGGCTGTCTGTTAGCTGCCAGAGG
GCGGCGGCAGCCTTCAGGAACCTCCCCTGGCCTCTGCCCTGTTCATTCCTTGCTGGAATGTCATG
GGTCTCCGGATTTGCTGAGCTCAGAGACCCCATGGGGCAACTTGGGATGGGGGCTAAGGAAGGCC
TCTTGGAGGAACCCTGAGGTGAGGTGGCCCTGGGGTGGGGTGGAGGAGGCCTTGAGCAGCAGGGG
AGGGGGCTGCCCCCTGCTCTCTGCATCCCTGAGTGAGTGGGGCGGGGCCTGCCCCCTGCTCTCTG
TGTCCCTGAGTGAGTGGGGCGGGAGGATGAACCCTGCTCTCTGTCCCTGAGTGCATGGGGCGGGG
CCTGCCCCCTGCTCTCTGCGTCCCTGAGTGAGAGGGGCGGGGGGCTGCACCCTGCTCTCTGCGTC
CCTGAGTGAGTGGGGTGGGGGGCTGCACCCTGCTCTCTGTGTCCCTGAGTGAGTGGGGCGGGGGC
TGGCCCCTGCTCTCTGCGTCCCTGAGTGAGTGGGGCGGGGGCTGGCCCCTGCTCTCTGCGTCCCT
GAGTGAGTGGGGCGGGGGGCTGCACCCTGCTCTCTGTGTCCCTGAGTGAGTGGGGCGGGGGCTGC
CTCCTGCTCTCTGTGTCCCTGAGTGGGGCGGGGCCTGCCCCCTGCTCTCTGTGTCCCTGAGTGAG
TGGGGTGGGGGCTGCAC 
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This is composite sequence consisting of a full insert sequence generated from an 
expressed mRNA in prostate gland of 2374 bp, insert homology is to nuc 2298 – 
2374. Then separated by comes the complementary strand of AP000344, thus 
allowing all primers to be shown. Italics show the homologous sequence to clone 
inserts, bolds the differences, shadowed boxing the insertions, relative to NM-
152509.1 sequence. Underlining indicates the cds based on comments for 
AK092581.1 and boxes the primer selections (lower shaded; 175,731; 
1881,2309) 
 
Up:  CCACCCCTGCGATGAAGA (18mer, 175-192)  577 bp  66C  
Lp:  TGTAGGACAGGCTGCGATTGT (21mer, 731-751) 
22/5/3: N and P pools, 32-50 cyc @60C. No products. Sigma said primers dodgy 
10/6/3: N pool, 30,35,40,45, then further 20,30,40,50 cyc @53C. No products. Sigma 
said primers dodgy  
24/6/3: N/P pool, 24-50 cyc @55C. No products. 18S and a2actin very poor. Fresh 
primers though  
4/7/3: N/P pool, 30-55 cyc @61C. No products  
3/10/03: N/P pool, 48,50,52 cyc @59C. Lots of bands in all 48>52 
No reaction – needs more optimisation, temp – 66C should stop non specific 
amplification 
 
Up:  GAGACCTGGCATTTCTTTGAT (21mer, 1881-1901)  447 bp 
 61C  
Lp:  CTGTCACCAGGCTGGAGTA (19mer, 2309-2327) 
22/5/3: N and P pools, 32-50 cyc @60C. No products. Sigma said primers dodgy 
27/5/3: N and P pools, 32-50 cyc @60C. No products even with further sub-
amplification 
24/6/3: N/P pool, 24-50 cyc @55C. No products. 18S and a2actin very poor. Fresh 
primers though  
4/7/3: N/P pool, 30-55 cyc @61C. Products 40 cyc onwards 
3/10/03: N/P pool, 40,42,44 @59C. High in all, 1000 bp and 450 bp at 40, 450 bp only 
at 42,44 cyc. 
Recommend 38 cyc (optimise for cyc number, also doublet),60C for x10-x80 cDNA 
dilutions 
 
Second phase 
Up:  TCCAGCCTGGTGACAG (18mer, 15-32) 
 
Lp:  GATTCGCCTTCCTCCAA (17mer, 181-197)  183 bp  62C 
16/6/3: 40,50 cyc @55C, N and P pools. Product at 50 cyc in N alone 
4/7/03: 30-55 cyc@61C, NP pool. Product 45 cyc onwards 
10/7/3: 46,48,50 cycles @59C, N and P pools, N>P but a2actin failed in P 
15/7/3: 46,49,50 cycles @59C, N and P pools, numerous products, problems 
somewhere 
Needs further optimising, multiple products 
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Lp:  GTCCCGGCTGCTCAG (15mer, 416-431)   416 bp 
 62C 
16/6/3: 40,50 cyc @55C, N and P pools. Product at 50 cyc in P alone 
4/7/03: 30-55 cyc@61C, NP pool. Product 50 cyc onwards, but doublet and odd 
sizes 
10/7/3: 46,48,50 cycles @59C, N and P pools, N>P but a2actin failed in P. Variable 
length of product 
15/7/3: 46,49,50 cycles @59C, N and P pools, N>>P , 18S N just above P as 
expected, also product length varies (416,516,280 bp) 
Needs further optimising, multiple products 
 
Analysis of P8 clones 
All P8 clones (P8.2, .3, .4) contained a unique sequence analysis of P8.2 clone 
insert. Single 106/106 hit with clone carrying human DNA (clone RP1-34B21) 
from chr 6p12.1-21.1. 
 
P8-2 
CCCCCGGGCTGCAGGAATTCACACGACTGTAATCCCAGCACTTTGGGAAGCCGAAGTGGGAGAATC
CTTTGAGCTCAGGAGTTTGAGACCAGCCTGGGTAGCATAGGGAGACCCCCTCTCTTAAAAGAAAAA
AAAAAAACTCGAGGGGGGGCCCGGTACCC 
 
AL031778.1, +/+ fit, Submitted 4/3/3 
GAGCTTAAGTAGTCTAAAAAACATGTATATTTGCCTTTGGAACGTTTTTTTGTTTGTTTTTGGAT
ACAGGGCTTTCCTCTGTCATCCAGGCTGGAGTACAGTGGCGCAATCGTAGCTCACTAACCTGGAA
CTCCTGGGCTCAAGCCATCCTCCCTTCTTGTTCTCCCAAAACGTTGGGATTACAGGCATGAGCCA
CTGCGTCCTGACCTGAAATAGATGTTTTAACCTTAGTATTTAAAAATAGGTATGTTCTGGTCACT
TCAAAATCACTAAATACTTTTGCTTGGCATCTTTCTAAAAGGCATTATAATCTGGTAACTTTTTT
GCTAAATACCTTACAAGCTTCCACCAGTCTGCAGAAGAATTTCTTTGTCTGACATTTTGAGAGAA
AGTAGTGTGGCCCCAAGCTTTTTTTCCTGTTTAGTCCACTGTTCACATGCTGAAATATTTCTGTT
CTTGTTTTTATGCTCTCTTGATTTGTAGTACTTCACCTTCCTCCACATCATCACATAGCTAAATC
TTTCTCACACTTAAGACCAGTTCATCCTGCAGGCCTCTGATAGCAAAGAAAAAAAAAGTTCAAGT
AGTACCTTTTTTTTTTTAAGCCTTGTTGATTTATCCCCAGCTGGAACAAATCTCTGTCCTCCAAA
TTCCCATATCACTTTATCTCTTAGGATTCCAGTATAGGTTTTTAGTCCATTACTAAACTTAAAGA
CTCTTTGAAGTTTGAATCTTCGTCAGAGATTTCTTTTTATTTTTAAAACCTTCAGAACAGTGTCT
GGCACATGGTACATAATTAGTGGAGAGAAGTGCATTAGAAAGCTCCAATCCAGAAATCTGTAGGA
TGATGGGGAAGCTGGACAGCCCTTTGTTGTAGTCTAGTCTTTCATCAAGCGTCTATCAGGACCCA
CTTGTTGAGTTGTGAAAGAAATTGAGTGAGCCAATGCTGGGAATTTTTAAATAATAGAATAGAAA
ATATCTGCCAGGCATGATGATGGCTCACGACTGTAATCCCAGCACTTTGGGAAGCCGAAGTGGGA
GAATCCTTTGAGCTCAGGAGTTTGAGACCAGCCTGGGTAGCATAGGGAGACCCCCTCTCTTAAAA
GAAAAAAAAGAATAGAAAATACCAAAGTGCATCTTGTGTTGTATAAAGGTAAATGCTGTTTCATG
AAACTTTCATTTCAGTTACATGCTTTATACATGTGTGCACTGAGTTGTGATAATGAAATGTGTTT
CTTACTAAGGGTTGTGGTCAAAAAAGTTAAAAAGCTACTGTTCTAGGCTTTGCCTGGTAGTGATT
ATCAACTGTGATAATCCTATGGCTTTTCATATGCTTACACTAGTTGAGTTTCTGAAGAGGTTTTA
GCTTTGGAGTTTGTGTAGGTCCACATAGAATGGGTTCCTAGTAAGTGGTTGGCTAAGTCTCAGCT
TTTGCACCTTGGAATAGTGGGGCAAAGAGAATTGCACTGAGAAGAGAATGCACTAGGAAGAGAAT
TTTCATGCTAGCCAGAATAAACACTTATTATTTGTTTCTCTCTCTTTGAGGAAAAACCATTCAAA
ACTTTGTGTTAAGAGCAAGAGCTAGACAGACTAAATCTGGCTTAGTTTGTCATAATCTTGGGCAA
AGAGGCACTTTGGGAAAGACTATCGAATTGTATTGCAGTCTTGCTAACTGAAGCTCACAGTAGTA
GGAACATATGACTTTACTGAAGCCAGTTGCTTATAGCATTAACCATTAACAGTATCAATATCATG
ATACAGGCTAAATCACTCTGTCATTAATGTGAGAGAGAATTGCTGCTAGATTTGAAGCTGCTCTT
CAAATCTTGATACTCTTCAAAGTATAAATTTAAATATTGCTAAATTGGTTCATTTGTATTACCAG
AATAAACTAGTTAAGAAGAAAATCTGTACGTTACATATATTAGTCATTATGTGCTTCAAGTTATA
TTTAGTCTTGTAAAGATGTAAACTTCTGGATATTAGTCAAGGAAAAAATCTCATATAAGAAGGAA
ATTTGGAGTTGGGGAGGCGTTGAAACCTAAAAGACATTCCTTTCATGATCCTTATTTTTTAAAAT
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CAATTTATTGAGAGATACTTTAGAAACAAAGTATAATAATTTTAAATGTGTATTTTGATGAGTTT
TGACAAATTTGTACA 
 
Insert homology to nuc 121751 - 121856 
 
Analysis of P8.3 clone insert. 
 
P8-3 
CCCCCGGGCTGCAGGAATTCACACGACTGTAGTCCTAGCTACTCAGGAAGCTGAGTTGGGAGGATT
GGCAGACTCTACAGCTTATACTGAAGAAGTCAGTACCAGTATAATCTGTTAGGTCTATTTAGGGAA
AAAAAAAAAACTCGAGGGGGGGCCCGGTACCC 
 
AC025594.5, +/- fit, Submitted 28/11/00.120/121 hit with clone carrying 
human male DNA (clone RP11-309L24) from chr 7. 
GCGGGGGTGGGTGCAGTTTGAAAACCACCAGACTAAATCATGACTAAGGTTGTGTG
GAGATACAAAATACCATGACTCAAACACAATACTAACATTAAAATTAAGAGAACAGCA
CGTGGGATTTAATTGTAAGCAATAAAACTTACTGCAGGTCCTAGATTAAAGGACGGAT
TCAACCAACCAACAGGATGAAATCGATGTGGCAAAATTTGAAGAGACTAAGCATGAT
GTTTGAAGAGTTTTCTAATAAACTAATAATTTTCTAGTATTTTTTTCTAAGCAAATAGAT
TTCTATATTCTTTTAAACTACAAAATCAGTATAAATAAGATTTAAAAAATGTGTATCTTC
ATGGGGCAAAATCATACACACAAATATTTCACTTTTGTATTAGTTTTCATCTAACCACT
TATTTTCTACTATTTAATAAGGTACAAAATTTTGGCCAGGGGCGGTGGCTCACACCTG
TAATCTCAGCACTTTGGGAGGCTGAGGTGGGTGGATCATGAGGTCAGGAGATCGAG
ACCATCCTGGCTAACACGGTGAAACCCCATCTCTACTAAATATACAAATAATTAGCCT
GGCATGGTGGCGGGTGCCTGTAATCCCAGCTACTCGGGAGGCTGAGACAGGAGAAT
GGCGTGAACCCAGGAGGCAGAGTTTGCAGTGAGCAGAGATCACGCCACTGCACTCC
AGCCTGGGTGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAG
AGTACATAATTTTACATTCTGATTTTTCTCTTACCATATCATCATTTCACTACCTTTTAA
TTGCTGCATCAAGTTGCTAAATCATAACTCTTCTTATATAATTCATATAACTCTTGTTAT
ACTGCTGTACATGGGTTTATAATTTTTACTTTTACAGATAACATTTTGTATATAAAATAG
CTGTTTTTTTCTTCTGCAGATTTAAGATATACTCCCAGGAAAAGAATTACTGGTTTAGC
TGGAGTGTTTTGCTTTTTTTTTTCCCTAAATAGACCTAACAGATTATACTGGTACTGAC
TTCTTCAGTATAAGCTGTAGAGTCTGCCAATCCTCCCAACTCAGCTTCCTGAGTAGCT
AGGACTACAGGCGTGTGCCACCAGGCCCAGCTAATTTTCTTTTATTTCTTTTTGTAGA
GACAGGGGATTCCCTATGTTGCCCAGGCTGGTCTTGAATTCCTGGGCTCTAACGATT
CATCTGCCTTGGCCTCCCAAAGTGCTGGACTACAGGCATGAGCCAGGGTGCCCAGC
CAGGTTTATTATCTATCTTCTCAGTTCCTTTTCAAGTTGGCACTGACAAGAGGAAGAA
ATTAAGATTTGAAGAGGTAGAGAAGGGAACTTACATGGTCTGGTTCCAGCTGGCAGT
GTCGAGCCAAGGCGTGAAGCAGCCTCTGAATGTAAGCTTTGAAGATGCCATGAATAA
CTTCATCGTTAGTTTTGTACAAATGTTCCCCCAGTCGGTACCAAAAGTTAAATGAAATT
TCTACTACCTGTTAGGTTAAAAGAGATGATTTATTTGAATGGGAAAGGAATAGAATAA
GAAGACATTTTATTATCACCACGACCATATAGGAAGAAAGATATATTTTTAAATAATAT
GAGTGGAGCCAGTTAAGAAGTCACCTTTTCTCTAGCAGATTTACTATTATCTCCCCAA
ATTGTCTTCCCACGTTAGGCCCAAATCTCCATTTAGAATGACTGGCTTTACATTCCATT
TAGTCCTGAGGTAATGCCTCCAAAAGTATACTGAATTTTGAATTTAGAGAAAACAATAA
CAGACATGGAAGTCTTTATTTTTATTTATTTTTTAGAGACGGAGTTTCATTCTGTTGCC
CCAGCTAGAGTGCAGTGGAATGAACACAGTTCACTGCTGCCTCAAACTCCTGAGCTC
AAGTGATCCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGTACACACCACCA
AGCTCAGCTAATTTTTTTTTTTTTTTTTTTTTTTAGTAGAAACAGGGCCTTGCCATCTTG
CTCAGGATGGTTTTGAACTCCTGCCCTCAAGTAATCCTCCCACCTAGGTCTCCCAAA
GTGCTGGGACTACAGGCATGAGCCACCACATAGTTTTATTTTATTTAAAACAAATTTC
AGCCAGGCGCGAAACACCATCTCTAAAAAAATACAAAAATTAGCCAGGCATGTAGGT
GGCACATGCCTGTATTCCCAGCTACTCAGGAGGCTGAGGTTGGAGGATCACCTGAG
CCCAGGAGGCTGAGGCTACAGTGAGCTGTGATTGCACCACAGCATTCCAGCCTAGG
CAACAGAGTGAGACCCTGTCTCAAAAGATATATATATTTTCTTTAGAGACAGGGTCGC
CTAGGCTGGAGCACAGTGGCACAATCATGGCTCACTGCAGCCTTGAACTTCTGGGCT
 246 
 
CAAGCAATCCTTCCACACAGCCTCCTGAGTAGCTAGGAGGACTACAGGCGCTTGCCA
CCATGTCTGGCTAATTTTTAAAATTTTCTGTAGCGACAGGG 
 
Insert comprises nuc 186172 - 186292 of this clone (RP13-262C2). Sequence 
here  includes 1100 bp each side. No details in NCBI report regarding this region. 
COMPLEMENTARY STRAND 
TATTATTTAAAAATATATCTTTCTTCCTATATGGTCGTGGTGATAATAAAATGTCTTCTTATTCT
ATTCCTTTCCCATTCAAATAAATCATCTCTTTTAACCTAACAGGTAGTAGAAATTTCATTTAACT
TTTGGTACCGACTGGGGGAACATTTGTACAAAACTAACGATGAAGTTATTCATGGCATCTTCAAA
GCTTACATTCAGAGGCTGCTTCACGCCTTGGCTCGACACTGCCAGCTGGAACCAGACCATGTAAG
TTCCCTTCTCTACCTCTTCAAATCTTAATTTCTTCCTCTTGTCAGTGCCAACTTGAAAAGGAACT
GAGAAGATAGATAATAAACCTGGCTGGGCACCCTGGCTCATGCCTGTAGTCCAGCACTTTGGGAG
GCCAAGGCAGATGAATCGTTAGAGCCCAGGAATTCAAGACCAGCCTGGGCAACATAGGGAATCCC
CTGTCTCTACAAAAAGAAATAAAAGAAAATTAGCTGGGCCTGGTGGCACACGCCTGTAGTCCTAG
CTACTCAGGAAGCTGAGTTGGGAGGATTGGCAGACTCTACAGCTTATACTGAAGAAGTCAGTACC
AGTATAATCTGTTAGGTCTATTTAGGGAAAAAAAAAAGCAAAACACTCCAGCTAAACCAGTAATT
CTTTTCCTGGGAGTATATCTTAAATCTGCAGAAGAAAAAAACAGCTATTTTATATACAAAATGTT
ATCTGTAAAAGTAAAAATTATAAACCCATGTACAGCAGTATAACAAGAGTTATATGAATTATATA
AGAAGAGTTATGATTTAGCAACTTGATGCAGCAATTAAAAGGTAGTGAAATGATGATATGGTAAG
AGAAAAATCAGAATGTAAAATTATGTACTCTTTTTTTTTTTTTTTTTTTTTTTTTTGAGACGGAG
TCTCGCTCTGTCACCCAGGCTGGAGTGCAGTGGCGTGATCTCTGCTCACTGCAAACTCTGCCTCC
TGGGTTCACGCCATTCTCCTGTCTCAGCCTCCCGAGTAGCTGGGATTACAGGCACCCGCCACCAT
GCCAGGCTAATTATTTGTATATTTAGTAGAGATGGGGTTTCACCGTGTTAGCCAGGATGGTCTCG
ATCTCCTGACCTCATG 
 
AC018639 +/- FIT. SUBMITTED 7/2000 .120/121 hit with clone carrying 
human male DNA (clone RP11-128A6) from chr 7.This sequence is identical to 
AC025594.5 above in the insert area and for 500 bp in each direction. 
CCGGTCTCAAATTCCTGACCTCAAGTGATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACA
GGCATGAGCCACCACGCCCAGTTGGATTCTTCACTTTAAAAAATAGCGGGGGTGGGTGCAGTTTG
AAAACCACCAGACTAAATCATGACTAAGGTTGTGTGGAGATACAAAATACCATGACTCAAACACA
ATACTAACATTAAAATTAAGAGAACAGCACGTGGGATTTAATTGTAAGCAATAAAACTTACTGCA
GGTCCTAGATTAAAGGACGGATTCAACCAACCAACAGGATGAAATCGATGTGGCAAAATTTGAAG
AGACTAAGCATGATGTTTGAAGAGTTTTCTAATAAACTAATAATTTTCTAGTATTTTTTTCTAAG
CAAATAGATTTCTATATTCTTTTAAACTACAAAATCAGTATAAATAAGATTTAAAAAATGTGTAT
CTTCATGGGGCAAAATCATACACACAAATATTTCACTTTTGTATTAGTTTTCATCTAACCACTTA
TTTTCTACTATTTAATAAGGTACAAAATTTTGGCCAGGGGCGGTGGCTCACACCTGTAATCTCAG
CACTTTGGGAGGCTGAGGTGGGTGGATCATGAGGTCAGGAGATCGAGACCATCCTGGCTAACACG
GTGAAACCCCATCTCTACTAAATATACAAATAATTAGCCTGGCATGGTGGCGGGTGCCTGTAATC
CCAGCTACTCGGGAGGCTGAGACAGGAGAATGGCGTGAACCCAGGAGGCAGAGTTTGCAGTGAGC
AGAGATCACGCCACTGCACTCCAGCCTGGGTGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAA
AAAAAAAAAAAAAGAGTACATAATTTTACATTCTGATTTTTCTCTTACCATATCATCATTTCACT
ACCTTTTAATTGCTGCATCAAGTTGCTAAATCATAACTCTTCTTATATAATTCATATAACTCTTG
TTATACTGCTGTACATGGGTTTATAATTTTTACTTTTACAGATAACATTTTGTATATAAAATAGC
TGTTTTTTTCTTCTGCAGATTTAAGATATACTCCCAGGAAAAGAATTACTGGTTTAGCTGGAGTG
TTTTGCTTTTTTTTTTCCCTAAATAGACCTAACAGATTATACTGGTACTGACTTCTTCAGTATAA
GCTGTAGAGTCTGCCAATCCTCCCAACTCAGCTTCCTGAGTAGCTAGGACTACAGGCGTGTGCCA
CCAGGCCCAGCTAATTTTCTTTTATTTCTTTTTGTAGAGACAGGGGATTCCCTATGTTGCCCAGG
CTGGTCTTGAATTCCTGGGCTCTAACGATTCATCTGCCTTGGCCTCCCAAAGTGCTGGACTACAG
GCATGAGCCAGGGTGCCCAGCCAGGTTTATTATCTATCTTCTCAGTTCCTTTTCAAGTTGGCACT
GACAAGAGGAAGAAATTAAGATTTGAAGAGGTAGAGAAGGGAACTTACATGGTCTGGTTCCAGCT
 247 
 
GGCAGTGTCGAGCCAAGGCGTGAAGCAGCCTCTGAATGTAAGCTTTGAAGATGCCATGAATAACT
TCATCGTTAGTTTTGTACAAATGTTCCCCCAGTCGGTACCAAAAGTTAAATGAAATTTCTACTAC
CTGTTAGGTTAAAAGAGATGATTTATTTGAATGGGAAAGGAATAGAATAAGAAGACATTTTATTA
TCACCACGACCATATAGGAAGAAAGATATATTTTTAAATAATATGAGTGGAGCCAGTTAAGAAGT
CACCTTTTCTCTAGCAGATTTACTATTATCTCCCCAAATTGTCTTCCCACGTTAGGCCCAAATCT
CCATTTAGAATGACTGGCTTTACATTCCATTTAGTCCTGAGGTAATGCCTCCAAAAGTATACTGA
ATTTTGAATTTAGAGAAAACAATAACAGACATGGAAGTCTTTATTTTTATTTATTTTTTAGAGAC
GGAGTTTCATTCTGTTGCCCCAGCTAGAGTGCAGTGGAATGAACACAGTTCACTGCTGCCTCAAA
CTCCTGAGCTCAAGTGATCCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACTACAGGTACACACCA
CCAAGCTCAGCTAATTTTTTTTTTTTTTTTTTTTTTTAGTAGAAACAGGGCCTTGCCATCTTGCT
CAGGATGGTTTTGAACTCCTGCCCTCAAGTAATCCTCCCACCTAGGTCTCCCAAAGTGCTGGGAC
T 
 
Insert comprises nuc 14062 - 14182 of this clone (RP13-262C2). Sequence here 
includes  CA1100 bp each side. No details in NCBI report regarding this region 
 
 
Analysis of P8.4 clone insert. 
P8-4 
CCCCCGGGCTGCAGGAATTCACACGACTGTACTGGAGCCTGGATGACAGCAAGACCCTGTCTCCAA
AAAAATGTCTAAGACATTGCTGGAGCCTTGAAAAAAAAAAAACTCGAGGGGGGGCCCGGTACCC 
 
AL355385 +/+ FIT. SUBMITTED 30/9/2000 
88/90 hit with clone carrying human male DNA (clone RP11-387M24) 
from chr 6. 
GGCCGTGATTTGGGTGGGAATCACAGCACATGTGTAACGAGTGCTCAGGACACTCACAGTGCAGG
TGCAAAGGCAAGATGCACAGTCAAGCCTTCCTCCAGTTGAGGTCTGAGAATCACCTGCTTTCATT
AGGGATACTTTTTCTTCTTTTGTTTGAGACGGAGTCTCACTCTGTCACCCAGGCTGGAGTGTAGT
GGTGTGATCTTGGCTCACTGCAACCTGCGCCTCCCAGGTTCAAGTGATTCTCGTGCCTCAGCCTC
CCAAGTAGCTGGGTTTAAAGGTGTGTGCCACCACACCTGGCTAATTTTTGTATTTTTAGTAGAGG
CGATGTTTTACCATGTTGGCCAGGCTAGTCTCAAACTCTTGACCTCAAGTGATCCACCTGCCTCG
GCCTCCTAAAGTGCTGGGATTATGGGTGTGAGCTGCCATGCCCGGCCTCATTAGGGATACTTTTT
AAAACACAGGCCAGGCGTGGTGGTTCACACCTATAATCCCAGTGCTTTGGGAGGCCGAGATAGGA
AGATCTCTTGAGCCCAGGAGTTTGAGACCAGGCTGGACAAAATAGTGAGACCTTGTGTCTACAGA
AATTTAAAAAGTTAGCTGGGCGCGGTGGCTCACGCTTGTAATCCCAGCACTTTGGGAGGCCGAGG
TGGGTGGATCACGAGGTCAGGAGTTCGAGATCAGCCTGACCAACATGGTGAAACCCCGTCTCTAC
TAAAAATACAAAAATTAGCTGGGCATGTTGGCACTCACCTGTAATCCCAGCTACTTGGGAGGCTG
GGGCAGGAGAATTGCTTGAATCCAGGAGGCAGAGGTTGCAGTGAGTCGAGATCGTGCCATTGCAC
TCCAGCCTGGGTGACAGAGCGAGACTTTGTCTCAGGAAAAAAAAAAAAAAAAATTTAGCCAGGTA
TGGTGATGCACACCTATAATCCCAACTATTTGGGAGGCTGAGGCTGGAGGATCATTTGAGCTCGG
GAGCTGGAGGTTCCAGTGAGCTATGATCACACTACTGTACTGGAGCCTGGATGACAGCAAGACCC
TGTCTCCAAAAAAATGTCTAAGACATTGCTGGAGCCTTGAAAAAAAGAAAAAAAATGCAGAATTC
GGGGCCCCACTCCACAGCTTCCAACCCAGGCTCTAGGGGTGGGACCCAGGTAGATGTGTATTTAA
CAAGTGCTCTGGGTGATACTTCATGTGTGTTCAAGTTGGGGAACTCTGGCTTTGATCAGTCATTC
CACAGATGCTGACTGAGGCTGACACTGAGCCATGCCAGTGTCCCTTGCTGTGCTCTGAGAAGGAG
GCCTGTGGCATTTGAGAGTGTGTGATGCAAACAGGGCCAGATCAGGTGCTGGGTGTTAGAGGGTA
GAGCCCAGAAGACGGAGAGCTCTGGGAATGCATTCAGTCAACAGAGATTTGTCGAGCACCTTGTG
CTAGCTCTTCCCAGTACTGGATGCAACTGTGAACAAAGCAGGCAGAAGCCCCTCTCCTTGTGGAG
TTCATATTCTAACAGCGGGGACAAAGCCAGTAAGAAAAACTATCAAATGAACAAATATAATTTTA
 248 
 
GGTGCCAGTAGAACAAGGGAGAACAATGAAATAGGGCAAGTGATAGAGAAAGGGCAGGGCCAGTG
AGAGTTTAGGGAAGACTTCTGTAAAAGGTGCATTGGAGTTGGTATTTAAATTAAGAAGGGAGCCA
GCCATGTGATAGGCCCTGAGATGGAAATGGGCTTGTATGTTGGAGGAACAGTAGTCGCCTGTGTG
GCTTGAGTTGAATAAACGATGGTGAGAGGGGTTGAAGTTGCCTGAGAGGTGGAAACTAAATCCCA
TAGGCCTTGTAAAAGCATAGTAAGGACTTTGGCTTCGGCATCAGTTATCCATTGCTACATAGCAA
ACCACTTCAAAACGTGGTGGCACTTTGGGAGGCCGAGGCAGGTGGATCACTTGAGGTCAGGAGTT
TGAGACCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAATGGCTGGGTGC
AGTGGCTCACGCCTTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGTGGATCACGAGGTCAGGA
ATTCGAGACCAG 
 
Insert comprises nuc 86974 - 87063 of this clone (RP11-387M24). Sequence 
includes CA1100 bp each side. No details in NCBI report regarding this region. 
According to the sequence primers were designed using Oligo 5.0 software and 
synthesized by Sigma Genosys Ltd. NCBI Genbank accession numbers for target 
gene sequences have been indicated, as have the sequence for upper (U) and 
lower (L) primers.  
 
